0001140361-18-021886.txt : 20180507 0001140361-18-021886.hdr.sgml : 20180507 20180507113921 ACCESSION NUMBER: 0001140361-18-021886 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180507 DATE AS OF CHANGE: 20180507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: U S PHYSICAL THERAPY INC /NV CENTRAL INDEX KEY: 0000885978 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 760364866 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11151 FILM NUMBER: 18810250 BUSINESS ADDRESS: STREET 1: 1300 WEST SAM HOUSTON PARKWAY STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77043 BUSINESS PHONE: 7132977000 MAIL ADDRESS: STREET 1: 1300 WEST SAM HOUSTON PARKWAY STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77043 10-Q 1 form10q.htm 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED March 31, 2018
 OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE TRANSITION PERIOD FROM            TO _____

COMMISSION FILE NUMBER 1-11151

U.S. PHYSICAL THERAPY, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

 
NEVADA
 
76-0364866
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)
 
(I.R.S. EMPLOYER IDENTIFICATION NO.)

1300 WEST SAM HOUSTON PARKWAY SOUTH,
SUITE 300, HOUSTON, TEXAS
 
77042
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
 
(ZIP CODE)

REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (713) 297-7000

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      Yes       No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes       No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Accelerated filer
Non-accelerated filer
(Do not check if a smaller reporting company)
Smaller reporting company
   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes      No

As of May 7, 2018, the number of shares outstanding (issued less treasury stock) of the registrant’s common stock, par value $.01 per share, was: 12,669,538.
 


PART I—FINANCIAL INFORMATION - UNAUDITED

Item 1.
3
     
 
3
     
 
4
     
 
5
     
 
6
     
 
7
     
Item 2.
25
     
Item 3.
33
     
Item 4.
33
   
PART II—OTHER INFORMATION
 
   
Item 1.
Legal Proceedings
33
   
Item 6.
34
     
 
35
     
 
Certifications
 
 
ITEM 1.
FINANCIAL STATEMENTS.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)
 
   
March 31, 2018
   
December 31, 2017
 
ASSETS
 
(unaudited)
       
Current assets:
           
Cash and cash equivalents
 
$
19,813
   
$
21,933
 
Patient accounts receivable, less allowance for doubtful accounts of $2,517  and $2,273, respectively
   
46,228
     
44,707
 
Accounts receivable - other
   
6,504
     
5,655
 
Other current assets
   
3,050
     
4,786
 
Total current assets
   
75,595
     
77,081
 
Fixed assets:
               
Furniture and equipment
   
51,569
     
51,100
 
Leasehold improvements
   
29,981
     
29,760
 
Fixed assets, gross
   
81,550
     
80,860
 
Less accumulated depreciation and amortization
   
61,742
     
60,475
 
Fixed assets, net
   
19,808
     
20,385
 
Goodwill
   
273,770
     
271,338
 
Other identifiable intangible assets, net
   
47,092
     
48,954
 
Other assets
   
1,357
     
1,224
 
Total assets
 
$
417,622
   
$
418,982
 
                 
LIABILITIES, REDEEMABLE NON-CONTROLLING INTERESTS, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS
               
Current liabilities:
               
Accounts payable - trade
 
$
1,722
   
$
2,165
 
Accrued expenses
   
38,342
     
33,342
 
Current portion of notes payable
   
5,317
     
4,044
 
Total current liabilities
   
45,381
     
39,551
 
Notes payable, net of current portion
   
782
     
2,728
 
Revolving line of credit
   
42,000
     
54,000
 
Mandatorily redeemable non-controlling interests
   
-
     
327
 
Deferred taxes
   
10,151
     
10,875
 
Deferred rent
   
2,005
     
2,116
 
Other long-term liabilities
   
733
     
743
 
Total liabilities
   
101,052
     
110,340
 
                 
Redeemable non-controlling interests
   
108,085
     
102,572
 
                 
Commitments and contingencies
               
                 
U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity:
               
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding
   
-
     
-
 
Common stock, $.01 par value, 20,000,000 shares authorized, 14,884,676 and 14,809,299 shares issued, respectively
   
149
     
148
 
Additional paid-in capital
   
75,543
     
73,940
 
Retained earnings
   
162,907
     
162,406
 
Treasury stock at cost, 2,214,737 shares
   
(31,628
)
   
(31,628
)
Total USPH shareholders’ equity
   
206,971
     
204,866
 
Non-controlling interests
   
1,514
     
1,204
 
Total USPH shareholders' equity and non-controlling interests
   
208,485
     
206,070
 
Total liabilities, redeemable non-controlling interests, USPH shareholders' equity and non-controlling interests
 
$
417,622
   
$
418,982
 

See notes to consolidated financial statements.
 
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF NET INCOME
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)

   
Three Months Ended
 
   
March 31, 2018
   
March 31, 2017
 
             
Net patient revenues
 
$
100,552
   
$
93,654
 
Other revenues
   
7,790
     
3,911
 
Net revenues
   
108,342
     
97,565
 
Operating costs:
               
Salaries and related costs
   
62,279
     
55,827
 
Rent, supplies, contract labor and other
   
21,776
     
20,087
 
Provision for doubtful accounts
   
1,061
     
898
 
Closure costs
   
12
     
6
 
Total operating costs
   
85,128
     
76,818
 
                 
Gross profit
   
23,214
     
20,747
 
                 
Corporate office costs
   
10,163
     
8,547
 
Operating income
   
13,051
     
12,200
 
                 
Interest and other income, net
   
32
     
24
 
Interest expense:
               
Mandatorily redeemable non-controlling interests - change in redemption value
   
-
     
(2,669
)
Mandatorily redeemable non-controlling interests - earnings allocable
   
-
     
(1,294
)
Debt and other
   
(553
)
   
(415
)
Total interest expense
   
(553
)
   
(4,378
)
                 
Income before taxes
   
12,530
     
7,846
 
                 
Provision for income taxes
   
2,476
     
1,812
 
                 
Net income
   
10,054
     
6,034
 
                 
Less: net income attributable to non-controlling interests
   
(2,937
)
   
(1,218
)
                 
Net income attributable to USPH shareholders
 
$
7,117
   
$
4,816
 
                 
Basic and diluted earnings per share attributable to USPH shareholders
 
$
0.27
   
$
0.38
 
                 
Shares used in computation - basic and diluted
   
12,616
     
12,528
 
                 
Dividends declared per common share
 
$
0.23
   
$
0.20
 

See notes to consolidated financial statements.
 
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(unaudited)

   
Three Months Ended
 
   
March 31, 2018
   
March 31, 2017
 
OPERATING ACTIVITIES
           
Net income including non-controlling interests
 
$
10,054
   
$
6,034
 
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities:
               
Depreciation and amortization
   
2,468
     
2,356
 
Provision for doubtful accounts
   
1,061
     
898
 
Equity-based awards compensation expense
   
1,381
     
1,280
 
Loss on sale of fixed assets
   
54
     
33
 
Deferred income taxes
   
(1,162
)
   
(250
)
Changes in operating assets and liabilities:
               
Increase in patient accounts receivable
   
(2,782
)
   
(1,542
)
Increase in accounts receivable - other
   
(849
)
   
(3,697
)
(Increase) decrease in other assets
   
(1,238
)
   
757
 
Increase in accounts payable and accrued expenses
   
7,389
     
5,315
 
Increase in mandatorily redeemable non-controlling interests
   
-
     
2,911
 
(Decrease) increase in other liabilities
   
(845
)
   
76
 
Net cash provided by operating activities
   
15,531
     
14,171
 
                 
INVESTING ACTIVITIES
               
Purchase of fixed assets
   
(1,404
)
   
(1,587
)
Purchase of businesses, net of cash acquired
   
(761
)
   
(15,670
)
Purchase of non-controlling interest
   
(246
)
   
-
 
Proceeds on sale of fixed assets
   
-
     
62
 
Net cash used in investing activities
   
(2,411
)
   
(17,195
)
                 
FINANCING ACTIVITIES
               
Distributions to non-controlling interests
   
(2,208
)
   
(937
)
Proceeds from revolving line of credit
   
19,000
     
32,000
 
Payments on revolving line of credit
   
(31,000
)
   
(20,000
)
Payments to settle mandatorily redeemable non-controlling interests
   
(265
)
   
(2,230
)
Principal payments on notes payable
   
(823
)
   
(702
)
Other
   
56
     
-
 
Net (cash used in) provided by financing activities
   
(15,240
)
   
8,131
 
                 
Net increase in cash and cash equivalents
   
(2,120
)
   
5,107
 
Cash and cash equivalents - beginning of period
   
21,933
     
20,047
 
Cash and cash equivalents - end of period
 
$
19,813
   
$
25,154
 
                 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
               
Cash paid during the period for:
               
Income taxes
 
$
2,941
   
$
86
 
Interest
 
$
526
   
$
599
 
Non-cash investing and financing transactions during the period:
               
Purchase of business - seller financing portion
 
$
150
   
$
900
 

See notes to consolidated financial statements.
 
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY
(IN THOUSANDS)
(unaudited)

   
U.S.Physical Therapy, Inc.
             
                                                       
   
Common Stock
   
Additional
   
Retained
   
Treasury Stock
   
Total Shareholders’
   
Non-Controlling
       
   
Shares
   
Amount
   
Paid-In Capital
   
Earnings
   
Shares
   
Amount
   
Equity
   
Interests
   
Total
 
                   
Balance December 31, 2017
   
14,809
   
$
148
   
$
73,940
   
$
162,406
     
(2,215
)
 
$
(31,628
)
 
$
204,866
   
$
1,204
   
$
206,070
 
Issuance of restricted stock, net of cancellation
   
76
     
1
     
-
     
-
     
-
     
-
     
1
     
-
     
1
 
Revaluation of redeemable non-controlling interest, net of tax
   
-
     
-
     
-
     
(3,747
)
   
-
     
-
     
(3,747
)
   
-
     
(3,747
)
Compensation expense - equity-based awards
   
-
     
-
     
1,381
     
-
     
-
     
-
     
1,381
     
-
     
1,381
 
Transfer of compensation liability for certain stock issued pursuant to long-term incentive plans
   
-
     
-
     
373
     
-
     
-
     
-
     
373
     
-
     
373
 
Purchase of non-controlling interest
   
-
     
-
     
(151
)
   
-
     
-
     
-
     
(151
)
   
(42
)
   
(193
)
Dividends payable to USPT shareholders
   
-
     
-
     
-
     
(2,914
)
   
-
     
-
     
(2,914
)
   
-
     
(2,914
)
Distributions to non-controlling interest partners
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
(849
)
   
(849
)
Other
   
-
     
-
     
-
     
45
     
-
     
-
     
45
     
-
     
45
 
Net income
   
-
     
-
     
-
     
7,117
     
-
     
-
     
7,117
     
1,201
     
8,318
 
Balance March 31, 2018
   
14,885
     
149
     
75,543
     
162,907
     
(2,215
)
   
(31,628
)
 
$
206,971
     
1,514
     
208,485
 

See notes to consolidated financial statements.
 
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2018
(unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries (the “Company”). All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest in all the Clinic Partnerships. Our limited partnership interests range from 49% to 99% in the Clinic Partnerships.  The managing therapist of each clinic owns, directly or indirectly, the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as “Clinic Partnerships”). To a lesser extent, the Company operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with therapists (hereinafter referred to as “Wholly-Owned Facilities”).

In March 2017, the Company acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. Services provided include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers including a number of Fortune 500 companies. Other clients include large insurers and their contractors.

The Company continues to seek to attract for employment physical therapists who have established relationships with physicians and other referral sources by offering these therapists a competitive salary and incentives based on the profitability of the clinic that they manage. The Company also looks for therapists with whom to establish new, de novo clinics to be owned jointly by the Company and such therapists; in these situations, the therapist is offered the opportunity to co-invest in the new clinic and also receives a competitive salary for managing the clinic. For multi-site clinic practices in which a controlling interest is acquired by the Company, the prior owners typically continue on as employees to manage the clinic operations, retaining a non-controlling ownership interest in the clinics and receiving a competitive salary for managing the clinic operations. In addition, the Company has developed satellite clinic facilities as part of existing Clinic Partnerships and Wholly-Owned facilities, with the result that a substantial number of Clinic Partnerships and Wholly-Owned facilities operate more than one clinic location. In 2018, we intend to continue to acquire clinic practices and continue to focus on developing new clinics and opening satellite clinics where appropriate, along with increasing our patient volume through marketing and new programs.

On February 28, 2018, the Company, through one of its majority owned Clinic Partnerships, acquired two clinic practices.  These practices will operate as satellites of the existing Clinic Partnership.

During the year ended December 31, 2017, the Company acquired an interest in the following clinic groups:

 
Date  
% Interest Acquired
   
Number of Clinics
 
 
 
           
January 2017 Acquisition
January 1
 
70%
 
   
17
 
May 2017 Acquisition
May 31
 
70%
 
   
4
 
June 2017 Acquisition
June 30
 
60%
 
   
9
 
October 2017 Acquisition
October 31
 
70%
 
   
9
 

Also, during the 2017 year, the Company purchased the assets and business of two physical therapy clinics in separate transactions.  One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing Clinic Partnerships.

As of March 31, 2018, the Company operated 580 clinics in 42 states as well as the industrial injury prevention business.  The Company also manages physical therapy facilities for third parties, primarily physicians, with 28 third-party facilities under management as of March 31, 2018.

The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.  The Company intends to continue to pursue additional acquisition opportunities, develop new clinics and open satellite clinics.
 
The accompanying unaudited consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions for Form 10-Q. However, the statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. Management believes this report contains all necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. For further information regarding the Company’s accounting policies, please read the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate Controller have certified, that the financial statements included in this report present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented.

Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results the Company expects for the entire year.  Please also review the Risk Factors section included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Clinic Partnerships

For non-acquired Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interests, typically owned by the managing therapist, directly or indirectly, are recorded within the balance sheets and income statements as non-controlling interests.  For acquired Clinic Partnerships with mandatorily redeemable non-controlling interests, the earnings and liabilities attributable to the non-controlling interest were recorded within the consolidated statements of income line item: Interest expense – mandatorily redeemable non-controlling interests – earnings allocable and in the consolidated balance sheet line item: Mandatorily redeemable non-controlling interests.  For acquired Clinic Partnerships with redeemable non-controlling interests, the earnings attributable to the redeemable non-controlling interests are recorded within the consolidated statements of income line item – net income attributable to non-controlling interests and the equity interests are recorded on the consolidated balance sheet as redeemable non-controlling interests.

Effective December 31, 2017, the Company entered into amendments to its acquired limited partnership agreements replacing the mandatory redemption feature. No monetary consideration was paid to the partners to amend the agreements.   The amended limited partnership agreements provide that, upon certain events, the Company has a call right (the “Call Right”) and the selling entity has a put right (the “Put Right”) for the purchase and sale of the limited partnership interest held by the partner.  Once triggered, the Put Right and the Call Right do not expire, even upon an individual partner’s death, and contain no mandatory redemption feature.  The purchase price of the partner’s limited partnership interest upon the exercise of either the Put Right or the Call Right is calculated per the terms of the respective agreements.  The Company accounted for the amendment of its limited partnership agreements as an extinguishment of the outstanding Seller Entity Interests, as defined in Footnote 5, classified as liabilities through the issuance of new Seller Entity Interests classified in temporary equity. Pursuant to ASC 470-50-40-2, the Company removed the outstanding liability-classified Seller Entity Interests at their carrying amounts, recognized the new temporary-equity-classified Seller Entity Interests at their fair value, and recorded  no gain or loss on extinguishment, as management believes the redemption value (i.e. the carrying amount) and fair value are the same.  In summary, the redemption values of the mandatorily redeemable non-controlling interest (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet. The remaining balance of $327,000 in the line item – Mandatorily redeemable non-controlling interests – relates to one limited partnership agreement that was not amended, as the non-controlling interest was purchased by the Company in January 2018.  See Footnote 5 - Mandatorily redeemable non-controlling interests – and Footnote 6 - Redeemable non-controlling interests – for further discussion.

Wholly-Owned Facilities

For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due to the profit sharing therapists. The amount is expensed as compensation and included in operating costs – salaries and related costs. The respective liability is included in current liabilities – accrued expenses on the balance sheets.
 
Significant Accounting Policies

Cash Equivalents

The Company maintains its cash and cash equivalents at financial institutions.  The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.  The combined account balances at several institutions typically exceed Federal Deposit Insurance Corporation (“FDIC”) insurance coverage and, as a result, there is a concentration of credit risk related on deposits in excess of FDIC insurance coverage. Management believes that the risk is not significant.

Long-Lived Assets

Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for purchased software from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.

Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Goodwill

Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain identifiable intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital.

The fair value of goodwill and other identifiable intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company evaluates indefinite lived tradenames using the relief from royalty method in conjunction with its annual goodwill impairment test.  The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining the Company’s reporting units when performing its annual goodwill impairment test. In the first quarter of 2018, there were six regions.  In addition to the six regions, in 2017, the impairment test included a separate analysis for the industrial injury prevention business, a separate reporting unit.

An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other identifiable intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2017, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation of goodwill in 2017, 2016 and 2015 did not result in any goodwill amounts that were deemed impaired.

The Company has not identified any triggering events occurring after the testing date that would impact the impairment testing results obtained.  The Company will continue to monitor for any triggering events or other indicators of impairment.
 
Redeemable Non-Controlling Interests

The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those that the owners and the Company have certain redemption rights, whether currently exercisable or not, and which currently, or in the future, require that the Company purchase or the owner sell the non-controlling interest held by the owner, if certain conditions are met.  The purchase price is derived at a predetermined formula based on a multiple of trailing twelve months earnings performance as defined in the respective limited partnership agreements.  The redemption rights can be triggered by the owner or the Company at such time as both of the following events have occurred: 1) termination of the owner’s employment, regardless of the reason for such termination, and 2) the passage of specified number of years after the closing of the transaction, typically three to five years, as defined in the limited partnership agreement.  The redemption rights are not automatic or mandatory (even upon death) and require either the owner or the Company to exercise its rights when the conditions triggering the redemption rights have been satisfied.

On the date the Company acquires a controlling interest in a partnership, and the limited partnership agreement for such partnership contains redemption rights not under the control of the Company, the fair value of the non-controlling interest is recorded in the consolidated balance sheet under the caption – Redeemable non-controlling interests.  Then, in each reporting period thereafter until it is purchased by the Company, the redeemable non-controlling interest is adjusted to the greater of its then current redemption value or initial value, based on the predetermined formula defined in the respective limited partnership agreement.  As a result, the value of the non-controlling interest is not adjusted below its initial value.  The Company records any adjustment in the redemption value, net of tax, directly to retained earnings and are not reflected in the consolidated statements of income.  Although the adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects the adjustments, net of tax, in the earnings per share calculation.  The amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income. Management believes the redemption value (i.e. the carrying amount) and fair value are the same.

Non-Controlling Interests

The Company recognizes non-controlling interests, in which the Company has no obligation but the right to purchase the non-controlling interests, as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the statements of net income. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling equity investment on the deconsolidation date.

When the purchase price of a non-controlling interest by the Company exceeds the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.

Revenue Recognition

Revenues are recognized in the period in which services are rendered. See Footnote 3 for further discussion of revenue recognition.

Allowance for Doubtful Accounts

The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.
 
Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Tax Cuts and Jobs Act of 2017 (the “TCJA”) was passed by Congress on December 20, 2017 and signed into law by President Trump on December 22, 2017. The TCJA makes significant changes to U.S. corporate income tax laws including a decrease in the corporate income tax rate to 21% effective January 1, 2018.

The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the twelve months ended March 31, 2018. The Company will book any interest or penalties, if required, in interest and other expense, as appropriate.

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount under the Amended Credit Agreement approximates its fair value. The interest rate on the Amended Credit Agreement, which is tied to the Eurodollar Rate, is set at various short-term intervals, as detailed in the Amended Credit Agreement.

Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance.  The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.

Use of Estimates

In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.

Self-Insurance Program

The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through March 31, 2018.

Restricted Stock

Restricted stock issued to employees and directors is subject to continued employment or continued service on the board, respectively. Generally, restrictions on the stock granted to employees, other than officers, lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the vesting period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.
 
Recently Adopted Accounting Guidance

In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The original standards were effective for fiscal years beginning after December 15, 2016; however, in July 2015, the FASB approved a one-year deferral of these standards, with a new effective date for fiscal years beginning after December 15, 2017. The standards require the selection of a retrospective or cumulative effect transition method.

The Company implemented the new standard beginning January 1, 2018 using a modified retrospective transition method.  Adoption of the new standard did not result in material changes to the presentation of net revenues and bad debt expense in the consolidated statements of income, and the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change relates to how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common forms of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company’s estimate for unrealizable amounts is recorded as a reduction of revenue. Under the new standards, the Company’s estimate for unrealizable amounts will continue to be recognized as a reduction to revenue. The bad debt expense historically reported will not materially change.

Recently Issued Accounting Guidance

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350), which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment change. ASU 2017-04 is effective prospectively for fiscal years, and the interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact.

In February 2016, the FASB issued amended accounting guidance (ASU 2016-02, Leases) which replaced most existing lease accounting guidance under U. S. generally accepted accounting principles. Among other changes, the amended guidance requires that a right-to-use asset, which is an asset that represents the lessee’s right to use, and a lease liability, which is a lessee’s obligation to make lease payments arising for a lease measured on a discounted basis, be recognized on the balance sheet by lessees for those leases with a term of greater than 12 months. The amended guidance is effective for reporting periods beginning after December 15, 2018; however, early adoption is permitted. Entities can use to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements or recognize the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings.

Since the Company leases all but one of its clinic facilities, upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will continue to be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of income.
 
The Company will implement the new standard beginning January 1, 2019. The Company’s implementation efforts are focused on populating the data in a lease accounting software package and developing internal controls in order to account for its leases under the new standard.
 
Subsequent Event

The Company has evaluated events occurring after the balance sheet date for possible disclosure as a subsequent event through the date that these consolidated financial statements were issued. On April 30, 2018, the Company acquired a 65% interest in a leading provider of industrial injury prevention for $9.0 million.

2. ACQUISITIONS OF BUSINESSES

On February 28, 2018, the Company purchased the assets and business of two physical therapy clinics, for an aggregate purchase price of $760,000 in cash and $150,000 in seller note that is payable, plus accrued interest, on August 31, 2019.

The purchase price for this acquisition has been preliminarily allocated as follows (in thousands):

Cash paid
 
$
760
 
Seller note
   
150
 
Total consideration
 
$
910
 
         
Referral relationships
   
36
 
Non-compete
   
18
 
Goodwill
   
856
 
   
$
910
 

On January 1, 2017, the Company acquired a 70% interest in a seventeen-clinic physical therapy practice.  The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that was payable in two principal installments totaling $250,000 each, plus accrued interest.  The first installment was paid in January 2018 and the second installment is due in January 2019.

On May 31, 2017, the Company acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, in May 2018 and 2019.

On June 30, 2017, the Company acquired a 60% interest in a nine-clinic physical therapy practice.  The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in June 2018 and 2019.

On October 31, 2017, the Company acquired a 70% interest in a nine-clinic physical therapy practice and two management contracts with third party providers.  The purchase price for the 70% interest was $4.0 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in October 2018 and 2019.

In addition to the above, as previously mentioned in March 2017, the Company acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. The purchase price for the 55% interest was $6.2 million in cash and $0.4 million in a seller note that is payable, principal plus accrued interest, in September 2018. Also, in 2017, the Company purchased the assets and business of two physical therapy clinics in separate transactions. One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing partnerships.

The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.
 
The purchase price for the 2017 acquisitions has been preliminarily allocated as follows (in thousands):

Cash paid, net of cash acquired
 
$
36,682
 
Seller notes
   
2,150
 
Total consideration
 
$
38,832
 
Estimated fair value of net tangible assets acquired:
       
Total current assets
 
$
6,048
 
Total non-current assets
   
1,642
 
Total liabilities
   
(2,909
)
Net tangible assets acquired
 
$
4,781
 
Referral relationships
   
4,085
 
Non-compete
   
1,224
 
Tradename
   
7,039
 
Goodwill
   
45,868
 
Fair value of non-controlling interest (classified as redeemable non-controlling interests)
   
(13,883
)
Fair value of non-controlling interest (originally classified as mandatorily redeemable non-controlling interests)
   
(10,282
)
   
$
38,832
 

The purchase prices plus the fair value of the non-controlling interests for the acquisitions in first quarter of 2017 were allocated to the fair value of the assets acquired, inclusive of identifiable intangible assets, i.e. trade names, referral relationships and non-compete agreements, and liabilities assumed based on the fair values at the acquisition date, with the amount exceeding the fair values being recorded as goodwill are finalized. For the acquisitions occurring on or after April 1, 2017, the Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and identifiable intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used at March 31, 2018 based on additional information obtained and completion of the valuation of the identifiable intangible assets. Changes in the estimated valuation of the tangible assets acquired, the completion of the valuation of identifiable intangible assets and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill.

For the acquisitions in 2017, the values assigned to the referral relationships and non-compete agreements are being amortized to expense equally over the respective estimated lives. For referral relationships, the range of the estimated lives was 7½ to 11 years, and for non-compete agreements the estimated lives were five to six years. Generally, the values assigned to tradenames are tested annually for impairment,

For the 2017 acquisitions, total current assets primarily represent patient accounts receivable. Total non-current assets are fixed assets, primarily equipment, used in the practices.

The consideration paid for each of the acquisitions was derived through arm’s length negotiations. Funding for the cash portions was derived from proceeds from the Company’s revolving credit facility. The results of operations of the acquisitions have been included in the Company’s consolidated financial statements since their respective date of acquisition. Unaudited proforma consolidated financial information for the acquisitions in 2018, and 2017 acquisitions have not been included as the results, individually and in the aggregate, were not material to current operations.

3.  REVENUE RECOGNITION

Categories

Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.

Management contract revenues, which are included in other revenues in the consolidated statements of net income, are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred.
 
Revenues from the industrial injury prevention business, which are also included in other revenues in the consolidated statements of net income, are derived from onsite services provided to clients’ employees including injury prevention, rehabilitation, ergonomic assessments and performance optimization. Revenues are determined based on the number of hours and respective rate for services provided.

Additionally, other revenues include services provided on-site, such as schools and industrial worksites, for physical or occupational therapy services, and athletic trainers and gym membership fees.  Contract terms and rates are agreed to in advance between the Company and the third parties. Services are typically performed over the contract period and revenue is recorded in accordance with the contract terms. If the services are paid in advance, revenue is deferred over the period of the agreement and recognized when the services are performed.

The following table details the revenue related to the various categories:

   
Three Months Ended
   
Three Months Ended
 
   
March 31, 2018
   
March 31, 2017
 
Net patient revenues
 
$
100,552
   
$
93,654
 
Management contract revenues
   
2,236
     
1,857
 
Industrial injury prevention services revenues
   
4,852
     
1,506
 
Other revenues
   
702
     
548
 
   
$
108,342
   
$
97,565
 

Net Patient Revenues - Physical / Occupational Therapy Revenue

Net patient revenues consists of revenues for physical therapy and occupational therapy clinics that provide pre-and post-operative care and treatment for orthopedic related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.

For ASC 606, there is an implied contract between the Company and the patient upon each patient visit.  Separate contractual arrangements exist between the Company and third party payors (e.g. insurers, managed care programs, government programs, workers' compensation) which establish the amounts the third parties pay on behalf of the patients for covered services rendered.   While these agreements are not considered contracts with the customer, they are used for determining the transaction price for services provided to the patients covered by the third party payors.  The payor contracts do not indicate performance obligations of the Company, but indicate reimbursement rates for patients who are covered by those payors when the services are provided.  At that time, the Company is obligated to provide services for the reimbursement rates stipulated in the payor contracts.  The execution of the contract alone does not indicate a performance obligation. For self-paying customers, the performance obligation exists when the Company provides the services at established rates. The difference between the Company’s established rate and the anticipated reimbursement rate is accounted for an as offset to revenue – contractual allowance.

Contractual Allowances

Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements by both insurance companies and government sponsored healthcare programs for such services. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow the Company to provide the necessary detail and accuracy with its collectability estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing system does not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, the need for a manual process for determining its contractual allowance reserve. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, historically the difference between net revenues and corresponding cash collections has generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent periods’ contractual write-offs on a payor basis reflects a difference within approximately 1% between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at March 31, 2018.
 
A contract’s transaction price is allocated to each distinct performance obligation and recognized when, or as, the performance obligation is satisfied. To determine the transaction price, the Company includes the effects of any variable consideration, such as the probability of collecting that amount.  The Company applies established rates to the services provided, and adjusts for the terms of payor contracts, as applicable.  These contracted amounts are different from the Company’s established rates.  The Company has established a “contractual allowance” for this difference. The allowance is based on the terms of payor contracts, historical and current reimbursement information and current experience with the clinic and partners. The Company’s established rates less the contractual allowance is the revenue that is recognized in the period in which the service is rendered. This revenue is deemed the transaction price and stated as “Net Patient Revenue” on the Company’s income statement.

The majority of the Company’s performance obligations are satisfied at one point in time. After the clinic has provided services and satisfied its obligation to the customer for the reimbursement rates stipulated in the payor contracts (i.e the transaction price), the Company recognizes the revenue, net of contractual allowances, in the period in which the services are rendered. The Company recognizes the full amount of revenue and reports the contractual allowances as a contra (or offset) revenue account to report a net revenue number based on the expected collections.

Medicare Reimbursement

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (‘‘MPFS’’). For services provided in 2018, a 0.5% increase has been applied to the fee schedule payment rates; for services provided in 2019, a 0.25% increase will be applied to the fee schedule payment rates, subject to an adjustment beginning in 2019 under the Merit-Based Incentive Payment System (“MIPS”).    For services provided in 2020 through 2025, a 0.0% percent update will be applied each year to the fee schedule payment rates, subject to adjustments under MIPS and any alternative payment models (“APMs”).   Beginning in 2019, payments to individual therapists (Physical/Occupational Therapist in Private Practice) under the fee schedule may be subject to adjustment based on performance in MIPS, which measures performance based on certain quality metrics, resource use, and meaningful use of electronic health records. Under the MIPS requirements, a provider's performance is assessed according to established performance standards and used to determine an adjustment factor that is then applied to the professional's payment for a year. Each year from 2019 through 2024, professionals who receive a significant share of their revenues through an APM (such as accountable care organizations or bundled payment arrangements) that involves risk of financial losses and a quality measurement component will receive a 5% bonus. The bonus payment for APM participation is intended to encourage participation and testing of new APMs and to promote the alignment of incentives across payors. The specifics of the MIPS and APM adjustments beginning in 2019 and 2020, respectively, will be subject to future notice and comment rule-making.

The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. On April 1, 2013, a 2% reduction to Medicare payments was implemented. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, extended the 2% reductions to Medicare payments through fiscal year 2025. The Bipartisan Budget Act of 2018, enacted on February 9, 2018, extends the 2% reductions to Medicare payments through fiscal year 2027.

Historically, the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary was subject to an annual dollar limit (i.e., the ‘‘Therapy Cap’’ or ‘‘Limit’’). For 2017, the annual Limit on outpatient therapy services was $1,980 for combined Physical Therapy and Speech Language Pathology services and $1,980 for Occupational Therapy services. As a result of Bipartisan Budget Act of 2018, the Therapy Caps have been eliminated, effective as of January 1, 2018.
 
Under the Middle Class Tax Relief and Job Creation Act of 2012 (‘‘MCTRA’’), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The MACRA directed CMS to modify the manual medical review process such that those reviews will no longer apply to all claims exceeding the $3,700 threshold and instead will be determined on a targeted basis based on a variety of factors that CMS considers appropriate. The Bipartisan Budget Act of 2018 extends the targeted medical review indefinitely, but reduces the threshold to $3,000 through December 31, 2027.  For 2028, the threshold amount will be increased by the percentage increase in the Medicare Economic Index (“MEI”) for 2028 and in subsequent years the threshold amount will increase based on the corresponding percentage increase in the MEI for such subsequent year.

CMS adopted a multiple procedure payment reduction (‘‘MPPR’’) for therapy services in the final update to the MPFS for calendar year 2011. The MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (‘‘RVU’’) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. Since 2013, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 50%. In addition, the MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. Reporting of these functional limitation codes and modifiers are required on the claim for payment.

Medicare claims for outpatient therapy services furnished by therapy assistants on or after January 1, 2022 must include a modifier indicating the service was furnished by a therapy assistant. CMS is required to develop a modifier to mark services provided by a therapy assistant by January 1, 2019, and then submitted claims must report the modifier mark starting January 1, 2020. Outpatient therapy services furnished on or after January 1, 2022 in whole or part by a therapy assistant will be paid at an amount equal to 85% of the payment amount otherwise applicable for the service.

Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. We believe that we are in compliance, in all material respects, with all applicable laws and regulations and are not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of March 31, 2018. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program. For three months ended March 31, 2018, net patient revenue from Medicare were approximately $24.6 million.
 
4. EARNINGS PER SHARE

The following tables provide a detail of the basic and diluted earnings per share computation.  In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest (see Footnote 6), net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation.

   
Three Months Ended March 31,
 
   
2018
   
2017
 
Computation of earnings per share - USPH shareholders
           
Net income attributable to USPH shareholders
 
$
7,117
   
$
4,816
 
Charges to retained earnings:
               
Revaluation of redeemable non-controlling interest
 
$
(5,081
)
 
$
-
 
Tax effect at statutory rate (federal and state) of 26.25%
   
1,334
     
-
 
   
$
3,370
   
$
4,816
 
                 
Basic and diluted per share
 
$
0.27
   
$
0.38
 

5. MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS

Prior to the second quarter of 2017, when the Company acquired a majority interest (the “Acquisition”) in a physical therapy clinic business (referred to as “Therapy Practice”), these Acquisitions occurred in a series of steps which are described below.

1.
Prior to the Acquisition, the Therapy Practice exists as a separate legal entity (the “Seller Entity”). The Seller Entity is owned by one or more individuals (the “Selling Shareholders”) most of whom are physical therapists that work in the Therapy Practice and provide physical therapy services to patients.
2.
In conjunction with the Acquisition, the Seller Entity contributes the Therapy Practice into a newly-formed limited partnership (“NewCo”), in exchange for one hundred percent (100%) of the limited and general partnership interests in NewCo. Therefore, in this step, NewCo becomes a wholly-owned subsidiary of the Seller Entity.
3.
The Company enters into an agreement (the “Purchase Agreement”) to acquire from the Seller Entity a majority (ranges from 50% to 90%) of the limited partnership interest and, in all cases, 100% of the general partnership interest in NewCo. The Company does not purchase 100% of the limited partnership interest because the Selling Shareholders, through the Seller Entity, want to maintain an ownership percentage. The consideration for the Acquisition is primarily payable in the form of cash at closing and a small two-year note in lieu of an escrow (the “Purchase Price”). The Purchase Agreement does not contain any future earn-out or other contingent consideration that is payable to the Seller Entity or the Selling Shareholders.
4.
The Company and the Seller Entity also execute a partnership agreement (the “Partnership Agreement”) for NewCo that sets forth the rights and obligations of the limited and general partners of NewCo. After the Acquisition, the Company is the general partner of NewCo.
5.
As noted above, the Company does not purchase 100% of the limited partnership interests in NewCo and the Seller Entity retains a portion of the limited partnership interest in NewCo (“Seller Entity Interest”).
6.
In most cases, some or all of the Selling Shareholders enter into an employment agreement (the  “Employment Agreement”) with NewCo with an initial term that ranges from three to five years (the “Employment Term”), with automatic one-year renewals, unless employment is terminated prior to the end of the Employment Term. As a result, a Selling Shareholder becomes an employee (“Employed Selling Shareholder”) of NewCo. The employment of an Employed Selling Shareholder can be terminated by the Employed Selling Shareholder or NewCo, with or without cause, at any time. In a few situations, a Selling Shareholder does not become employed by NewCo and is not involved with NewCo following the closing; in those situations, such Selling Shareholders sell their entire ownership interest in the Seller Entity as of the closing of the Acquisition.
7.
The compensation of each Employed Selling Shareholder is specified in the Employment Agreement and is customary and commensurate with his or her responsibilities based on other employees in similar capacities within NewCo, the Company and the industry.
 
8.
The Company and the Selling Shareholder (including both Employed Selling Shareholders and Selling Shareholders not employed by NewCo) execute a non-compete agreement (the “Non- Compete Agreement”) which restricts the Selling Shareholder from engaging in competing business activities for a specified period of time (the “Non-Compete Term”). A Non-Compete Agreement is executed with the Selling Shareholders in all cases. That is, even if the Selling Shareholder does not become an Employed Selling Shareholder, the Selling Shareholder is restricted from engaging in a competing business during the Non-Compete Term.
9.
The Non-Compete Term commences as of the date of the Acquisition and expires on the later of:
a.
Two years after the date an Employed Selling Shareholders’ employment is terminated (if the Selling Shareholder becomes an Employed Selling Shareholder) or
b.
Five to six years from the date of the Acquisition, as defined in the Non-Compete Agreement, regardless of whether the Selling Shareholder is employed by NewCo.
10.
The Non-Compete Agreement applies to a restricted region which is defined as a 15-mile radius from the Therapy Practice. That is, an Employed Selling Shareholder is permitted to engage in competing businesses or activities outside the 15-mile radius (after such Employed Selling Shareholder no longer is employed by NewCo) and a Selling Shareholder who is not employed by NewCo immediately is permitted to engage in the competing business or activities outside the 15-mile radius.
11.
The Partnership Agreement contains provisions for the redemption of the Seller Entity Interest, either at the option of the Company (the “Call Option”) or on a required basis (the “Required Redemption”):
a.
Required Redemption
i.
Once the Required Redemption is triggered, the Company is obligated to purchase from the Seller Entity and the Seller Entity is obligated to sell to the Company, the allocable portion of the Seller Entity Interest based on the terminated Selling Shareholder’s pro rata ownership interest in the Seller Entity (the “Allocable Portion”). Required Redemption is
triggered when both of the following events have occurred:
1.
Termination of an Employed Selling Shareholder’s employment with NewCo, regardless of the reason for such termination, and
2.
The expiration of an agreed upon period of time, typically three to five years, as set forth in the relevant Partnership Agreement (the “Holding Period”).
ii.
In the event an Employed Selling Shareholder’s employment terminates prior to the expiration of the Holding Period, the Required Redemption would occur only upon expiration of the Holding Period.
b.
Call Option
i.
In the event that an Employed Selling Shareholder’s employment terminates prior to expiration of the Holding Period, the Company has the contractual right, but not the obligation, to acquire the Employed Selling Shareholder’s Allocable Portion of the Seller Entity Interest from the Seller Entity through exercise of the Call Option.
c.
For the Required Redemption and the Call Option, the purchase price is derived from a formula based on a specified multiple of NewCo’s trailing twelve months of earnings before interest, taxes, depreciation, amortization, and the Company’s internal management fee, plus an Allocable Portion of any undistributed earnings of NewCo (the “Redemption Amount”). NewCo’s earnings are distributed monthly based on available cash within NewCo; therefore, the undistributed earnings amount is small, if any.
d.
The Purchase Price for the initial equity interest purchased by the Company is also based on the same specified multiple of the trailing twelve-month earnings that is used in the Required Redemption noted above.
e.
Although, the Required Redemption and the Call Option do not have an expiration date, the Seller Entity Interest eventually will be purchased by the Company.
f.
The Required Redemption and the Call Option never apply to Selling Shareholders who do not become employed by NewCo, since the Company requires that such Selling Shareholders sell their entire ownership interest in the Seller Entity at the closing of the Acquisition.
12.
An Employed Selling Shareholder’s ownership of his or her equity interest in the Seller Entity predates the Acquisition and the Company’s purchase of its partnership interest in NewCo. The Employment Agreement and the Non-Compete Agreement do not contain any provision to escrow or “claw back” the equity interest in the Seller Entity held by such Employed Selling Shareholder, nor the Seller Entity Interest in NewCo, in the event of a breach of the employment or non-compete terms. More specifically, even if the Employed Selling Shareholder is terminated for “cause” by NewCo, such Employed Selling Shareholder does not forfeit his or her right to his or her full equity interest in the Seller Entity and the Seller Entity does not forfeit its right to any portion of the Seller Entity Interest. The Company’s only recourse against the Employed Selling Shareholder for breach of either the Employment Agreement or the Non-Compete Agreement is to seek damages and other legal remedies under such agreements. There are no conditions in any of the arrangements with an Employed Selling Shareholder that would result in a forfeiture of the equity interest held in the Seller Entity or of the Seller Entity Interest.
 
As previously mentioned, due to the amendments that were made to partnerships agreements, the Call Option and Required Redemption provisions described in number 11 of Footnote 5 have been modified to be consistent with the provisions described in Footnote 6 below.  As a result, the redemption values of the mandatorily redeemable non-controlling interest (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet.  For 2017, the earnings and liabilities attributable to mandatorily redeemable non-controlling interests were recorded within the consolidated statements of income line item: Interest expense – mandatorily redeemable non-controlling interests – earnings allocable and in the consolidated balance sheet line item: Mandatorily redeemable non-controlling interests.

6. REDEEMABLE NON-CONTROLLING INTERESTS

When the Company acquires a majority interest in a Therapy Practice, those Acquisitions occur in a series of steps as described in numbers 1 through 10 of footnote 5 – Mandatorily Redeemable Non-Controlling Interests.  For the Acquisitions that occurred after the first quarter of 2017, and for the acquisitions that occurred during and prior to the first quarter of 2017 but for which the partnership agreements were amended, the applicable Partnership Agreement contains provisions for the redemption of the Seller Entity Interest, either at the option of the Company (the “Call Right”) or at the option of the Seller Entity (the “Put Right”) as follows:
1.
Put Right
a.
In the event that any Selling Shareholder’s employment is terminated involuntarily by the Company without “Cause” pursuant to Section 7(d) of such Selling Shareholder’s Employment Agreement prior to the fifth anniversary of the Closing Date, the Seller Entity thereafter shall have an irrevocable right to cause the Company to purchase from Seller Entity the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest at the purchase price described in “3” below.
b.
In the event that any Selling Shareholder is not employed by NewCo as of the fifth anniversary of the Closing Date and the Company has not exercised its Call Right with respect to the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest, Seller Entity thereafter shall have the Put Right to cause the Company to purchase from Seller Entity the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest at the purchase price described in “3” below.
c.
In the event that any Selling Shareholder’s employment with NewCo is terminated for any reason on or after the fifth anniversary of the Closing Date, the Seller Entity shall have the Put Right, and upon the exercise of the Put Right, the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest shall be redeemed by the Company at the purchase price described in “3” below.
2.
Call Right
a.
If any Selling Shareholder’s employment by NewCo is terminated (i) pursuant to a voluntary termination by the Selling Shareholder or (ii) by NewCo with “Cause” (as defined in the Selling Shareholder’s Employment Agreement), prior to the fifth anniversary of the Closing Date, the Company thereafter shall have an irrevocable right to purchase from Seller Entity the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest, in each case at the purchase price described in “3” below.
b.
In the event that any Selling Shareholder’s employment with NewCo is terminated for any reason on or after the fifth anniversary of the Closing Date, the Company shall have the Call Right, and upon the exercise of the Call Right, the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest shall be redeemed by the Company at the purchase price described in “3” below.
3.
For the Put Right and the Call Right, the purchase price is derived from a formula based on a specified multiple of NewCo’s trailing twelve months of earnings before interest, taxes, depreciation, amortization, and the Company’s internal management fee, plus an Allocable Percentage of any undistributed earnings of NewCo (the “Redemption Amount”). NewCo’s earnings are distributed monthly based on available cash within NewCo; therefore, the undistributed earnings amount is small, if any.
 
4.
The Purchase Price for the initial equity interest purchased by the Company is also based on the same specified multiple of the trailing twelve-month earnings that is used in the Put Right and the Call Right noted above.
5.
The Put Right and the Call Right do not have an expiration date, but the Seller Entity Interest is not required to be purchased by the Company or sold by the Seller Entity.
6.
The Put Right and the Call Right never apply to Selling Shareholders who do not become employed by NewCo, since the Company requires that such Selling Shareholders sell their entire ownership interest in the Seller Entity at the closing of the Acquisition.

An Employed Selling Shareholder’s ownership of his or her equity interest in the Seller Entity predates the Acquisition and the Company’s purchase of its partnership interest in NewCo. The Employment Agreement and the Non-Compete Agreement do not contain any provision to escrow or “claw back” the equity interest in the Seller Entity held by such Employed Selling Shareholder, nor the Seller Entity Interest in NewCo, in the event of a breach of the employment or non-compete terms. More specifically, even if the Employed Selling Shareholder is terminated for “cause” by NewCo, such Employed Selling Shareholder does not forfeit his or her right to his or her full equity interest in the Seller Entity and the Seller Entity does not forfeit its right to any portion of the Seller Entity Interest. The Company’s only recourse against the Employed Selling Shareholder for breach of either the Employment Agreement or the Non-Compete Agreement is to seek damages and other legal remedies under such agreements. There are no conditions in any of the arrangements with an Employed Selling Shareholder that would result in a forfeiture of the equity interest held in the Seller Entity or of the Seller Entity Interest.

For the three months ended March 31, 2018, the following table details the changes in the carrying amount of redeemable non-controlling interest (in thousands):

Three Months Ended
March 31, 2018
       
Beginning balance
 
$
102,572
 
Operating results allocated to redeemable non-controlling interest partners
   
1,736
 
Distributions to redeemable non-controlling interest partners
   
(1,359
)
Changes in the fair value of redeemable non-controlling interest
   
5,081
 
Other
   
55
 
Ending balance
 
$
108,085
 

The following table categorizes the carrying amount (fair value) of the redeemable non-controlling interests (in thousands):

   
March 31, 2018
 
       
Contractual time period has lapsed but holder's employment has not been terminated
 
$
34,127
 
Contractual time period has not lapsed and holder's employment has not been terminated
   
73,958
 
Fair value
 
$
108,085
 
 
7. GOODWILL

The changes in the carrying amount of goodwill consisted of the following (in thousands):

Beginning balance
 
$
271,338
 
Goodwill acquired during the year
   
856
 
Goodwill adjustments for purchase price allocation of businesses acquired in prior year
   
1,576
 
Ending balance
 
$
273,770
 

8. INTANGIBLE ASSETS, NET

Intangible assets, net as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

   
March 31, 2018
   
December 31, 2017
 
Tradenames
 
$
28,273
   
$
29,673
 
Referral relationships, net of accumulated amortization of $7,729 and $7,209, respectively
   
16,527
     
16,811
 
Non-compete agreements, net of accumulated amortization of $4,297 and $4,100, respectively
   
2,292
     
2,470
 
   
$
47,092
   
$
48,954
 

Tradenames, referral relationships and non-compete agreements are related to the businesses acquired. Typically, the value assigned to tradenames has an indefinite life and is tested at least annually for impairment using the relief from royalty method in conjunction with the Company’s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non-compete agreements are amortized over the respective term of the agreements which range from five to six years.

The following table details the amount of amortization expense recorded for intangible assets for the three months ended March 31, 2018 and 2017 (in thousands):

   
Three Months Ended
   
Three Months Ended
 
   
March 31, 2018
   
March 31, 2017
 
Referral relationships
 
$
520
   
$
458
 
Non-compete agreements
   
197
     
195
 
   
$
717
   
$
653
 

Based on the balance of referral relationships and non-compete agreements as of March 31, 2018, the expected amount to be amortized in 2018 and thereafter by year is as follows (in thousands):

Referral Relationships
   
Non-Compete Agreements
 
Years
 
Annual Amount
   
Years
   
Annual Amount
 
Ending December 31,
       
Ending December 31,
       
2018
 
$
2,068
     
2018
   
$
766
 
2019
 
$
1,965
     
2019
   
$
693
 
2020
 
$
1,965
     
2020
   
$
481
 
2021
 
$
1,965
     
2021
   
$
403
 
2022
 
$
1,917
     
2022
   
$
143
 
2023
 
$
1,809
     
2023
   
$
3
 
Thereafter
 
$
5,358
                 
 
9. ACCRUED EXPENSES

Accrued expenses as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

   
March 31, 2018
   
December 31, 2017
 
Salaries and related costs
 
$
22,677
   
$
16,828
 
Credit balances due to patients and payors
   
3,841
     
4,158
 
Group health insurance claims
   
2,637
     
2,929
 
Income taxes payable
   
2,139
     
2,833
 
Dividend payable to USPH shareholders
   
2,914
     
-
 
Other
   
4,134
     
6,594
 
Total
 
$
38,342
   
$
33,342
 

10. NOTES PAYABLE AND AMENDED CREDIT AGREEMENT

Amounts outstanding under the Amended Credit Agreement and notes payable as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

   
March 31, 2018
   
December 31, 2017
 
Credit Agreement average effective interest rate of 3.8% inclusive of unused fee
 
$
42,000
   
$
54,000
 
Various notes payable with $5,317 plus accrued interest due in the next year, interest accrues in the range of 3.25% through 4.25% per annum
   
6,099
     
6,772
 
     
48,099
     
60,772
 
Less current portion
   
(5,317
)
   
(4,044
)
Long term portion
 
$
42,782
   
$
56,728
 

Effective December 5, 2013, the Company entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility. This agreement was amended in August 2015, January 2016, March 2017 and November 2017 (hereafter referred to as “Amended Credit Agreement”). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common stockholders, capital expenditures and other corporate purposes. The pricing grid which is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.25% to 2.0% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.25% to 0.3% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement.

The January 2016 amendment to the Amended Credit Agreement increased the cash and noncash consideration that the Company could pay with respect to acquisitions permitted under the Amended Credit Agreement to $50,000,000 for any fiscal year, and increased the amount the Company may pay in cash dividends to its shareholders in an aggregate amount not to exceed $10,000,000 in any fiscal year.  The March 2017 amendment, among other items, increased the amount the Company may pay in cash dividends to its shareholders in an aggregate amount not to exceed $15,000,000 in any fiscal year. The November 2017 amendment, among other items, adjusted the pricing grid as described above, increased the aggregate amount the Company may pay in cash dividends to its shareholders to an amount not to exceed $20,000,000 and extended the maturity date to November 30, 2021.

On March 31, 2018, $42.0 million was outstanding on the Amended Credit Agreement resulting in $83.0 million of availability. As of March 31, 2018 and the date of this report, the Company was in compliance with all of the covenants thereunder.

The Company generally enters into various notes payable as a means of financing a portion of its acquisitions and purchases of non-controlling interests. In conjunction with the acquisition of the two clinic practices on February 28, 2018, the Company entered into a note payable in the amount of $150,000, which is payable on August 31, 2019.  Interest accrues at the rate of 4.5% per annum and is payable on August 31, 2019.  In conjunction with the acquisitions in 2017, the Company entered into notes payable in the aggregate amount of $2.2 million of which an aggregate principal payment of $1.3 million is due in 2018 (of which $250,000 was paid in January 2018) and $0.9 million in 2019.   Interest accrues in the range of 3.25% to 4.0% per annum and is payable with each principal installment.
 
Aggregate annual payments of principal required pursuant to the Amended Credit Agreement and the above notes payable subsequent to March 31, 2018 are as follows (in thousands):

During the twelve months ended March 31, 2019
 
$
5,317
 
During the twelve months ended March 31, 2020
   
782
 
During the twelve months ended March 31, 2021
   
-
 
During the twelve months ended March 31, 2022
   
42,000
 
   
$
48,099
 

The revolving credit facility (balance at March 31, 2018 of $42.0 million) matures on November 30, 2021.

11. COMMON STOCK

From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company’s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (“March 2009 Authorization”). The Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. The Company is required to retire shares purchased under the March 2009 Authorization.

Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. There are currently an additional estimated 184,502 shares (based on the closing price of $81.30 on March 31, 2018) that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company’s cash position. The Company did not purchase any shares of its common stock during the three months ended March 31, 2018.
 
Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2018; and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2017 Form 10-K. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017.

References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.

EXECUTIVE SUMMARY

Our Business

We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers and also operate an industrial injury prevention business. As of March 31, 2018, we operated 580 clinics in 42 states.  We also manage physical therapy facilities for third parties, primarily physicians, with 28 third-party facilities under management as of March 31, 2018.

On February 28, 2018, through one of our majority owned Clinic Partnerships, we acquired two clinic practices for an aggregate purchase price of $760,000 and $150,000 in seller note that is payable, plus accrued interest, on August 31, 2019.  These practices will operate as satellites of the existing Clinic Partnership.

During the year ended 2017, we acquired the following clinic groups:

 Date
 
% Interest Acquired
   
Number of Clinics
 
 
 
           
January 2017 Acquisition
January 1
 
70%
 
   
17
 
May 2017 Acquisition
May 31
 
70%
 
   
4
 
June 2017 Acquisition
June 30
 
60%
 
   
9
 
October 2017 Acquisition
October 31
 
70%
 
   
9
 

On January 1, 2017, we acquired a 70% interest in a seventeen-clinic physical therapy practice.  The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that was payable in two principal installments totaling $250,000 each, plus accrued interest.  The first installment was paid in January 2018 and the second installment is due in January 2019.

On May 31, 2017, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, in May 2018 and 2019.

On June 30, 2017, we acquired a 60% interest in a nine-clinic physical therapy practice.  The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in June 2018 and 2019.

On October 31, 2017, we acquired a 70% interest in a nine-clinic physical therapy practice and two management contracts with third party providers.  The purchase price for the 70% interest was $4.0 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in October 2018 and 2019.
 
In addition to the clinic groups above, in March 2017, we acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. Services provided include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers including a number of Fortune 500 companies. The purchase price for the 55% interest was $6.2 million in cash and $0.4 million in a seller note that is payable, principal plus accrued interest, in September 2018.  Also, during the 2017 year, we purchased the assets and business of two physical therapy clinics in separate transactions.  One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing partnerships.
 
Selected Operating and Financial Data

The following table presents selected operating and financial data that we believe are key indicators of our operating performance.

   
For the Three Months Ended,
 
   
March 31, 2018
   
March 31, 2017
 
Number of clinics, at the end of period
   
580
     
558
 
Working Days
   
64
     
64
 
Average visits per day per clinic
   
25.7
     
25.2
 
Total patient visits
   
956,237
     
891,630
 
Net patient revenue per visit
 
$
105.15
   
$
105.04
 

RESULTS OF OPERATIONS

Three Months Ended March 31, 2018 Compared to the Three Months Ended March 31, 2017

·
For the quarter ended March 31, 2018 (“2018 First Quarter”), our Operating Results increased 10.6% to $7.1 million, or $.56 per diluted share, as compared to $6.4 million, or $.51 per diluted share, in the first quarter of 2017 (“2017 First Quarter”).  Operating Results, a non-generally accepted accounting principles (“non-GAAP”) measure, for the 2018 First Quarter equal net income attributable to our shareholders.  For the 2017 First Quarter, Operating Results, was defined as net income attributable to common shareholders prior to interest expense – mandatorily redeemable non-controlling interests – change in redemption value, net of tax.

·
For the 2018 First Quarter, our net income attributable to its shareholders, in accordance with generally accepted accounting principles (“GAAP”), was $7.1 million as compared to $4.8 million for the 2017 First Quarter. Earnings per diluted share of $0.27 in the 2018 First Quarter compares to $0.38 per diluted share for the 2017 First Quarter.  For 2018, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, which is charged directly to retained earnings is included in the earnings per basic and diluted share calculation.  See the schedule below for a computation of basic and diluted earnings per share and a reconciliation of net income attributable to our shareholders to Operating Results.

The following tables provide a detail of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Operating Results. We believe providing Operating Results to investors is useful information for comparing our period-to-period results.

For 2018, Operating Results equal net income attributable to our shareholders and, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation.   For the 2017 First Quarter, Operating Results, a non-GAAP measure, is defined as net income attributable to common shareholders prior to interest expense – mandatorily redeemable non-controlling interests – change in redemption value, net of tax.  Operating Results for the two periods are comparable, however, the calculations differ.  Management uses Operating Results, which eliminates this current non-cash item that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period.  Management believes that Operating Results is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have mandatorily redeemable instruments and therefore have different liability and equity structures.
 
   
Three Months Ended March 31,
 
   
2018
   
2017
 
Computation of earnings per share - USPH shareholders
           
Net income attributable to USPH shareholders
 
$
7,117
   
$
4,816
 
Charges to retained earnings:
               
Revaluation of redeemable non-controlling interest
 
$
(5,081
)
 
$
-
 
Tax effect at statutory rate (federal and state) of 26.25%
   
1,334
     
-
 
   
$
3,370
   
$
4,816
 
                 
Basic and diluted per share
 
$
0.27
   
$
0.38
 
                 
Adjustments:
               
Interest expense MRNCI * - change in redemption value
   
-
     
2,669
 
Revaluation of redeemable non-controlling interest
   
5,090
     
-
 
Tax effect at statutory rate (federal and state) of 26.25% and 39.25%, respectively
   
(1,343
)
   
(1,048
)
Operating results
 
$
7,117
   
$
6,437
 
                 
Basic and diluted operating results per share
 
$
0.56
   
$
0.51
 
                 
Shares used in computation:
               
Basic and diluted
   
12,616
     
12,528
 

Revenues

·
Net revenues increased $10.8 million or 11.0% from $97.6 million in the 2017 First Quarter to $108.3 million in 2018 First Quarter, primarily due to a 7.4% increase in net patient revenues from the physical therapy operations, an increase of 20.4% in revenue from management contracts and an increase in the revenue from the industrial injury prevention business for a full quarter of operations versus one month in the 2017 First Quarter.  The industrial injury prevention business was acquired in March 2017.  (See above discussion under “Executive Summary”).

·
Net patient revenues from physical therapy operations increased approximately $6.9 million, or 7.4%, to $100.6 million in the 2018 First Quarter from $93.7 million in the 2017 First Quarter due to an increase in total patient visits of 7.2% from 892,000 to 956,000 and an increase in the average net patient revenue per visit to $105.15 from $105.04.  Of the $6.9 million increase, $5.9 million related to clinics opened or acquired after April 1, 2017 (“New Clinics”) and an increase of $1.0 million in net patient revenues related to clinics opened or acquired prior to April 1, 2017 (“Mature Clinics”).

·
Revenue from management contracts was $2.2 million in the 2018 First Quarter as compared to $1.9 million for the 2017 First Quarter. The revenue from the industrial injury prevention business was $4.9 million for the 2018 First Quarter compared $1.5 million in the 2017 First Quarter (only one month of operation).  Other revenue was $0.7 million in the 2018 First Quarter and $0.5 million in the 2017 First Quarter.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.
 
Operating Costs

Total operating costs were $85.1 million, or 78.6% of net revenues, in the 2018 First Quarter as compared to $76.8 million, or 78.7% of net revenues, in the 2017 First Quarter. The $8.3 million increase was attributable to $5.5 million in operating costs related to New Clinics, an increase of $2.8 million related to the industrial injury prevention business due to a full quarter of operations and an increase of $0.3 million related to management contracts while Mature Clinics were reduced by a $0.3 million. Each component of operating costs is discussed below:

Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $62.3 million for the 2018 First Quarter from $55.8 million for the 2017 First Quarter, an increase of $6.5 million. Salaries and related costs for New Clinics amounted to $4.0 million for the 2018 First Quarter. Salaries and related costs for the industrial injury prevention business increased by $2.3 million in the 2018 First Quarter compared to the 2017 First Quarter due to a full quarter of operations in the 2018 period.  For Mature Clinics, salaries and related costs increased by $0.2 million for the 2018 First Quarter compared to the 2017 First Quarter. Salaries and related costs as a percentage of net revenues were 57.5% for the 2018 First Quarter and 57.2% for the 2017 First Quarter.

Operating Costs—Rent, Supplies, Contract Labor and Other

Rent, supplies, contract labor and other were $21.8 million for the 2018 First Quarter and $20.1 million for the 2017 First Quarter. For New Clinics, rent, supplies, contract labor and other amounted to $1.9 million for the 2018 First Quarter. Rent, supplies, contract labor and other for the industrial injury prevention business increased by $0.5 million in the 2018 First Quarter compared to the 2017 First Quarter due to a full quarter of operations in the 2018 period. For Mature Clinics, rent, supplies, contract labor and other decreased by $0.7 million in the 2018 First Quarter. Rent, supplies, contract labor and other as a percentage of net revenues was 20.1% for the 2018 First Quarter and 20.6% for the 2017 First Quarter.

Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $1.1 million for both the 2018 First Quarter and $0.9 million for the 2017 First Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.0% for the 2018 First Quarter and 0.9% for the 2017 First Quarter.

Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.1% at March 31, 2018, as compared to 4.9% at December 31, 2017. Our day’s sales outstanding were 40 days at March 31, 2018 and 36 days at December 31, 2017.

Gross Profit

The gross profit for the 2018 First Quarter was $23.2 million, or 21.4% of revenue, as compared to $20.7 million, or 21.3% of revenue, for the 2017 First Quarter. The gross profit percentage for the Company’s physical therapy clinics was 21.9% in the 2018 First Quarter as compared to 21.5% in the 2017 First Quarter. The gross profit percentage on management contracts was 13.8% in the 2018 First Quarter as compared to 14.8% in the 2017 First Quarter. The gross profit percentage for the recently acquired industrial injury prevention business was 15.8% for the recent quarter as compared to 14.3% for the one month of operation in the 2017 First Quarter.

Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $10.2 million for the 2018 First Quarter and $8.5 million for the 2017 First Quarter. As a percentage of net revenues, corporate office costs were 9.4% for the 2018 First Quarter and 8.8% for the 2017 First Quarter.
 
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value and earnings allocable

The Company no longer has mandatorily redeemable non-controlling interests.  As previously mentioned, due to amended partnerships agreements, the redemption values of the mandatorily redeemable non-controlling interests (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet.  For 2017, the earnings and liabilities attributable to mandatorily redeemable non-controlling interests were recorded within the consolidated statements of income line item: Interest expense – mandatorily redeemable non-controlling interests – earnings allocable and in the consolidated balance sheet line item: Mandatorily redeemable non-controlling interests. For 2018, any adjustments in the redemption value, net of tax, are recorded directly to retained earnings and are not reflected in the consolidated statements of income.  Although the adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects the adjustments, net of tax, in the earnings per share calculation.

Interest Expense mandatorily redeemable non-controlling interest – change in redemption value for the 2017 First Quarter was $2.7 million.  The change in redemption value for acquired partnerships was based on the redemption amount (which is derived from a formula based on a specified multiple times the underlying business’ trailing twelve months of earnings before interest, taxes, depreciation, amortization and our internal management fee) at the end of the reporting period compared to the end of the previous period. This change is directly related to an increase or decrease in the profitability and underlying value of the Company’s partnerships as compared to the prior quarter.

For 2018, the amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income in the line item – Net income attributable to non-controlling interests.  For 2017, interest expense – mandatorily redeemable non-controlling interest – earnings allocable, which represent the portion of earnings allocable to the holders of mandatorily redeemable non-controlling interest, was $1.3 million in 2017 First Quarter.

Interest Expense – debt and other

Interest expense increased to $553,000 in the 2018 First Quarter compared to $415,000 in the 2017 First Quarter due to a higher average effective interest rate, inclusive of unused fees, outstanding under our Amended Credit Agreement.  At March 31, 2018, $42.0 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.

Provision for Income Taxes

The provision for income taxes for the 2018 First Quarter was $2.5 million and for the 2017 First Quarter was $1.8 million both inclusive of the reduction of $0.3 million and $0.8 million, respectively, for the excess tax benefit, which is a component of the provision for income taxes, related to equity compensation.  The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest was 25.8% and 27.3%, respectively, for the 2018 First Quarter and 2017 First Quarter.

Non-controlling Interests

Net income attributable to non-controlling interests (permanent equity) was $1.2 million for the 2018 First Quarter and $1.2 million for the 2017 First Quarter. Net income attributable to redeemable non-controlling interests (temporary equity) was $1.7 million in the 2018 First Quarter.  See discussion above.
 
LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At March 31, 2018 and December 31, 2017, we had $19.8 million and $21.9 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, future clinic development and acquisitions and investments through at least March 2019. Significant acquisitions would likely require additional financing.

Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility. This agreement was amended in August 2015, January 2016, March 2017 and November 2017 (hereafter referred to as “Amended Credit Agreement”). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common stockholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.25% to 2.0% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.25% to 0.3% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement.

The January 2016 amendment to the Amended Credit Agreement increased the cash and noncash consideration that we could pay with respect to acquisitions permitted under the Amended Credit Agreement to $50,000,000 for any fiscal year, and increased the amount we may pay in cash dividends to our shareholders in an aggregate amount not to exceed $10,000,000 in any fiscal year.  The March 2017 amendment, among other items, increased the amount we may pay in cash dividends to our shareholders in an aggregate amount not to exceed $15,000,000 in any fiscal year. The November 2017 amendment, among other items, adjusted the pricing grid as described above, increased the aggregate amount we may pay in cash dividends to $20,000,000 to our shareholders and extended the maturity date to November 30, 2021.

Cash and cash equivalents decreased by $2.1 million from December 31, 2017 to March 31, 2018.  During the three months ended March 31, 2018, $15.6 million was provided by operations. The major uses of cash for investing and financing activities included: $12.0 million net reduction of the balance drawn on the line of credit provided in our Amended Credit Agreement, distributions to non-controlling interests, inclusive of those classified as redeemable non-controlling interests, ($2.2 million), purchases of fixed assets ($1.4 million), payments on notes payable ($0.8 million), purchases of businesses ($0.8 million), payments to settle mandatorily redeemable non-controlling interests ($0.3 million) and purchase of non-controlling interest ($0.2 million).

On March 1, 2018, through one of our majority owned partnerships, we acquired the assets and business of two physical therapy clinics, for an aggregate purchase price of $760,000 in cash and $150,000 in seller note that is payable, plus accrued interest, on August 31, 2019.

On January 1, 2017, we acquired a 70% interest in a seventeen-clinic physical therapy practice.  The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that was payable in two principal installments totaling $250,000 each, plus accrued interest.  The first installment was paid in January 2018 and the second installment is due in January 2019.

On May 31, 2017, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, in May 2018 and 2019.

On June 30, 2017, we acquired a 60% interest in a nine-clinic physical therapy practice.  The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in June 2018 and 2019.

On October 31, 2017, we acquired a 70% interest in a nine-clinic physical therapy practice and two management contracts with third party providers.  The purchase price for the 70% interest was $4.0 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in October 2018 and 2019.
 
Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.

We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.

We generally enter into various notes payable as a means of financing our acquisitions. Our outstanding notes payable as of March 31, 2018 relate to certain of the acquisitions of businesses, purchases of non-controlling interests and settlements of mandatorily redeemable non-controlling interests that occurred in 2015 through March 2018. Typically, the notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 4.5% per annum, subject to adjustment. At March 31, 2018, the balance on these notes payable was $6.1 million.  In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities.

In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after a specified date that is between three and five years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.

As of March 31, 2018, we have accrued $3.8 million related to credit balances due to patients and payors.  This amount is expected to be paid in the next twelve months.

From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). Our Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. We are required to retire shares purchased under the March 2009 Authorization.

There is no expiration date for the share repurchase program. As of March 31, 2018, there are currently an additional estimated 184,502 shares (based on the closing price of $81.30 on March 31, 2018)  that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the three months ended March 31, 2018.
 
FACTORS AFFECTING FUTURE RESULTS

The risks related to our business and operations include:

  ·
changes as the result of government enacted national healthcare reform;
·
changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
·
revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
·
business and regulatory conditions including federal and state regulations;
·
governmental and other third party payor inspections, reviews, investigations and audits;
·
compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
·
changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
·
revenue and earnings expectations;
·
cost, risks and uncertainties associated with the Company’s recent restatement of its prior financial statements due to the correction of its accounting methodology for redeemable noncontrolling partnership interests, and including any pending and future claims or proceedings relating to such matters;
·
legal actions, which could subject us to increased operating costs and uninsured liabilities;
·
general economic conditions;
·
availability and cost of qualified physical therapists;
·
personnel productivity and retaining key personnel;
·
competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
·
acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
·
maintaining our information technology systems with adequate safeguards to protect against cyber attacks;
·
maintaining adequate internal controls;
·
maintaining necessary insurance coverage;
·
availability, terms, and use of capital; and
·
weather and other seasonal factors.

See Risk Factors in Item 1A of our Annual Report on Form 10-K.

Forward-Looking Statements

We make statements in this report that are considered to be forward-looking statements within the meaning given such term under Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment.  The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to the risks listed above.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.
 
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Amended Credit Agreement. The interest on our Amended Credit Agreement is based on a variable rate. At March 31, 2018, $42.0 million was outstanding under our Amended Credit Agreement. Based on the balance of the Amended Credit Agreement at March 31, 2018, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $420,000.

ITEM 4.
CONTROLS AND PROCEDURES.

(a)
Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.

(b)
Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1.
LEGAL PROCEEDINGS.

We are involved in litigation and other proceedings arising in the ordinary course of business.

In addition, on March 31, 2017, an alleged shareholder filed a putative class action lawsuit in the United States District Court for the Southern District of New York (the “Court”) against the Company, chief executive officer Christopher J. Reading, chief financial officer Lawrance C. McAfee and corporate controller Jon C. Bates, alleging, inter alia, that the defendants misstated or omitted to state material information concerning the Company’s historical accounting for redeemable non-controlling interests of acquired partnerships, in alleged violation of Sections 10(b) and 20(a) of the Exchange Act. The complaint seeks a declaration that the action is a proper class action under Rule 23 of the Federal Rules of Civil Procedure, unspecified compensatory damages in an amount to be determined at trial and interest, costs and expenses.  On June 26, 2017, the Court appointed a lead plaintiff in the matter. On July 31, 2017, the lead plaintiff filed an amended complaint, alleging substantially the same violations and seeking substantially the same unspecified damages. The amended complaint also names Glenn McDowell, the Company’s Co-Chief Operating Officer, as an additional defendant. On December 1, 2017, the Company filed a Motion to Dismiss and subsequent filings related to the Motion to Dismiss were completed on February 7, 2018. The Motion to Dismiss is currently pending before the Court.
 
While the ultimate outcome of lawsuits or other proceedings cannot be predicted with certainty, we do not believe the impact of existing lawsuits or other proceedings will have a material impact on our business, financial condition or results of operations.
 
ITEM 6.
EXHIBITS.

Exhibit
Number
Description
   
10.1
Employment Agreement commencing on March 1, 2018 by and between the Company and Graham Reeve (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 7, 2018).
   
31.1*
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
   
31.2*
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
   
31.3*
Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller.
   
32*
Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS*
XBRL Instance Document
   
101.SCH*
XBRL Taxonomy Extension Schema Document
   
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF*
XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document

*
Filed herewith
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.

 
U.S. PHYSICAL THERAPY, INC.
     
Date: May 7, 2018
By:
/s/ LAWRANCE W. MCAFEE
   
Lawrance W. McAfee
   
Chief Financial Officer
   
(duly authorized officer and principal financial and accounting officer)
     
 
By:
 /s/ JON C. BATES
   
Jon C. Bates
   
Vice President/Corporate Controller
 
INDEX OF EXHIBITS

Exhibit
Number
Description
   
Employment Agreement commencing on March 1, 2018 by and between the Company and Graham Reeve (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 7, 2018).
   
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
   
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
   
Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller.
   
Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS*
XBRL Instance Document
   
101.SCH*
XBRL Taxonomy Extension Schema Document
   
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF*
XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document

*
Filed herewith

 
36

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

EXHIBIT 31.1
CERTIFICATION

I, Christopher Reading, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of U.S. Physical Therapy, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
/s/ CHRISTOPHER READING
 
Christopher Reading
 
President and Chief Executive Officer
 
(principal executive officer)

Date: May 7, 2018
 
 

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

EXHIBIT 31.2
CERTIFICATION

I, Lawrance W. McAfee, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of U.S. Physical Therapy, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
/s/ LAWRANCE W. MCAFEE
 
Lawrance W. McAfee
 
Chief Financial Officer
 
(principal financial and accounting officer)

Date: May 7, 2018
 
 

EX-31.3 4 ex31_3.htm EXHIBIT 31.3

EXHIBIT 31.3
CERTIFICATION

I, Jon C. Bates, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of U.S. Physical Therapy, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
/s/ JON C. BATES
 
Jon C. Bates
 
Vice President/Corporate Controller

Date: May 7, 2018
 
 

EX-32 5 ex32.htm EXHIBIT 32

EXHIBIT 32
CERTIFICATION OF PERIODIC REPORT

In connection with the Quarterly Report of U.S. Physical Therapy, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher J. Reading, President and Chief Executive Officer of the Company, Lawrance W. McAfee, Chief Financial Officer of the Company, and Jon C. Bates, Vice President and Corporate Controller of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 7, 2018

/s/ CHRISTOPHER J. READING
 
Christopher J. Reading
 
Chief Executive Officer
 
   
/s/ LAWRANCE W. MCAFEE
 
Lawrance W. McAfee
 
Chief Financial Officer
 
   
/s/ JON C. BATES
 
Jon C. Bates
 
Vice President/Corporate Controller
 

This certification is made solely pursuant to the requirement of Section 1350 of 18 U.S.C., and is not for any other purpose. A signed original of this written statement required by Section 906 has been provided to U. S. Physical Therapy, Inc. and will be retained by U. S. Physical Therapy, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 
 

EX-101.INS 6 usph-20180331.xml XBRL INSTANCE DOCUMENT 0000885978 2018-01-01 2018-03-31 0000885978 2018-05-07 0000885978 2017-12-31 0000885978 2018-03-31 0000885978 usph:NetPatientRevenuesMember 2018-01-01 2018-03-31 0000885978 2017-01-01 2017-03-31 0000885978 usph:NetPatientRevenuesMember 2017-01-01 2017-03-31 0000885978 usph:OtherRevenuesIncludingManagementContractRevenuesAndIndustrialInjuryPreventionServicesRevenuesMember 2017-01-01 2017-03-31 0000885978 usph:OtherRevenuesIncludingManagementContractRevenuesAndIndustrialInjuryPreventionServicesRevenuesMember 2018-01-01 2018-03-31 0000885978 2016-12-31 0000885978 2017-03-31 0000885978 us-gaap:TreasuryStockMember 2017-12-31 0000885978 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000885978 us-gaap:ParentMember 2017-12-31 0000885978 us-gaap:NoncontrollingInterestMember 2017-12-31 0000885978 us-gaap:CommonStockMember 2017-12-31 0000885978 us-gaap:RetainedEarningsMember 2017-12-31 0000885978 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000885978 us-gaap:ParentMember 2018-01-01 2018-03-31 0000885978 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000885978 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000885978 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000885978 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-03-31 0000885978 us-gaap:TreasuryStockMember 2018-03-31 0000885978 us-gaap:CommonStockMember 2018-03-31 0000885978 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000885978 us-gaap:RetainedEarningsMember 2018-03-31 0000885978 us-gaap:NoncontrollingInterestMember 2018-03-31 0000885978 us-gaap:ParentMember 2018-03-31 0000885978 us-gaap:MinimumMember 2018-01-01 2018-03-31 0000885978 us-gaap:MaximumMember 2018-01-01 2018-03-31 0000885978 us-gaap:SubsequentEventMember usph:LeadingProviderOfIndustrialInjuryPreventionMember 2018-04-30 0000885978 usph:MarchTwoThousandSeventeenAcquisitionMember 2018-03-31 0000885978 2017-01-01 2017-12-31 0000885978 2018-02-28 2018-02-28 0000885978 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0000885978 us-gaap:MinimumMember us-gaap:LeaseholdImprovementsMember 2018-01-01 2018-03-31 0000885978 us-gaap:MaximumMember us-gaap:LeaseholdImprovementsMember 2018-01-01 2018-03-31 0000885978 us-gaap:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2018-01-01 2018-03-31 0000885978 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0000885978 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0000885978 us-gaap:SubsequentEventMember usph:LeadingProviderOfIndustrialInjuryPreventionMember 2018-04-30 2018-04-30 0000885978 us-gaap:OfficerMember 2018-01-01 2018-03-31 0000885978 usph:EmployeeMember 2018-01-01 2018-03-31 0000885978 us-gaap:DirectorMember 2018-01-01 2018-03-31 0000885978 usph:JuneTwoThousandSeventeenAcquisitionMember 2017-01-01 2017-12-31 0000885978 usph:OctoberTwoThousandSeventeenAcquisitionMember 2017-01-01 2017-12-31 0000885978 usph:MayTwoThousandSeventeenAcquisitionMember 2017-01-01 2017-12-31 0000885978 usph:JanuaryTwoThousandSeventeenAcquisitionMember 2017-01-01 2017-12-31 0000885978 usph:JuneTwoThousandSeventeenAcquisitionMember 2017-12-31 0000885978 usph:OctoberTwoThousandSeventeenAcquisitionMember 2017-12-31 0000885978 usph:MayTwoThousandSeventeenAcquisitionMember 2017-12-31 0000885978 usph:JanuaryTwoThousandSeventeenAcquisitionMember 2017-12-31 0000885978 usph:AcquisitionOfTwoClinicPracticesMember 2018-02-28 2018-02-28 0000885978 usph:AcquisitionOfNineClinicPracticesMember 2017-06-30 2017-06-30 0000885978 usph:AcquisitionOfFourClinicPracticesMember 2017-05-31 2017-05-31 0000885978 usph:AcquisitionOfSeventeenClinicPracticesMember 2017-01-01 2017-01-01 0000885978 usph:AcquisitionOfNineClinicPracticesMember 2017-10-31 2017-10-31 0000885978 usph:AcquisitionOfSeventeenClinicPracticesMember 2016-12-31 0000885978 usph:AcquisitionOfFourClinicPracticesMember 2017-05-31 0000885978 usph:AcquisitionOfNineClinicPracticesMember 2017-06-30 0000885978 usph:WorkforcePerformanceSolutionsMember 2017-03-23 0000885978 usph:AcquisitionOfNineClinicPracticesMember 2017-10-31 0000885978 usph:WorkforcePerformanceSolutionsMember 2017-03-23 2017-03-23 0000885978 usph:AcquisitionOfFourClinicPracticesMember usph:MayTwoThousandEighteenMember 2017-05-31 2017-05-31 0000885978 usph:JuneTwoThousandNineteenMember usph:AcquisitionOfNineClinicPracticesMember 2017-06-30 2017-06-30 0000885978 usph:JuneTwoThousandEighteenMember usph:AcquisitionOfNineClinicPracticesMember 2017-06-30 2017-06-30 0000885978 usph:OctoberTwoThousandNineteenMember usph:AcquisitionOfNineClinicPracticesMember 2017-10-31 2017-10-31 0000885978 usph:OctoberTwoThousandEighteenMember usph:AcquisitionOfNineClinicPracticesMember 2017-10-31 2017-10-31 0000885978 usph:AcquisitionOfSeventeenClinicPracticesMember usph:JanuaryTwoThousandEighteenMember 2017-01-01 2017-01-01 0000885978 usph:JanuaryTwoThousandNineteenMember usph:AcquisitionOfSeventeenClinicPracticesMember 2017-01-01 2017-01-01 0000885978 usph:AcquisitionOfFourClinicPracticesMember usph:MayTwoThousandNineteenMember 2017-05-31 2017-05-31 0000885978 us-gaap:MinimumMember usph:ReferralRelationshipMember 2018-01-01 2018-03-31 0000885978 usph:ReferralRelationshipMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0000885978 us-gaap:MinimumMember us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-03-31 0000885978 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0000885978 2018-02-28 0000885978 usph:ManagementContractRevenuesMember 2018-01-01 2018-03-31 0000885978 usph:IndustrialInjuryPreventionServicesRevenuesMember 2018-01-01 2018-03-31 0000885978 usph:IndustrialInjuryPreventionServicesRevenuesMember 2017-01-01 2017-03-31 0000885978 usph:ManagementContractRevenuesMember 2017-01-01 2017-03-31 0000885978 usph:OtherRevenuesMember 2017-01-01 2017-03-31 0000885978 usph:OtherRevenuesMember 2018-01-01 2018-03-31 0000885978 usph:Year2018Member 2018-01-01 2018-03-31 0000885978 usph:Year2019Member 2018-01-01 2018-03-31 0000885978 usph:FromTwoThousandTwentyThroughTwoThousandTwentyFiveMember 2018-01-01 2018-03-31 0000885978 usph:FromTwoThousandNineteenThroughTwoThousandTwentyFourMember 2018-01-01 2018-03-31 0000885978 2015-11-02 0000885978 2018-02-09 0000885978 2013-04-01 0000885978 usph:Year2017Member us-gaap:MaximumMember 2018-01-01 2018-03-31 0000885978 usph:TherapyPracticeMember us-gaap:SubsidiariesMember 2017-06-30 0000885978 us-gaap:MaximumMember usph:TherapyPracticeMember 2017-06-30 0000885978 us-gaap:MinimumMember usph:TherapyPracticeMember 2017-06-30 0000885978 usph:TherapyPracticeMember us-gaap:SubsidiariesMember 2018-01-01 2018-03-31 0000885978 usph:TherapyPracticeMember us-gaap:MaximumMember us-gaap:SubsidiariesMember 2018-01-01 2018-03-31 0000885978 us-gaap:MinimumMember us-gaap:SubsidiariesMember usph:TherapyPracticeMember 2018-01-01 2018-03-31 0000885978 usph:RedeemableNonControllingInterestMember 2017-12-31 0000885978 usph:RedeemableNonControllingInterestMember 2018-01-01 2018-03-31 0000885978 usph:RedeemableNonControllingInterestMember 2018-03-31 0000885978 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000885978 usph:ReferralRelationshipMember 2018-03-31 0000885978 usph:ReferralRelationshipMember 2017-12-31 0000885978 us-gaap:NoncompeteAgreementsMember 2018-03-31 0000885978 us-gaap:TrademarksMember 2018-03-31 0000885978 us-gaap:TrademarksMember 2017-12-31 0000885978 usph:ReferralRelationshipMember 2018-01-01 2018-03-31 0000885978 us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-03-31 0000885978 usph:ReferralRelationshipMember 2017-01-01 2017-03-31 0000885978 us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-03-31 0000885978 usph:PromissoryNotesMember 2017-12-31 0000885978 us-gaap:RevolvingCreditFacilityMember 2017-12-31 0000885978 usph:PromissoryNotesMember 2018-03-31 0000885978 us-gaap:RevolvingCreditFacilityMember 2018-03-31 0000885978 us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-03-31 0000885978 us-gaap:MinimumMember usph:PromissoryNotesMember 2018-03-31 0000885978 usph:PromissoryNotesMember us-gaap:MaximumMember 2018-03-31 0000885978 us-gaap:RevolvingCreditFacilityMember 2013-12-05 0000885978 us-gaap:MinimumMember 2018-03-31 0000885978 us-gaap:MaximumMember 2018-03-31 0000885978 usph:CreditAgreementMember 2016-01-01 2016-01-31 0000885978 us-gaap:MaximumMember usph:CreditAgreementMember 2017-11-01 2017-11-30 0000885978 usph:CreditAgreementMember us-gaap:MaximumMember 2017-03-01 2017-03-31 0000885978 usph:CreditAgreementMember us-gaap:MaximumMember 2016-01-01 2016-01-31 0000885978 usph:NotesPayableMember usph:TwoThousandSeventeenAcquisitionMember 2018-03-31 0000885978 usph:NotesPayableMember usph:TwoThousandEighteenAcquisitionMember 2018-02-28 0000885978 us-gaap:MaximumMember usph:NotesPayableMember 2018-01-01 2018-03-31 0000885978 usph:NotesPayableMember usph:TwoThousandEighteenAcquisitionMember 2018-02-28 2018-02-28 0000885978 usph:NotesPayableMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0000885978 usph:NotesPayableMember usph:TwoThousandSeventeenAcquisitionMember 2018-01-01 2018-01-31 0000885978 2008-12-31 0000885978 2009-03-31 0000885978 us-gaap:MaximumMember 2009-03-31 0000885978 2009-03-01 2009-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure usph:Clinic usph:State usph:Facility usph:Segment usph:Region usph:Contract usph:Installment false --12-31 2018-03-31 No No Yes Accelerated Filer U S PHYSICAL THERAPY INC /NV 0000885978 12669538 2018 Q1 10-Q 2165000 1722000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">9. ACCRUED EXPENSES</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accrued expenses as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Salaries and related costs</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">22,677</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,828</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Credit balances due to patients and payors</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,841</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,158</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Group health insurance claims</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,637</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,929</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Income taxes payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,139</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,833</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Dividend payable to USPH shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,914</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,594</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38,342</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33,342</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> 5655000 6504000 46228000 44707000 2833000 2139000 2637000 2929000 38342000 33342000 61742000 60475000 75543000 73940000 1381000 0 1381000 0 1381000 0 0 2517000 2273000 520000 197000 717000 458000 195000 653000 418982000 417622000 75595000 77081000 6048000 1642000 9000000 2017-06-30 2017-10-31 2017-05-31 2017-01-01 0.65 0.55 0.6 0.7 0.7 0.7 0.7 0.7 0.6 0.55 0.7 856000 45868000 -2909000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2. ACQUISITIONS OF BUSINESSES</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On February 28, 2018, the Company purchased the assets and business of two physical therapy clinics, for an aggregate purchase price of $760,000 in cash and $150,000 in seller note that is payable, plus accrued interest, on August 31, 2019.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The purchase price for this acquisition has been preliminarily allocated as follows (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash paid</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">760</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Seller note</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">150</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total consideration</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">910</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">36</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">18</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">910</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On January 1, 2017, the Company acquired a 70% interest in a seventeen-clinic physical therapy practice.&#160; The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that was payable in two principal installments totaling $250,000 each, plus accrued interest.&#160; The first installment was paid in January 2018 and the second installment is due in January 2019.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On May 31, 2017, the Company acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, in May 2018 and 2019.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On June 30, 2017, the Company acquired a 60% interest in a nine-clinic physical therapy practice.&#160; The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in June 2018 and 2019.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On October 31, 2017, the Company acquired a 70% interest in a nine-clinic physical therapy practice and two management contracts with third party providers.&#160; The purchase price for the 70% interest was $4.0 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in October 2018 and 2019.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In addition to the above, as previously mentioned in March 2017, the Company acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. The purchase price for the 55% interest was $6.2 million in cash and $0.4 million in a seller note that is payable, principal plus accrued interest, in September 2018. Also, in 2017, the Company purchased the assets and business of two physical therapy clinics in separate transactions. One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing partnerships.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The results of operations of the acquired clinics have been included in the Company&#8217;s consolidated financial statements since the date of their respective acquisition.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The purchase price for the 2017 acquisitions has been preliminarily allocated as follows (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash paid, net of cash acquired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">36,682</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Seller notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,150</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total consideration</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38,832</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Estimated fair value of net tangible assets acquired:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total current assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,048</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total non-current assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,642</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,909</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Net tangible assets acquired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,781</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,085</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,224</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tradename</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,039</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">45,868</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value of non-controlling interest (classified as redeemable non-controlling interests)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(13,883</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value of non-controlling interest (originally classified as mandatorily redeemable non-controlling interests)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(10,282</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38,832</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The purchase prices plus the fair value of the non-controlling interests for the acquisitions in first quarter of 2017 were allocated to the fair value of the assets acquired, inclusive of identifiable intangible assets, i.e. trade names, referral relationships and non-compete agreements, and liabilities assumed based on the fair values at the acquisition date, with the amount exceeding the fair values being recorded as goodwill are finalized. For the acquisitions occurring on or after April 1, 2017, the Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and identifiable intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used at March 31, 2018 based on additional information obtained and completion of the valuation of the identifiable intangible assets. Changes in the estimated valuation of the tangible assets acquired, the completion of the valuation of identifiable intangible assets and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For the acquisitions in 2017, the values assigned to the referral relationships and non-compete agreements are being amortized to expense equally over the respective estimated lives. For referral relationships, the range of the estimated lives was 7&#189; to 11 years, and for non-compete agreements the estimated lives were five to six years. Generally, the values assigned to tradenames are tested annually for impairment,</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For the 2017 acquisitions, total current assets primarily represent patient accounts receivable. Total non-current assets are fixed assets, primarily equipment, used in the practices.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The consideration paid for each of the acquisitions was derived through arm&#8217;s length negotiations. Funding for the cash portions was derived from proceeds from the Company&#8217;s revolving credit facility. The results of operations of the acquisitions have been included in the Company&#8217;s consolidated financial statements since their respective date of acquisition. Unaudited proforma consolidated financial information for the acquisitions in 2018, and 2017 acquisitions have not been included as the results, individually and in the aggregate, were not material to current operations.</div></div> 10282000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Cash Equivalents</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company maintains its cash and cash equivalents at financial institutions.&#160; The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&#160; The combined account balances at several institutions typically exceed Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance coverage and, as a result, there is a concentration of credit risk related on deposits in excess of FDIC insurance coverage. Management believes that the risk is not significant.</div></div> 21933000 19813000 20047000 25154000 5107000 -2120000 0.23 0.20 20000000 20000000 14884676 14809299 0.01 0.01 148000 149000 76818000 85128000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details the revenue related to the various categories:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net patient revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">93,654</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Management contract revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,236</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,857</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Industrial injury prevention services revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,852</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,506</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">702</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">548</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">108,342</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">97,565</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> 0.001 0.010 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">10. NOTES PAYABLE AND AMENDED CREDIT AGREEMENT</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Amounts outstanding under the Amended Credit Agreement and notes payable as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Credit Agreement average effective interest rate of 3.8% inclusive of unused fee</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">54,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Various notes payable with $5,317 plus accrued interest due in the next year, interest accrues in the range of 3.25% through 4.25% per annum</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,099</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,772</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,099</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">60,772</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Less current portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(5,317</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4,044</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Long term portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">56,728</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Effective December 5, 2013, the Company entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility. This agreement was amended in August 2015, January 2016, March 2017 and November 2017 (hereafter referred to as &#8220;Amended Credit Agreement&#8221;). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of the Company&#8217;s common stock, dividend payments to the Company&#8217;s common stockholders, capital expenditures and other corporate purposes. The pricing grid which is based on the Company&#8217;s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.25% to 2.0% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.25% to 0.3% depending on the Company&#8217;s consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The January 2016 amendment to the Amended Credit Agreement increased the cash and noncash consideration that the Company could pay with respect to acquisitions permitted under the Amended Credit Agreement to $50,000,000 for any fiscal year, and increased the amount the Company may pay in cash dividends to its shareholders in an aggregate amount not to exceed $10,000,000 in any fiscal year.&#160; The March 2017 amendment, among other items, increased the amount the Company may pay in cash dividends to its shareholders in an aggregate amount not to exceed $15,000,000 in any fiscal year. The November 2017 amendment, among other items, adjusted the pricing grid as described above, increased the aggregate amount the Company may pay in cash dividends to its shareholders to an amount not to exceed $20,000,000 and extended the maturity date to November 30, 2021.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On March 31, 2018, $42.0 million was outstanding on the Amended Credit Agreement resulting in $83.0 million of availability. As of March 31, 2018 and the date of this report, the Company was in compliance with all of the covenants thereunder.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company generally enters into various notes payable as a means of financing a portion of its acquisitions and purchases of non-controlling interests. In conjunction with the acquisition of the two clinic practices on February 28, 2018, the Company entered into a note payable in the amount of $150,000, which is payable on August 31, 2019.&#160; Interest accrues at the rate of 4.5% per annum and is payable on August 31, 2019.&#160; In conjunction with the acquisitions in 2017, the Company entered into notes payable in the aggregate amount of $2.2 million of which an aggregate principal payment of $1.3 million is due in 2018 (of which $250,000 was paid in January 2018) and $0.9 million in 2019.&#160;&#160; Interest accrues in the range of 3.25% to 4.0% per annum and is payable with each principal installment.</div><div style="text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Aggregate annual payments of principal required pursuant to the Amended Credit Agreement and the above notes payable subsequent to March 31, 2018 are as follows (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 70%;"><tr><td valign="bottom" style="width: 58%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,317</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2021</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2022</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,099</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The revolving credit facility (balance at March 31, 2018 of $42.0 million) matures on November 30, 2021.</div></div> 2021-11-30 0.0325 0.0425 2200000 150000 5317000 P4Y P4Y P1Y -1162000 -250000 2116000 2005000 10875000 10151000 2468000 2356000 0 2914000 2914000 0 2914000 0 0 0 2914000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">4. EARNINGS PER SHARE</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following tables provide a detail of the basic and diluted earnings per share computation.&#160; In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest (see Footnote 6), net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Computation of earnings per share - USPH shareholders</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income attributable to USPH shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,117</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,816</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Charges to retained earnings:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Revaluation of redeemable non-controlling interest</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(5,081</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: middle; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Tax effect at statutory rate (federal and state) of 26.25%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,334</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,370</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,816</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: middle; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Basic&#160;and diluted per share</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">0.27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">0.38</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> 0.38 0.27 0.21 22677000 16828000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Fair Value of Financial Instruments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount under the Amended Credit Agreement approximates its fair value. The interest rate on the Amended Credit Agreement, which is tied to the Eurodollar Rate, is set at various short-term intervals, as detailed in the Amended Credit Agreement.</div></div> 143000 1917000 766000 2068000 403000 1965000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details the amount of amortization expense recorded for intangible assets for the three months ended March 31, 2018 and 2017 (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td valign="bottom" style="width: 56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">520</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">458</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete agreements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">197</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">717</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">653</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> 5358000 7729000 4100000 7209000 4297000 1809000 3000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The purchase price for this acquisition has been preliminarily allocated as follows (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash paid</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">760</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Seller note</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">150</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total consideration</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">910</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">36</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">18</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">910</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The purchase price for the 2017 acquisitions has been preliminarily allocated as follows (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash paid, net of cash acquired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">36,682</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Seller notes</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,150</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total consideration</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38,832</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Estimated fair value of net tangible assets acquired:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total current assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,048</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total non-current assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,642</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(2,909</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Net tangible assets acquired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,781</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,085</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,224</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tradename</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,039</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">45,868</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value of non-controlling interest (classified as redeemable non-controlling interests)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(13,883</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value of non-controlling interest (originally classified as mandatorily redeemable non-controlling interests)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(10,282</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38,832</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> P6Y P16Y P5Y P6Y 481000 1965000 1965000 693000 51569000 51100000 -33000 -54000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">7. GOODWILL</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The changes in the carrying amount of goodwill consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Beginning balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">271,338</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill acquired during the year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill adjustments for purchase price allocation of businesses acquired in prior year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,576</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Ending balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">273,770</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div> 271338000 273770000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Goodwill</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain identifiable intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management&#8217;s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The fair value of goodwill and other identifiable intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company evaluates indefinite lived tradenames using the relief from royalty method in conjunction with its annual goodwill impairment test.&#160; The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining the Company&#8217;s reporting units when performing its annual goodwill impairment test. In the first quarter of 2018, there were six regions.&#160; In addition to the six regions, in 2017, the impairment test included a separate analysis for the industrial injury prevention business, a separate reporting unit.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other identifiable intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2017, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation of goodwill in 2017, 2016 and 2015 did not result in any goodwill amounts that were deemed impaired.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has not identified any triggering events occurring after the testing date that would impact the impairment testing results obtained.&#160; The Company will continue to monitor for any triggering events or other indicators of impairment.</div></div> 856000 1576000 20747000 23214000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Long-Lived Assets</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for purchased software from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</div></div> 12530000 7846000 1812000 2476000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Income Taxes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;) was passed by Congress on December 20, 2017 and signed into law by President Trump on December 22, 2017. The TCJA makes significant changes to U.S. corporate income tax laws including a decrease in the corporate income tax rate to 21% effective January 1, 2018.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the twelve months ended March 31, 2018. The Company will book any interest or penalties, if required, in interest and other expense, as appropriate.</div></div> 86000 2941000 849000 3697000 1542000 2782000 7389000 5315000 1238000 -757000 76000 -845000 48954000 47092000 2470000 16527000 16811000 2292000 28273000 29673000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">8. INTANGIBLE ASSETS, NET</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Intangible assets, net as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tradenames</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">28,273</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">29,673</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships, net of accumulated amortization of $7,729 and $7,209, respectively</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,527</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,811</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete agreements, net of accumulated amortization of $4,297 and $4,100, respectively</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,292</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,470</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">47,092</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,954</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div style="text-align: left;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Tradenames, referral relationships and non-compete agreements are related to the businesses acquired. Typically, the value assigned to tradenames has an indefinite life and is tested at least annually for impairment using the relief from royalty method in conjunction with the Company&#8217;s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non-compete agreements are amortized over the respective term of the agreements which range from five to six years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details the amount of amortization expense recorded for intangible assets for the three months ended March 31, 2018 and 2017 (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%;"><tr><td valign="bottom" style="width: 56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">520</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">458</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete agreements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">197</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">717</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">653</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Based on the balance of referral relationships and non-compete agreements as of March 31, 2018, the expected amount to be amortized in 2018 and thereafter by year is as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td colspan="4" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Referral Relationships</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Non-Compete Agreements</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Years</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: right;">Annual Amount</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Years</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: right;">Annual Amount</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Ending December 31,</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Ending December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">766</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,965</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2019</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">693</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,965</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2020</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">481</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2021</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,965</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2021</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">403</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2022</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,917</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2022</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">143</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2023</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,809</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,358</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 29%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> 32000 24000 0 4378000 553000 526000 599000 62279000 55827000 29981000 29760000 418982000 417622000 101052000 110340000 39551000 45381000 0.0030 0.0025 125000000 83000000 0.038 0.0400 0.045 0.0325 6772000 48099000 54000000 6099000 60772000 42000000 42000000 0 5317000 4044000 1300000 5317000 2728000 782000 42782000 56728000 900000 782000 54000000 42000000 0 0 -193000 -151000 -151000 -42000 0 1204000 1514000 0 0 849000 0 0 0 849000 -15240000 8131000 1736000 7117000 0 8318000 0 1201000 0 7117000 -17195000 -2411000 15531000 14171000 4816000 7117000 1218000 2937000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Recently Adopted Accounting Guidance</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively &#8220;the standards&#8221;), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The original standards were effective for fiscal years beginning after December 15, 2016; however, in July 2015, the FASB approved a one-year deferral of these standards, with a new effective date for fiscal years beginning after December 15, 2017. The standards require the selection of a retrospective or cumulative effect transition method.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company implemented the new standard beginning January 1, 2018 using a modified retrospective transition method.&#160; Adoption of the new standard did not result in material changes to the presentation of net revenues and bad debt expense in the consolidated statements of income, and the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change relates to how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common forms of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company&#8217;s estimate for unrealizable amounts is recorded as a reduction of revenue. Under the new standards, the Company&#8217;s estimate for unrealizable amounts will continue to be recognized as a reduction to revenue. The bad debt expense historically reported will not materially change.</div></div> 1 2 2 9 9 4 17 2 9 4 17 9 2 42 55000 5081000 12200000 13051000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries (the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest in all the Clinic Partnerships. Our limited partnership interests range from 49% to 99% in the Clinic Partnerships.&#160; The managing therapist of each clinic owns, directly or indirectly, the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as &#8220;Clinic Partnerships&#8221;). To a lesser extent, the Company operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with therapists (hereinafter referred to as &#8220;Wholly-Owned Facilities&#8221;).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In March 2017, the Company acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. Services provided include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers including a number of Fortune 500 companies. Other clients include large insurers and their contractors.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company continues to seek to attract for employment physical therapists who have established relationships with physicians and other referral sources by offering these therapists a competitive salary and incentives based on the profitability of the clinic that they manage. The Company also looks for therapists with whom to establish new, de novo clinics to be owned jointly by the Company and such therapists&#894; in these situations, the therapist is offered the opportunity to co-invest in the new clinic and also receives a competitive salary for managing the clinic. For multi-site clinic practices in which a controlling interest is acquired by the Company, the prior owners typically continue on as employees to manage the clinic operations, retaining a non-controlling ownership interest in the clinics and receiving a competitive salary for managing the clinic operations. In addition, the Company has developed satellite clinic facilities as part of existing Clinic Partnerships and Wholly-Owned facilities, with the result that a substantial number of Clinic Partnerships and Wholly-Owned facilities operate more than one clinic location. In 2018, we intend to continue to acquire clinic practices and continue to focus on developing new clinics and opening satellite clinics where appropriate, along with increasing our patient volume through marketing and new programs.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On February 28, 2018, the Company, through one of its majority owned Clinic Partnerships, acquired two clinic practices.&#160; These practices will operate as satellites of the existing Clinic Partnership.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">During the year ended December 31, 2017, the Company acquired an interest in the following clinic groups:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;">Date</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">% Interest Acquired</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Number of Clinics</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">January 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">January 1</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">70%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">17</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">May 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">May 31</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">70%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">June 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">June 30</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">60%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">October 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">October 31</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">70%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Also, during the 2017 year, the Company purchased the assets and business of two physical therapy clinics in separate transactions.&#160; One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing Clinic Partnerships.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">As of March 31, 2018, the Company operated 580 clinics in 42 states as well as the industrial injury prevention business.&#160; The Company also manages physical therapy facilities for third parties, primarily physicians, with 28 third-party facilities under management as of March 31, 2018.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The results of operations of the acquired clinics have been included in the Company&#8217;s consolidated financial statements since the date of their respective acquisition.&#160; The Company intends to continue to pursue additional acquisition opportunities, develop new clinics and open satellite clinics.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The accompanying unaudited consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions for Form 10-Q. However, the statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. Management believes this report contains all necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all material respects, the Company&#8217;s financial position, results of operations and cash flows for the interim periods presented. For further information regarding the Company&#8217;s accounting policies, please read the audited financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate Controller have certified, that the financial statements included in this report present fairly, in all material respects, the Company&#8217;s financial position, results of operations and cash flows for the interim periods presented.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results the Company expects for the entire year.&#160; Please also review the Risk Factors section included in our Annual Report on Form 10-K for the year ended December 31, 2017.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Clinic Partnerships</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For non-acquired Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interests, typically owned by the managing therapist, directly or indirectly, are recorded within the balance sheets and income statements as non-controlling interests.&#160; For acquired Clinic Partnerships with mandatorily redeemable non-controlling interests, the earnings and liabilities attributable to the non-controlling interest were recorded within the consolidated statements of income line item: <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Interest expense &#8211; mandatorily redeemable non-controlling interests &#8211; earnings allocable</font> and in the consolidated balance sheet line item: <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Mandatorily redeemable non-controlling interests</font>.&#160; For acquired Clinic Partnerships with redeemable non-controlling interests, the earnings attributable to the redeemable non-controlling interests are recorded within the consolidated statements of income line item &#8211; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">net income attributable to non-controlling interests</font> and the equity interests are recorded on the consolidated balance sheet as <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">redeemable non-controlling interests</font>.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Effective December 31, 2017, the Company entered into amendments to its acquired limited partnership agreements replacing the mandatory redemption feature. No monetary consideration was paid to the partners to amend the agreements.&#160;&#160; The amended limited partnership agreements provide that, upon certain events, the Company has a call right (the &#8220;Call Right&#8221;) and the selling entity has a put right (the &#8220;Put Right&#8221;) for the purchase and sale of the limited partnership interest held by the partner.&#160; Once triggered, the Put Right and the Call Right do not expire, even upon an individual partner&#8217;s death, and contain no mandatory redemption feature.&#160; The purchase price of the partner&#8217;s limited partnership interest upon the exercise of either the Put Right or the Call Right is calculated per the terms of the respective agreements.&#160; The Company accounted for the amendment of its limited partnership agreements as an extinguishment of the outstanding Seller Entity Interests, as defined in Footnote 5, classified as liabilities through the issuance of new Seller Entity Interests classified in temporary equity. Pursuant to ASC 470-50-40-2, the Company removed the outstanding liability-classified Seller Entity Interests at their carrying amounts, recognized the new temporary-equity-classified Seller Entity Interests at their fair value, and recorded&#160; no gain or loss on extinguishment, as management believes the redemption value (i.e. the carrying amount) and fair value are the same.&#160; In summary, the redemption values of the mandatorily redeemable non-controlling interest (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet. The remaining balance of $327,000 in the line item <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#8211; Mandatorily redeemable non-controlling interests</font> &#8211; relates to one limited partnership agreement that was not amended, as the non-controlling interest was purchased by the Company in January 2018.&#160; See Footnote 5 - Mandatorily redeemable non-controlling interests &#8211; and Footnote 6 - Redeemable non-controlling interests &#8211; for further discussion.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Wholly-Owned Facilities</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due to the profit sharing therapists. The amount is expensed as compensation and included in operating costs &#8211; salaries and related costs. The respective liability is included in current liabilities &#8211; accrued expenses on the balance sheets.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Significant Accounting Policies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Cash Equivalents</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company maintains its cash and cash equivalents at financial institutions.&#160; The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&#160; The combined account balances at several institutions typically exceed Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance coverage and, as a result, there is a concentration of credit risk related on deposits in excess of FDIC insurance coverage. Management believes that the risk is not significant.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Long-Lived Assets</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for purchased software from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Goodwill</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain identifiable intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management&#8217;s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The fair value of goodwill and other identifiable intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company evaluates indefinite lived tradenames using the relief from royalty method in conjunction with its annual goodwill impairment test.&#160; The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining the Company&#8217;s reporting units when performing its annual goodwill impairment test. In the first quarter of 2018, there were six regions.&#160; In addition to the six regions, in 2017, the impairment test included a separate analysis for the industrial injury prevention business, a separate reporting unit.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other identifiable intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2017, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation of goodwill in 2017, 2016 and 2015 did not result in any goodwill amounts that were deemed impaired.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has not identified any triggering events occurring after the testing date that would impact the impairment testing results obtained.&#160; The Company will continue to monitor for any triggering events or other indicators of impairment.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Redeemable Non-Controlling Interests</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those that the owners and the Company have certain redemption rights, whether currently exercisable or not, and which currently, or in the future, require that the Company purchase or the owner sell the non-controlling interest held by the owner, if certain conditions are met.&#160; The purchase price is derived at a predetermined formula based on a multiple of trailing twelve months earnings performance as defined in the respective limited partnership agreements.&#160; The redemption rights can be triggered by the owner or the Company at such time as both of the following events have occurred: 1) termination of the owner&#8217;s employment, regardless of the reason for such termination, and 2) the passage of specified number of years after the closing of the transaction, typically three to five years, as defined in the limited partnership agreement.&#160; The redemption rights are not automatic or mandatory (even upon death) and require either the owner or the Company to exercise its rights when the conditions triggering the redemption rights have been satisfied.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On the date the Company acquires a controlling interest in a partnership, and the limited partnership agreement for such partnership contains redemption rights not under the control of the Company, the fair value of the non-controlling interest is recorded in the consolidated balance sheet under the caption &#8211; Redeemable non-controlling interests.&#160; Then, in each reporting period thereafter until it is purchased by the Company, the redeemable non-controlling interest is adjusted to the greater of its then current redemption value or initial value, based on the predetermined formula defined in the respective limited partnership agreement.&#160; As a result, the value of the non-controlling interest is not adjusted below its initial value.&#160; The Company records any adjustment in the redemption value, net of tax, directly to retained earnings and are not reflected in the consolidated statements of income.&#160; Although the adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects the adjustments, net of tax, in the earnings per share calculation.&#160; The amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income. Management believes the redemption value (i.e. the carrying amount) and fair value are the same.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Non-Controlling Interests</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company recognizes non-controlling interests, in which the Company has no obligation but the right to purchase the non-controlling interests, as equity in the consolidated financial statements separate from the parent entity&#8217;s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the statements of net income. Changes in a parent entity&#8217;s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling equity investment on the deconsolidation date.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">When the purchase price of a non-controlling interest by the Company exceeds the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Revenue Recognition</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Revenues are recognized in the period in which services are rendered. See Footnote 3 for further discussion of revenue recognition.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Allowance for Doubtful Accounts</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Income Taxes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;) was passed by Congress on December 20, 2017 and signed into law by President Trump on December 22, 2017. The TCJA makes significant changes to U.S. corporate income tax laws including a decrease in the corporate income tax rate to 21% effective January 1, 2018.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the twelve months ended March 31, 2018. The Company will book any interest or penalties, if required, in interest and other expense, as appropriate.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Fair Value of Financial Instruments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount under the Amended Credit Agreement approximates its fair value. The interest rate on the Amended Credit Agreement, which is tied to the Eurodollar Rate, is set at various short-term intervals, as detailed in the Amended Credit Agreement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Segment Reporting</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance.&#160; The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Use of Estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In preparing the Company&#8217;s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Self-Insurance Program</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company&#8217;s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through March 31, 2018.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Restricted Stock</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Restricted stock issued to employees and directors is subject to continued employment or continued service on the board, respectively. Generally, restrictions on the stock granted to employees, other than officers, lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the vesting period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Recently Adopted Accounting Guidance</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively &#8220;the standards&#8221;), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The original standards were effective for fiscal years beginning after December 15, 2016; however, in July 2015, the FASB approved a one-year deferral of these standards, with a new effective date for fiscal years beginning after December 15, 2017. The standards require the selection of a retrospective or cumulative effect transition method.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company implemented the new standard beginning January 1, 2018 using a modified retrospective transition method.&#160; Adoption of the new standard did not result in material changes to the presentation of net revenues and bad debt expense in the consolidated statements of income, and the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change relates to how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common forms of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company&#8217;s estimate for unrealizable amounts is recorded as a reduction of revenue. Under the new standards, the Company&#8217;s estimate for unrealizable amounts will continue to be recognized as a reduction to revenue. The bad debt expense historically reported will not materially change.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Recently Issued Accounting Guidance</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350), which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment change. ASU 2017-04 is effective prospectively for fiscal years, and the interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In February 2016, the FASB issued amended accounting guidance (ASU 2016-02, Leases) which replaced most existing lease accounting guidance under U. S. generally accepted accounting principles. Among other changes, the amended guidance requires that a right-to-use asset, which is an asset that represents the lessee&#8217;s right to use, and a lease liability, which is a lessee&#8217;s obligation to make lease payments arising for a lease measured on a discounted basis, be recognized on the balance sheet by lessees for those leases with a term of greater than 12 months. The amended guidance is effective for reporting periods beginning after December 15, 2018&#894; however, early adoption is permitted. Entities can use to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements or recognize the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Since the Company leases all but one of its clinic facilities, upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will continue to be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of income.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; text-align: left;">The Company will implement the new standard beginning January 1, 2019. The Company&#8217;s implementation efforts are focused on populating the data in a lease accounting software package and developing internal controls in order to account for its leases under the new standard.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Subsequent Event</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has evaluated events occurring after the balance sheet date for possible disclosure as a subsequent event through the date that these consolidated financial statements were issued. On April 30, 2018, the Company acquired a 65% interest in a leading provider of industrial injury prevention for $9.0 million.</div></div> 1357000 1224000 4786000 3050000 743000 733000 6594000 4134000 246000 0 2230000 265000 2208000 937000 15670000 761000 760000 36682000 2300000 4000000 6200000 15800000 10700000 1404000 1587000 0.01 0.01 0 0 0 0 0 0 500000 500000 56000 0 19000000 32000000 0 62000 10054000 6034000 19808000 20385000 80860000 81550000 P3Y P3Y P5Y P7Y P3Y P8Y 1061000 898000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Allowance for Doubtful Accounts</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For the three months ended March 31, 2018, the following table details the changes in the carrying amount of redeemable non-controlling interest (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"></td></tr><tr><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Beginning balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">102,572</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Operating results allocated to redeemable non-controlling interest partners</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,736</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Distributions to redeemable non-controlling interest partners</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,359</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Changes in the fair value of redeemable non-controlling interest</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,081</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">55</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Ending balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">108,085</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div> 108085000 102572000 102572000 108085000 702000 823000 31000000 20000000 250000 12000 6000 162907000 162406000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">3.&#160; REVENUE RECOGNITION</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Categories</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Management contract revenues, which are included in other revenues in the consolidated statements of net income, are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company&#8217;s employees, are recorded when incurred.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Revenues from the industrial injury prevention business, which are also included in other revenues in the consolidated statements of net income, are derived from onsite services provided to clients&#8217; employees including injury prevention, rehabilitation, ergonomic assessments and performance optimization. Revenues are determined based on the number of hours and respective rate for services provided.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Additionally, other revenues include services provided on-site, such as schools and industrial worksites, for physical or occupational therapy services, and athletic trainers and gym membership fees.<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; </font>Contract terms and rates are agreed to in advance between the Company and the third parties. Services are typically performed over the contract period and revenue is recorded in accordance with the contract terms. If the services are paid in advance, revenue is deferred over the period of the agreement and recognized when the services are performed.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table details the revenue related to the various categories:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net patient revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">100,552</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">93,654</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Management contract revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,236</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,857</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Industrial injury prevention services revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,852</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,506</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">702</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">548</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">108,342</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">97,565</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Net Patient Revenues - Physical / Occupational Therapy Revenue</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Net patient revenues consists of revenues for physical therapy and occupational therapy clinics that provide pre-and post-operative care and treatment for orthopedic related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For ASC 606, there is an implied contract between the Company and the patient upon each patient visit.&#160; Separate contractual arrangements exist between the Company and third party payors (e.g. insurers, managed care programs, government programs, workers' compensation) which establish the amounts the third parties pay on behalf of the patients for covered services rendered.&#160;&#160; While these agreements are not considered contracts with the customer, they are used for determining the transaction price for services provided to the patients covered by the third party payors.&#160; The payor contracts do not indicate performance obligations of the Company, but indicate reimbursement rates for patients who are covered by those payors when the services are provided.&#160; At that time, the Company is obligated to provide services for the reimbursement rates stipulated in the payor contracts.&#160; The execution of the contract alone does not indicate a performance obligation. For self-paying customers, the performance obligation exists when the Company provides the services at established rates. The difference between the Company&#8217;s established rate and the anticipated reimbursement rate is accounted for an as offset to revenue &#8211; contractual allowance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; margin-left: 18pt;">Contractual Allowances</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements by both insurance companies and government sponsored healthcare programs for such services. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company&#8217;s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow the Company to provide the necessary detail and accuracy with its collectability estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company&#8217;s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company&#8217;s billing system does not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, the need for a manual process for determining its contractual allowance reserve. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, historically the difference between net revenues and corresponding cash collections has generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent periods&#8217; contractual write-offs on a payor basis reflects a difference within approximately 1% between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at March 31, 2018.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized when, or as, the performance obligation is satisfied. To determine the transaction price, the Company includes the effects of any variable consideration, such as the probability of collecting that amount.&#160; The Company applies established rates to the services provided, and adjusts for the terms of payor contracts, as applicable.&#160; These contracted amounts are different from the Company&#8217;s established rates.&#160; The Company has established a &#8220;contractual allowance&#8221; for this difference. The allowance is based on the terms of payor contracts, historical and current reimbursement information and current experience with the clinic and partners. The Company&#8217;s established rates less the contractual allowance is the revenue that is recognized in the period in which the service is rendered. This revenue is deemed the transaction price and stated as &#8220;Net Patient Revenue&#8221; on the Company&#8217;s income statement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The majority of the Company&#8217;s performance obligations are satisfied at one point in time. After the clinic has provided services and satisfied its obligation to the customer for the reimbursement rates stipulated in the payor contracts (i.e the transaction price), the Company recognizes the revenue, net of contractual allowances, in the period in which the services are rendered. The Company recognizes the full amount of revenue and reports the contractual allowances as a contra (or offset) revenue account to report a net revenue number based on the expected collections.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; margin-left: 18pt;">Medicare Reimbursement</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (&#8216;&#8216;MPFS&#8217;&#8217;). For services provided in 2018, a 0.5% increase has been applied to the fee schedule payment rates; for services provided in 2019, a 0.25% increase will be applied to the fee schedule payment rates, subject to an adjustment beginning in 2019 under the Merit-Based Incentive Payment System (&#8220;MIPS&#8221;).&#160; &#160; For services provided in 2020 through 2025, a 0.0% percent update will be applied each year to the fee schedule payment rates, subject to adjustments under MIPS and any alternative payment models (&#8220;APMs&#8221;).&#160;&#160; Beginning in 2019, payments to individual therapists (Physical/Occupational Therapist in Private Practice) under the fee schedule may be subject to adjustment based on performance in MIPS, which measures performance based on certain quality metrics, resource use, and meaningful use of electronic health records. Under the MIPS requirements, a provider's performance is assessed according to established performance standards and used to determine an adjustment factor that is then applied to the professional's payment for a year. Each year from 2019 through 2024, professionals who receive a significant share of their revenues through an APM (such as accountable care organizations or bundled payment arrangements) that involves risk of financial losses and a quality measurement component will receive a 5% bonus. The bonus payment for APM participation is intended to encourage participation and testing of new APMs and to promote the alignment of incentives across payors. The specifics of the MIPS and APM adjustments beginning in 2019 and 2020, respectively, will be subject to future notice and comment rule-making.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. On April 1, 2013, a 2% reduction to Medicare payments was implemented. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, extended the 2% reductions to Medicare payments through fiscal year 2025. The Bipartisan Budget Act of 2018, enacted on February 9, 2018, extends the 2% reductions to Medicare payments through fiscal year 2027.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Historically, the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary was subject to an annual dollar limit (i.e., the &#8216;&#8216;Therapy Cap&#8217;&#8217; or &#8216;&#8216;Limit&#8217;&#8217;). For 2017, the annual Limit on outpatient therapy services was $1,980 for combined Physical Therapy and Speech Language Pathology services and $1,980 for Occupational Therapy services. As a result of Bipartisan Budget Act of 2018, the Therapy Caps have been eliminated, effective as of January 1, 2018.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Under the Middle Class Tax Relief and Job Creation Act of 2012 (&#8216;&#8216;MCTRA&#8217;&#8217;), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The MACRA directed CMS to modify the manual medical review process such that those reviews will no longer apply to all claims exceeding the $3,700 threshold and instead will be determined on a targeted basis based on a variety of factors that CMS considers appropriate. The Bipartisan Budget Act of 2018 extends the targeted medical review indefinitely, but reduces the threshold to $3,000 through December 31, 2027.&#160; For 2028, the threshold amount will be increased by the percentage increase in the Medicare Economic Index (&#8220;MEI&#8221;) for 2028 and in subsequent years the threshold amount will increase based on the corresponding percentage increase in the MEI for such subsequent year.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">CMS adopted a multiple procedure payment reduction (&#8216;&#8216;MPPR&#8217;&#8217;) for therapy services in the final update to the MPFS for calendar year 2011. The MPPR applied to all outpatient therapy services paid under Medicare Part B &#8212; occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (&#8216;&#8216;RVU&#8217;&#8217;) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. Since 2013, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 50%. In addition, the MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient&#8217;s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. Reporting of these functional limitation codes and modifiers are required on the claim for payment.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Medicare claims for outpatient therapy services furnished by therapy assistants on or after January 1, 2022 must include a modifier indicating the service was furnished by a therapy assistant. CMS is required to develop a modifier to mark services provided by a therapy assistant by January 1, 2019, and then submitted claims must report the modifier mark starting January 1, 2020. Outpatient therapy services furnished on or after January 1, 2022 in whole or part by a therapy assistant will be paid at an amount equal to 85% of the payment amount otherwise applicable for the service.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. We believe that we are in compliance, in all material respects, with all applicable laws and regulations and are not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company&#8217;s financial statements as of March 31, 2018. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program. For three months ended March 31, 2018, net patient revenue from Medicare were approximately $24.6 million.</div></div> 100552000 108342000 97565000 93654000 3911000 7790000 2236000 4852000 1506000 1857000 548000 702000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Revenue Recognition</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Revenues are recognized in the period in which services are rendered. See Footnote 3 for further discussion of revenue recognition.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Based on the balance of referral relationships and non-compete agreements as of March 31, 2018, the expected amount to be amortized in 2018 and thereafter by year is as follows (in thousands):</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td colspan="4" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Referral Relationships</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Non-Compete Agreements</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Years</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: right;">Annual Amount</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Years</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: right;">Annual Amount</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Ending December 31,</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Ending December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2018</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,068</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2018</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">766</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,965</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2019</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">693</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,965</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2020</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">481</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2021</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,965</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2021</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">403</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2022</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,917</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2022</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">143</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">2023</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,809</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td style="width: 29%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2023</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 30%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Thereafter</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,358</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 29%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 11%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following tables provide a detail of the basic and diluted earnings per share computation.&#160; In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest (see Footnote 6), net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation.</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="6" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended March 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Computation of earnings per share - USPH shareholders</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net income attributable to USPH shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">7,117</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,816</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Charges to retained earnings:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Revaluation of redeemable non-controlling interest</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(5,081</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: middle; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Tax effect at statutory rate (federal and state) of 26.25%</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,334</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,370</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,816</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: middle; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Basic&#160;and diluted per share</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">0.27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">0.38</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Aggregate annual payments of principal required pursuant to the Amended Credit Agreement and the above notes payable subsequent to March 31, 2018 are as follows (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 70%;"><tr><td valign="bottom" style="width: 58%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2019</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,317</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2020</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2021</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">During the twelve months ended March 31, 2022</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 58%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,099</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Intangible assets, net as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Tradenames</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">28,273</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">29,673</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Referral relationships, net of accumulated amortization of $7,729 and $7,209, respectively</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,527</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,811</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-compete agreements, net of accumulated amortization of $4,297 and $4,100, respectively</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,292</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,470</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">47,092</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,954</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Accrued expenses as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Salaries and related costs</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">22,677</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">16,828</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Credit balances due to patients and payors</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,841</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,158</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Group health insurance claims</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,637</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,929</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Income taxes payable</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,139</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,833</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Dividend payable to USPH shareholders</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,914</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">4,134</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,594</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">38,342</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">33,342</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">During the year ended December 31, 2017, the Company acquired an interest in the following clinic groups:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 90%;"><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;">Date</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">% Interest Acquired</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">Number of Clinics</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">January 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">January 1</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">70%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">17</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">May 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">May 31</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">70%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">4</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">June 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">June 30</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">60%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 56.99%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">October 2017 Acquisition</div></td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">October 31</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">70%</div></td><td nowrap="nowrap" valign="bottom" style="width: 2.15%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 12.01%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center;">9</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.08%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Amounts outstanding under the Amended Credit Agreement and notes payable as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">December 31, 2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Credit Agreement average effective interest rate of 3.8% inclusive of unused fee</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">54,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 9pt; text-indent: -9pt;">Various notes payable with $5,317 plus accrued interest due in the next year, interest accrues in the range of 3.25% through 4.25% per annum</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,099</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">6,772</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">48,099</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">60,772</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Less current portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(5,317</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(4,044</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: top; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Long term portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">42,782</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">56,728</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The changes in the carrying amount of goodwill consisted of the following (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Beginning balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">271,338</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill acquired during the year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">856</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Goodwill adjustments for purchase price allocation of businesses acquired in prior year</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,576</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: top; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Ending balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">273,770</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Segment Reporting</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance.&#160; The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.</div></div> 10163000 8547000 1381000 1280000 327000 0 81.30 -2215000 14809000 14885000 -2215000 0 1000 1000 0 0 1000 0 2250000 1200000 76000 0 0 859499 208485000 206070000 -31628000 73940000 204866000 1204000 148000 162406000 -31628000 149000 75543000 162907000 1514000 206971000 206971000 204866000 0 45000 0 45000 45000 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">11. COMMON STOCK</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company&#8217;s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (&#8220;March 2009 Authorization&#8221;). The Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. The Company is required to retire shares purchased under the March 2009 Authorization.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. There are currently an additional estimated 184,502 shares (based on the closing price of $81.30 on March 31, 2018) that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company&#8217;s cash position. The Company did not purchase any shares of its common stock during the three months ended March 31, 2018.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Subsequent Event</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company has evaluated events occurring after the balance sheet date for possible disclosure as a subsequent event through the date that these consolidated financial statements were issued. On April 30, 2018, the Company acquired a 65% interest in a leading provider of industrial injury prevention for $9.0 million.</div></div> 31628000 31628000 2214737 2214737 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Use of Estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In preparing the Company&#8217;s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.</div></div> 12616000 12528000 150000 900000 2911000 0 553000 415000 21776000 20087000 0 1294000 2669000 0 3370000 4816000 -1334000 0 0 -5081000 0.2625 18000 1224000 13883000 910000 38832000 36000 4085000 2 4781000 7039000 250000 500000 400000 500000 500000 2150000 150000 1 2 2 2 2 1 125000 250000 250000 250000 250000 250000 250000 125000 P7Y6M P11Y P5Y P6Y 6 28 P5Y P3Y 0.49 0.99 0.01 580 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Non-Controlling Interests</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company recognizes non-controlling interests, in which the Company has no obligation but the right to purchase the non-controlling interests, as equity in the consolidated financial statements separate from the parent entity&#8217;s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the statements of net income. Changes in a parent entity&#8217;s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling equity investment on the deconsolidation date.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">When the purchase price of a non-controlling interest by the Company exceeds the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Self-Insurance Program</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company&#8217;s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through March 31, 2018.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Redeemable Non-Controlling Interests</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those that the owners and the Company have certain redemption rights, whether currently exercisable or not, and which currently, or in the future, require that the Company purchase or the owner sell the non-controlling interest held by the owner, if certain conditions are met.&#160; The purchase price is derived at a predetermined formula based on a multiple of trailing twelve months earnings performance as defined in the respective limited partnership agreements.&#160; The redemption rights can be triggered by the owner or the Company at such time as both of the following events have occurred: 1) termination of the owner&#8217;s employment, regardless of the reason for such termination, and 2) the passage of specified number of years after the closing of the transaction, typically three to five years, as defined in the limited partnership agreement.&#160; The redemption rights are not automatic or mandatory (even upon death) and require either the owner or the Company to exercise its rights when the conditions triggering the redemption rights have been satisfied.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">On the date the Company acquires a controlling interest in a partnership, and the limited partnership agreement for such partnership contains redemption rights not under the control of the Company, the fair value of the non-controlling interest is recorded in the consolidated balance sheet under the caption &#8211; Redeemable non-controlling interests.&#160; Then, in each reporting period thereafter until it is purchased by the Company, the redeemable non-controlling interest is adjusted to the greater of its then current redemption value or initial value, based on the predetermined formula defined in the respective limited partnership agreement.&#160; As a result, the value of the non-controlling interest is not adjusted below its initial value.&#160; The Company records any adjustment in the redemption value, net of tax, directly to retained earnings and are not reflected in the consolidated statements of income.&#160; Although the adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects the adjustments, net of tax, in the earnings per share calculation.&#160; The amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income. Management believes the redemption value (i.e. the carrying amount) and fair value are the same.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Recently Issued Accounting Guidance</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350), which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment change. ASU 2017-04 is effective prospectively for fiscal years, and the interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">In February 2016, the FASB issued amended accounting guidance (ASU 2016-02, Leases) which replaced most existing lease accounting guidance under U. S. generally accepted accounting principles. Among other changes, the amended guidance requires that a right-to-use asset, which is an asset that represents the lessee&#8217;s right to use, and a lease liability, which is a lessee&#8217;s obligation to make lease payments arising for a lease measured on a discounted basis, be recognized on the balance sheet by lessees for those leases with a term of greater than 12 months. The amended guidance is effective for reporting periods beginning after December 15, 2018&#894; however, early adoption is permitted. Entities can use to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements or recognize the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Since the Company leases all but one of its clinic facilities, upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will continue to be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of income.</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; text-align: left;">The Company will implement the new standard beginning January 1, 2019. The Company&#8217;s implementation efforts are focused on populating the data in a lease accounting software package and developing internal controls in order to account for its leases under the new standard.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">Restricted Stock</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Restricted stock issued to employees and directors is subject to continued employment or continued service on the board, respectively. Generally, restrictions on the stock granted to employees, other than officers, lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the vesting period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.</div></div> 0 0 0 -3747000 -3747000 -3747000 0 373000 0 0 373000 373000 0 0 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">5. MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Prior to the second quarter of 2017, when the Company acquired a majority interest (the &#8220;Acquisition&#8221;) in a physical therapy clinic business (referred to as &#8220;Therapy Practice&#8221;), these Acquisitions occurred in a series of steps which are described below.</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">1.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Prior to the Acquisition, the Therapy Practice exists as a separate legal entity (the &#8220;Seller Entity&#8221;). The Seller Entity is owned by one or more individuals (the &#8220;Selling Shareholders&#8221;) most of whom are physical therapists that work in the Therapy Practice and provide physical therapy services to patients.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">2.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In conjunction with the Acquisition, the Seller Entity contributes the Therapy Practice into a newly-formed limited partnership (&#8220;NewCo&#8221;), in exchange for one hundred percent (100%) of the limited and general partnership interests in NewCo. Therefore, in this step, NewCo becomes a wholly-owned subsidiary of the Seller Entity.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">3.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Company enters into an agreement (the &#8220;Purchase Agreement&#8221;) to acquire from the Seller Entity a majority (ranges from 50% to 90%) of the limited partnership interest and, in all cases, 100% of the general partnership interest in NewCo. The Company does not purchase 100% of the limited partnership interest because the Selling Shareholders, through the Seller Entity, want to maintain an ownership percentage. The consideration for the Acquisition is primarily payable in the form of cash at closing and a small two-year note in lieu of an escrow (the &#8220;Purchase Price&#8221;). The Purchase Agreement does not contain any future earn-out or other contingent consideration that is payable to the Seller Entity or the Selling Shareholders.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">4.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Company and the Seller Entity also execute a partnership agreement (the &#8220;Partnership Agreement&#8221;) for NewCo that sets forth the rights and obligations of the limited and general partners of NewCo. After the Acquisition, the Company is the general partner of NewCo.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">5.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">As noted above, the Company does not purchase 100% of the limited partnership interests in NewCo and the Seller Entity retains a portion of the limited partnership interest in NewCo (&#8220;Seller Entity Interest&#8221;).</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">6.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In most cases, some or all of the Selling Shareholders enter into an employment agreement (the&#160; &#8220;Employment Agreement&#8221;) with NewCo with an initial term that ranges from three to five years (the &#8220;Employment Term&#8221;), with automatic one-year renewals, unless employment is terminated prior to the end of the Employment Term. As a result, a Selling Shareholder becomes an employee (&#8220;Employed Selling Shareholder&#8221;) of NewCo. The employment of an Employed Selling Shareholder can be terminated by the Employed Selling Shareholder or NewCo, with or without cause, at any time. In a few situations, a Selling Shareholder does not become employed by NewCo and is not involved with NewCo following the closing&#894; in those situations, such Selling Shareholders sell their entire ownership interest in the Seller Entity as of the closing of the Acquisition.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">7.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The compensation of each Employed Selling Shareholder is specified in the Employment Agreement and is customary and commensurate with his or her responsibilities based on other employees in similar capacities within NewCo, the Company and the industry.</div></td></tr></table></div><div>&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">8.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Company and the Selling Shareholder (including both Employed Selling Shareholders and Selling Shareholders not employed by NewCo) execute a non-compete agreement (the &#8220;Non- Compete Agreement&#8221;) which restricts the Selling Shareholder from engaging in competing business activities for a specified period of time (the &#8220;Non-Compete Term&#8221;). A Non-Compete Agreement is executed with the Selling Shareholders in all cases. That is, even if the Selling Shareholder does not become an Employed Selling Shareholder, the Selling Shareholder is restricted from engaging in a competing business during the Non-Compete Term.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">9.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Non-Compete Term commences as of the date of the Acquisition and expires on the later of:</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">a.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Two years after the date an Employed Selling Shareholders&#8217; employment is terminated (if the Selling Shareholder becomes an Employed Selling Shareholder) or</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">b.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Five to six years from the date of the Acquisition, as defined in the Non-Compete Agreement, regardless of whether the Selling Shareholder is employed by NewCo.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">10.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Non-Compete Agreement applies to a restricted region which is defined as a 15-mile radius from the Therapy Practice. That is, an Employed Selling Shareholder is permitted to engage in competing businesses or activities outside the 15-mile radius (after such Employed Selling Shareholder no longer is employed by NewCo) and a Selling Shareholder who is not employed by NewCo immediately is permitted to engage in the competing business or activities outside the 15-mile radius.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">11.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Partnership Agreement contains provisions for the redemption of the Seller Entity Interest, either at the option of the Company (the &#8220;Call Option&#8221;) or on a required basis (the &#8220;Required Redemption&#8221;):</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">a.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Required Redemption</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">i.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Once the Required Redemption is triggered, the Company is obligated to purchase from the Seller Entity and the Seller Entity is obligated to sell to the Company, the allocable portion of the Seller Entity Interest based on the terminated Selling Shareholder&#8217;s pro rata ownership interest in the Seller Entity (the &#8220;Allocable Portion&#8221;). Required Redemption is</div></td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 90pt;">triggered when both of the following events have occurred:</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">1.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Termination of an Employed Selling Shareholder&#8217;s employment with NewCo, regardless of the reason for such termination, and</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">2.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The expiration of an agreed upon period of time, typically three to five years, as set forth in the relevant Partnership Agreement (the &#8220;Holding Period&#8221;).</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">ii.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In the event an Employed Selling Shareholder&#8217;s employment terminates prior to the expiration of the Holding Period, the Required Redemption would occur only upon expiration of the Holding Period.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">b.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Call Option</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">i.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In the event that an Employed Selling Shareholder&#8217;s employment terminates prior to expiration of the Holding Period, the Company has the contractual right, but not the obligation, to acquire the Employed Selling Shareholder&#8217;s Allocable Portion of the Seller Entity Interest from the Seller Entity through exercise of the Call Option.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">c.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">For the Required Redemption and the Call Option, the purchase price is derived from a formula based on a specified multiple of NewCo&#8217;s trailing twelve months of earnings before interest, taxes, depreciation, amortization, and the Company&#8217;s internal management fee, plus an Allocable Portion of any undistributed earnings of NewCo (the &#8220;Redemption Amount&#8221;). NewCo&#8217;s earnings are distributed monthly based on available cash within NewCo&#894; therefore, the undistributed earnings amount is small, if any.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">d.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Purchase Price for the initial equity interest purchased by the Company is also based on the same specified multiple of the trailing twelve-month earnings that is used in the Required Redemption noted above.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">e.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Although, the Required Redemption and the Call Option do not have an expiration date, the Seller Entity Interest eventually will be purchased by the Company.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 54pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">f.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Required Redemption and the Call Option never apply to Selling Shareholders who do not become employed by NewCo, since the Company requires that such Selling Shareholders sell their entire ownership interest in the Seller Entity at the closing of the Acquisition.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">12.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">An Employed Selling Shareholder&#8217;s ownership of his or her equity interest in the Seller Entity predates the Acquisition and the Company&#8217;s purchase of its partnership interest in NewCo. The Employment Agreement and the Non-Compete Agreement do not contain any provision to escrow or &#8220;claw back&#8221; the equity interest in the Seller Entity held by such Employed Selling Shareholder, nor the Seller Entity Interest in NewCo, in the event of a breach of the employment or non-compete terms. More specifically, even if the Employed Selling Shareholder is terminated for &#8220;cause&#8221; by NewCo, such Employed Selling Shareholder does not forfeit his or her right to his or her full equity interest in the Seller Entity and the Seller Entity does not forfeit its right to any portion of the Seller Entity Interest. The Company&#8217;s only recourse against the Employed Selling Shareholder for breach of either the Employment Agreement or the Non-Compete Agreement is to seek damages and other legal remedies under such agreements. There are no conditions in any of the arrangements with an Employed Selling Shareholder that would result in a forfeiture of the equity interest held in the Seller Entity or of the Seller Entity Interest.</div></td></tr></table></div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">As previously mentioned, due to the amendments that were made to partnerships agreements, the Call Option and Required Redemption provisions described in number 11 of Footnote 5 have been modified to be consistent with the provisions described in Footnote 6 below.&#160; As a result, the redemption values of the mandatorily redeemable non-controlling interest (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet.&#160; For 2017, the earnings and liabilities attributable to mandatorily redeemable non-controlling interests were recorded within the consolidated statements of income line item: <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Interest expense &#8211; mandatorily redeemable non-controlling interests &#8211; earnings allocable</font> and in the consolidated balance sheet line item: <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Mandatorily redeemable non-controlling interests</font>.</div></div> 20000000 15000000 10000000 0.0125 0.0200 50000000 3841000 4158000 15000000 0.1 184502 P2Y P2Y P3Y P5Y 1 P5Y P3Y P1Y 1 P6Y P5Y 0.9 0.5 0.005 0.0025 0.000 3700 0.02 0.02 0.02 0.050 0.01 0.01 0.01 1980 3000 0.02 1980 0.5 P10Y 0.85 1200000000000 24600000 1 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">6. REDEEMABLE NON-CONTROLLING INTERESTS</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">When the Company acquires a majority interest in a Therapy Practice, those Acquisitions occur in a series of steps as described in numbers 1 through 10 of footnote 5 &#8211; Mandatorily Redeemable Non-Controlling Interests.&#160; For the Acquisitions that occurred after the first quarter of 2017, and for the acquisitions that occurred during and prior to the first quarter of 2017 but for which the partnership agreements were amended, the applicable Partnership Agreement contains provisions for the redemption of the Seller Entity Interest, either at the option of the Company (the &#8220;Call Right&#8221;) or at the option of the Seller Entity (the &#8220;Put Right&#8221;) as follows:</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">1.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Put Right</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">a.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In the event that any Selling Shareholder&#8217;s employment is terminated involuntarily by the Company without &#8220;Cause&#8221; pursuant to Section 7(d) of such Selling Shareholder&#8217;s Employment Agreement prior to the fifth anniversary of the Closing Date, the Seller Entity thereafter shall have an irrevocable right to cause the Company to purchase from Seller Entity the Terminated Selling Shareholder&#8217;s Allocable Percentage of Seller Entity&#8217;s Interest at the purchase price described in &#8220;3&#8221; below.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">b.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In the event that any Selling Shareholder is not employed by NewCo as of the fifth anniversary of the Closing Date and the Company has not exercised its Call Right with respect to the Terminated Selling Shareholder&#8217;s Allocable Percentage of Seller Entity&#8217;s Interest, Seller Entity thereafter shall have the Put Right to cause the Company to purchase from Seller Entity the Terminated Selling Shareholder&#8217;s Allocable Percentage of Seller Entity&#8217;s Interest at the purchase price described in &#8220;3&#8221; below.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">c.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In the event that any Selling Shareholder&#8217;s employment with NewCo is terminated for any reason on or after the fifth anniversary of the Closing Date, the Seller Entity shall have the Put Right, and upon the exercise of the Put Right, the Terminated Selling Shareholder&#8217;s Allocable Percentage of Seller Entity&#8217;s Interest shall be redeemed by the Company at the purchase price described in &#8220;3&#8221; below.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">2.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">Call Right</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">a.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">If any Selling Shareholder&#8217;s employment by NewCo is terminated (i) pursuant to a voluntary termination by the Selling Shareholder or (ii) by NewCo with &#8220;Cause&#8221; (as defined in the Selling Shareholder&#8217;s Employment Agreement), prior to the fifth anniversary of the Closing Date, the Company thereafter shall have an irrevocable right to purchase from Seller Entity the Terminated Selling Shareholder&#8217;s Allocable Percentage of Seller Entity&#8217;s Interest, in each case at the purchase price described in &#8220;3&#8221; below.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 108pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">b.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">In the event that any Selling Shareholder&#8217;s employment with NewCo is terminated for any reason on or after the fifth anniversary of the Closing Date, the Company shall have the Call Right, and upon the exercise of the Call Right, the Terminated Selling Shareholder&#8217;s Allocable Percentage of Seller Entity&#8217;s Interest shall be redeemed by the Company at the purchase price described in &#8220;3&#8221; below.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">3.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">For the Put Right and the Call Right, the purchase price is derived from a formula based on a specified multiple of NewCo&#8217;s trailing twelve months of earnings before interest, taxes, depreciation, amortization, and the Company&#8217;s internal management fee, plus an Allocable Percentage of any undistributed earnings of NewCo (the &#8220;Redemption Amount&#8221;). NewCo&#8217;s earnings are distributed monthly based on available cash within NewCo&#894; therefore, the undistributed earnings amount is small, if any.</div></td></tr></table></div><div>&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">4.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Purchase Price for the initial equity interest purchased by the Company is also based on the same specified multiple of the trailing twelve-month earnings that is used in the Put Right and the Call Right noted above.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">5.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Put Right and the Call Right do not have an expiration date, but the Seller Entity Interest is not required to be purchased by the Company or sold by the Seller Entity.</div></td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 72pt;"></td><td style="font-size: 10pt; font-family: 'Times New Roman'; width: 18pt; vertical-align: top; align: right;">6.</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';">The Put Right and the Call Right never apply to Selling Shareholders who do not become employed by NewCo, since the Company requires that such Selling Shareholders sell their entire ownership interest in the Seller Entity at the closing of the Acquisition.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">An Employed Selling Shareholder&#8217;s ownership of his or her equity interest in the Seller Entity predates the Acquisition and the Company&#8217;s purchase of its partnership interest in NewCo. The Employment Agreement and the Non-Compete Agreement do not contain any provision to escrow or &#8220;claw back&#8221; the equity interest in the Seller Entity held by such Employed Selling Shareholder, nor the Seller Entity Interest in NewCo, in the event of a breach of the employment or non-compete terms. More specifically, even if the Employed Selling Shareholder is terminated for &#8220;cause&#8221; by NewCo, such Employed Selling Shareholder does not forfeit his or her right to his or her full equity interest in the Seller Entity and the Seller Entity does not forfeit its right to any portion of the Seller Entity Interest. The Company&#8217;s only recourse against the Employed Selling Shareholder for breach of either the Employment Agreement or the Non-Compete Agreement is to seek damages and other legal remedies under such agreements. There are no conditions in any of the arrangements with an Employed Selling Shareholder that would result in a forfeiture of the equity interest held in the Seller Entity or of the Seller Entity Interest.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">For the three months ended March 31, 2018, the following table details the changes in the carrying amount of redeemable non-controlling interest (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"></td></tr><tr><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Beginning balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">102,572</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Operating results allocated to redeemable non-controlling interest partners</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,736</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Distributions to redeemable non-controlling interest partners</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,359</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Changes in the fair value of redeemable non-controlling interest</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5,081</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: middle; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">55</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">Ending balance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">108,085</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table categorizes the carrying amount (fair value) of the redeemable non-controlling interests (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Contractual time period has lapsed but holder's employment has not been terminated</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34,127</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Contractual time period has not lapsed and holder's employment has not been terminated</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">73,958</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">108,085</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> 34127000 73958000 1359000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">The following table categorizes the carrying amount (fair value) of the redeemable non-controlling interests (in thousands):</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">March 31, 2018</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Contractual time period has lapsed but holder's employment has not been terminated</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">34,127</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Contractual time period has not lapsed and holder's employment has not been terminated</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">73,958</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Fair value</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">108,085</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div> EX-101.SCH 7 usph-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED STATEMENTS OF NET INCOME (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - ACQUISITIONS OF BUSINESSES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - REDEEMABLE NON-CONTROLLING INTERESTS link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - GOODWILL link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - INTANGIBLE ASSETS, NET link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - ACQUISITIONS OF BUSINESSES (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080601 - Disclosure - REDEEMABLE NON-CONTROLLING INTERESTS (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 090102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Clinic Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - ACQUISITIONS OF BUSINESSES (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - REVENUE RECOGNITION (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - REDEEMABLE NON-CONTROLLING INTERESTS (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - INTANGIBLE ASSETS, NET - Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 090802 - Disclosure - INTANGIBLE ASSETS, NET - Amortization Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090804 - Disclosure - INTANGIBLE ASSETS, NET - Amortization of Tradename, Referral Relationships and Non-Competition Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT - Summary of Notes Payable and Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 091002 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 091004 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT- Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - COMMON STOCK (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 usph-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 usph-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 usph-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Document Period End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Public Float Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Type Document Type BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounts payable - trade Accounts Payable, Trade, Current ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts receivable - other Accounts and Other Receivables, Net, Current Patient accounts receivable, less allowance for doubtful accounts of $2,517 and $2,273, respectively Accounts Receivable, Net, Current Income taxes payable Accrued Income Taxes, Current Group health insurance claims Accrued Insurance, Current Accrued expenses Total Accrued Liabilities, Current Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Additional paid-in capital Additional Paid in Capital Compensation expense - equity-based awards Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Allowance for doubtful accounts, patient accounts receivable Allowance for Doubtful Accounts Receivable, Current Total amortization expenses Amortization of Intangible Assets ASSETS Assets [Abstract] Total assets Assets Current assets: Assets, Current [Abstract] Total current assets Assets, Current Total current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] ACQUISITIONS OF BUSINESSES [Abstract] Total non-current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets Business Acquisition [Line Items] Business Acquisition [Line Items] Value of interest acquired Acquisition date Business Acquisition, Date of Acquisition Agreement Percentage of interest acquired Business Acquisition, Percentage of Voting Interests Acquired Goodwill Business Acquisition, Goodwill, Expected Tax Deductible Amount Total liabilities ACQUISITIONS OF BUSINESSES Fair value of non-controlling interest (originally classified as mandatorily redeemable non-controlling interests) Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Cash Equivalents Cash and cash equivalents Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash and Cash Equivalents, at Carrying Value Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Non-cash investing and financing transactions during the period: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Class of Treasury Stock [Table] Commitments and contingencies Commitments and Contingencies Dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Common Stock [Member] Common Stock [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, $.01 par value, 20,000,000 shares authorized, 14,884,676 and 14,809,299 shares issued, respectively Common Stock, Value, Issued Software [Member] Computer Software, Intangible Asset [Member] Consolidated Entities [Domain] Consolidated Entities [Axis] Operating costs: Costs and Expenses [Abstract] Total operating costs Costs and Expenses Credit Facility [Domain] Credit Facility [Domain] Credit Facility [Axis] Credit Facility [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Disaggregation of Revenue, Categories Debt Instrument [Axis] Debt Instrument [Axis] Spread on variable rate Debt Instrument, Basis Spread on Variable Rate NOTES PAYABLE AND AMENDED CREDIT AGREEMENT Debt Disclosure [Text Block] NOTES PAYABLE AND AMENDED CREDIT AGREEMENT [Abstract] Revolving credit facility maturity date Debt Instrument, Maturity Date Percentage of interest accrued Debt Instrument, Interest Rate, Stated Percentage Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Aggregate amount of notes payable Debt Instrument, Face Amount Annual installments Debt Instrument, Annual Principal Payment Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Period in which restrictions lapse on stock granted Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Deferred income taxes Deferred Income Tax Expense (Benefit) Deferred rent Deferred Rent Credit, Noncurrent Deferred taxes Depreciation and amortization Depreciation, Depletion and Amortization Director [Member] Dividends payable to USPT shareholders Dividends, Common Stock, Cash Dividend payable to USPH shareholders EARNINGS PER SHARE Basic and diluted earnings per share attributable to USPH shareholders (in dollars per share) Basic and diluted per share (in dollars per share) EARNINGS PER SHARE [Abstract] Corporate income tax rate Salaries and related costs Employee-related Liabilities, Current COMMON STOCK [Abstract] Equity Component [Domain] Equity, Class of Treasury Stock [Line Items] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] 2022 Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four 2018 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite Lived Intangible Assets [Line Items] 2021 Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three Amortization Expenses Finite-lived Intangible Assets Amortization Expense [Table Text Block] Thereafter Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization 2023 Schedule of Preliminary Purchase Prices Allocation Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Estimated useful life Finite-Lived Intangible Asset, Useful Life 2020 Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two Finite-Lived Intangible Assets, Major Class Name [Domain] 2019 Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months Furniture & Equipment [Member] Furniture and Fixtures [Member] Furniture and equipment Furniture and Fixtures, Gross Loss on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment GOODWILL Goodwill Disclosure [Text Block] Goodwill Beginning balance Ending balance Goodwill Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Goodwill acquired during the year Goodwill, Acquired During Period Goodwill adjustments for purchase price allocation of business acquired in prior year Goodwill [Roll Forward] Goodwill [Roll Forward] GOODWILL [Abstract] Gross Profit Gross Profit Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest CONSOLIDATED STATEMENTS OF NET INCOME (unaudited) [Abstract] Provision for income taxes Income Tax Expense (Benefit) Income Taxes Income Tax, Policy [Policy Text Block] Income taxes Income Taxes Paid, Net Increase in accounts receivable - other Increase (Decrease) in Accounts Receivable and Other Operating Assets Increase in patient accounts receivable Increase (Decrease) in Accounts Receivable Increase in accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] (Increase) decrease in other assets Increase (Decrease) in Other Operating Assets (Decrease) increase in other liabilities Increase (Decrease) in Other Operating Liabilities Increase (Decrease) in Stockholders' Equity [Roll Forward] INTANGIBLE ASSETS, NET [Abstract] Other identifiable intangible assets, net Total Intangible Assets, Net (Excluding Goodwill) INTANGIBLE ASSETS, NET Intangible Assets Disclosure [Text Block] Interest and other income, net Interest and Other Income Interest expense recognized Interest Expense on Prepetition Liabilities Recognized in Statement of Operations Interest expense: Interest Expense [Abstract] Total interest expense Interest Expense Interest Interest Paid, Net Salaries and related costs Labor and Related Expense Leasehold improvements Leasehold Improvements, Gross Leasehold Improvements [Member] Leasehold Improvements [Member] Total liabilities, redeemable non-controlling interests, USPH shareholders' equity and non-controlling interests Liabilities and Equity Total liabilities Liabilities LIABILITIES, REDEEMABLE NON-CONTROLLING INTERESTS, USPH SHAREHOLDERS' EQUITY AND NON-CONTROLLING INTERESTS Liabilities and Equity [Abstract] Total current liabilities Liabilities, Current Current liabilities: Liabilities, Current [Abstract] Percentage of unused commitment fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Revolving credit facility commitment Line of Credit Facility, Maximum Borrowing Capacity Remaining revolving credit outstanding Line of Credit Facility, Remaining Borrowing Capacity Average effective interest rate Average effective interest rate Line of Credit Facility, Interest Rate During Period Payments/Long term debt, Total Payments/Long term debt, Total Long Term Debt By Maturity [Abstract] Long-term Debt, Fiscal Year Maturity [Abstract] During the twelve months ended March 31, 2022 During the twelve months ended March 31, 2021 Long-term Debt, Maturities, Repayments of Principal in Year Three Current portion of notes payable Less current portion Long-term Debt, Current Maturities During the twelve months ended March 31, 2019 Aggregate principal payment due in 2018 Notes payable, net of current portion Notes Payable, Noncurrent Long term portion Long-term Debt, Excluding Current Maturities During the twelve months ended March 31, 2020 Aggregate principal payment due in 2019 Long-term Debt, Maturities, Repayments of Principal in Year Two Revolving line of credit Long-term Line of Credit, Noncurrent Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Purchase of non-controlling interest Non-controlling interests Stockholders' Equity Attributable to Noncontrolling Interest Distributions to non-controlling interest partners Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Net (cash used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Operating results allocated to redeemable non-controlling interest partners Net Income (Loss) Attributable to Redeemable Noncontrolling Interest INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Computation of earnings per share - USPH shareholders Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net income attributable to USPH shareholders Net income attributable to USPH shareholders Less: net income attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Recently Adopted Accounting Guidance Non-compete Agreements [Member] Number of business segments Number of clinic practices acquired Number of clinics Number of Businesses Acquired Number of states where clinics are operated Number of States in which Entity Operates Other Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable Changes in the fair value of redeemable non-controlling interest Noncontrolling Interest, Increase from Sale of Parent Equity Interest Non-controlling Interests [Member] Noncontrolling Interest [Member] Ownership [Axis] Ownership [Domain] Officer [Member] Operating income Operating Income (Loss) BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Other assets Other Assets, Noncurrent Other current assets Other Assets, Current Other long-term liabilities Other Liabilities, Noncurrent Other Other Accrued Liabilities, Current Products and Services [Domain] Total Shareholders' Equity [Member] Parent [Member] ACCRUED EXPENSES [Abstract] Purchase of non-controlling interest Payments for (Proceeds from) Businesses and Interest in Affiliates Payments to settle mandatorily redeemable non-controlling interests Payments for Repurchase of Redeemable Noncontrolling Interest Distributions to non-controlling interests Payments of Ordinary Dividends, Noncontrolling Interest Purchase of businesses, net of cash acquired Cash paid, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Cash paid for acquisition of interest in clinic Payments to Acquire Businesses, Gross Purchase of fixed assets Payments to Acquire Productive Assets Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding Preferred Stock, Value, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Other Proceeds from (Payments for) Other Financing Activities Proceeds from revolving line of credit Proceeds from Lines of Credit Proceeds on sale of fixed assets Proceeds from Sale of Productive Assets Products and Services [Axis] Net income including non-controlling interests Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Fixed assets: Property, Plant and Equipment, Net [Abstract] Fixed assets, net Property, Plant and Equipment, Net Fixed assets, gross Property, Plant and Equipment, Gross Estimated useful lives Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Provision for doubtful accounts Provision for Doubtful Accounts Range [Domain] Range [Domain] Range [Axis] Range [Axis] Allowance for Doubtful Accounts Changes in Carrying Amount of Redeemable Non-Controlling Interests [Roll Forward] Changes in Carrying Amount of Redeemable Non-Controlling Interest Redeemable Noncontrolling Interest [Table Text Block] Redeemable Noncontrolling Interest, by Legal Entity [Table] Redeemable Noncontrolling Interest [Line Items] Redeemable non-controlling interests Beginning balance Ending balance Fair value Principal payments on notes payable Repayments of Notes Payable Payments on revolving line of credit Repayments of Lines of Credit Payment of debt Repayments of Debt Closure costs Restructuring Charges Retained earnings Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Retained Earnings [Member] Revenue from Contract with Customer, Excluding Assessed Tax [Abstract] REVENUE RECOGNITION REVENUE RECOGNITION [Abstract] Net revenues Revenue related to the various categories Revenue from Contract with Customer, Excluding Assessed Tax Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Credit Facility [Member] Revolving Credit Facility [Member] Amortization of Tradename, Referral Relationships and Non-Competition Agreements Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Scenario, Unspecified [Domain] Computations of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Finite Lived Intangible Assets [Table] Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility Schedule of Maturities of Long-term Debt [Table Text Block] Intangible Assets, Net Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Schedule of Clinic Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Summary of Credit Agreement and Notes Payable Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Summary of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Corporate office costs Selling, General and Administrative Expense Equity-based awards compensation expense Mandatorily redeemable non-controlling interests Closing price (in dollars per share) Ending balance (in shares) Beginning balance (in shares) Shares, Outstanding Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Statement [Line Items] CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY [Abstract] CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) [Abstract] CONSOLIDATED BALANCE SHEETS (unaudited) [Abstract] Scenario [Axis] Statement [Table] Equity Components [Axis] Issuance of restricted stock, net of cancellation Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Common stock authorized by the Board of Directors (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Issuance of restricted stock, net of cancellation (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Total purchased shares (in shares) Total USPH shareholders' equity and non-controlling interests Ending balance Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total USPH shareholders' equity Stockholders' Equity Attributable to Parent U.S. Physical Therapy, Inc. ("USPH") shareholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Other Stockholders' Equity, Other COMMON STOCK Stockholders' Equity Note Disclosure [Text Block] Subsequent Event Subsequent Events, Policy [Policy Text Block] Subsequent Event Type [Domain] Subsequent Event Type [Axis] Subsequent Event [Member] NewCo. [Member] SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Relationship to Entity [Domain] Relationship to Entity [Domain] Title of Individual [Axis] Title of Individual [Axis] Tradenames [Member] Trademarks [Member] Treasury stock at cost, 2,214,737 shares Treasury Stock, Value Treasury Stock [Member] Treasury Stock [Member] Treasury stock (in shares) Treasury Stock, Shares Unrecognized tax benefit Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Accrued interest and penalties associated with any unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Shares used in computation - basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Cash Paid During Period For [Abstract] Cash paid during the period for: Purchase of business - seller financing portion in noncash investing or financing activities. Purchase Of Business Seller Financing Portion Purchase of business - seller financing portion Amount of increase (decrease) in mandatorily redeemable non-controlling interests. Increase (decrease) in Mandatorily Redeemable Non-controlling Interests Increase in mandatorily redeemable non-controlling interests Debt related expenses and other expenses associated with nonoperating financing activities of the entity. Interest Expense, Debt and Other Expense Debt and other Amount of expense related to rent, supplies, contract labor and other. Rent Supplies Contract Labor And Other Rent, supplies, contract labor and other Refers to expenses related to earnings from mandatorily redeemable non-controlling interests. This expenses associated with nonoperating financing activities of the entity. Interest Expense, Mandatorily Redeemable Non-controlling Interests - Earnings Allocable Mandatorily redeemable non-controlling interests - earnings allocable Refers to expenses related to increase (decrease) in redemption value from mandatorily redeemable non-controlling interests. This expenses associated with non-operating financing activities of the entity. Interest Expense, Mandatorily Redeemable Non-controlling Interests - Increase (Decrease) in Redemption Value Mandatorily redeemable non-controlling interests - change in redemption value Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. Net Patient Revenues [Member] Net Patient Revenues [Member] Other revenues includes management contract revenues, industrial injury prevention services revenues and services provided on-site, such as schools and industrial worksites, for physical or occupational therapy services, and athletic trainers and gym membership fees. Contract terms and rates are agreed to in advance between the Company and the third parties. Services are typically performed over the contract period and revenue is recorded in accordance with the contract terms. If the services are paid in advance, revenue is deferred over the period of the agreement and recognized when the services are performed. Other Revenues Including Management Contract Revenues and Industrial Injury Prevention Services Revenues [Member] Other Revenues [Member] Charges to Retained Earnings [Abstract] Charges to Retained Earnings [Abstract] The portion of profit or loss for the period, net of income taxes, which is attributable to the parent after revaluation of noncontrolling interest. Income Loss From Operations After Revaluation Of NonControlling Interests Net income attributable to common shareholders The amount of income tax expense or benefit for the period computed by applying the domestic federal and state statutory tax rates to pretax income. Income Tax Reconciliation Income Tax Expense Benefit At Federal and State Statutory Income Tax Rate Tax effect at statutory rate (federal and state) of 26.25% The amount of income (loss) from revaluation of redeemable noncontrolling interest. Charges To Retained Earnings Revaluation Of Non Controlling Interests Revaluation of redeemable non-controlling interest Percentage of domestic federal and state statutory tax rate applicable to pretax income (loss). Effective Income Tax Rate Reconciliation At Federal and State Statutory Income Tax Rate Federal and state statutory income tax rate Document And Entity Information [Abstract] Estimated Fair Value Of Net Tangible Assets Acquired [Abstract] Estimated fair value of net tangible assets acquired [Abstract] The amount of non-competition agreements recognized as of the acquisition date. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Non Competition Agreements Non-compete This element represents the fair value of the redeemable noncontrolling interest in the acquiree at the acquisition date. Business Combination Acquisition Fair Value of Redeemable Non-Controlling Interests Fair value of non-controlling interest (classified as redeemable non-controlling interests) Payments to acquire businesses total consideration. Payments To Acquire Businesses Consideration Total consideration Total consideration Amount of referral relationships at the acquisition date. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Referral Relationships Referral relationships Refers to number of management contracts. Number of management contracts Number of management contracts Amount of net tangible asset acquired at the acquisition date. Business Acquisition Purchase Price Allocation Net Tangible Asset Net tangible assets acquired The amount of tradename recognized as of the acquisition date. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tradename Tradename The amount of business acquisition cost of acquired entity debt issued on the date of acquisition. Business Acquisition Cost Of Acquired Entity Debt Issued Seller notes Seller notes issued for acquisition of interest in clinic Number of clinics consolidated with the existing clinics during the period. Number Of Clinics Consolidated With Existing Clinics Number of clinics consolidated with an existing clinic Business acquisition number of installments to payment of purchase consideration. Business Acquisition Number Of Installments To Payment Of Purchase Consideration Business acquisition number of installments to payment of purchase consideration Acquisition of nine clinic practices for an aggregate amount of cash. Acquisition Of Nine Clinic Practices [Member] Acquisition of seventeen clinic practices for an aggregate amount of cash. Acquisition of Seventeen Clinic Practices [Member] Acquisition of Seventeen Clinic Practices [Member] Number of clinics operates as a satellite clinic with existing partnerships during the period. Number Of Clinics Operates As a Satellite Clinic With Existing Partnerships Number of clinics that operate as a satellite clinic with existing partnerships Acquisition of four clinic practices for an aggregate amount of cash. Acquisition Of Four Clinic Practices [Member] Amount of business acquisition principal installments payable at cost of acquired by entity at accrued interest. Business Acquisition Principal Installments Payable At Cost Of Acquired By Entity At Accrued Interest Acquisition cost payable in two principal installments including accrued interest Acquisition of part of a company which provides workforce performance solutions. Workforce Performance Solutions [Member] Useful life of acquired finite-lived intangible assets in business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Business Combination, Acquired Finite-Lived Intangible Asset, Useful Life Estimated useful lives of acquired intangibles Acquisition of two clinic practices for an for an aggregate amount of cash. Acquisition Of Two Clinic Practices [Member] Acquisition Of Two Clinic Practices [Member] Referral relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships. Referral Relationship [Member] Referral Relationships [Member] Refers to the first principal installment plus accrued interest payable date. October Two Thousand Nineteen [Member] October 2019 [Member] Refers to the principal installment plus accrued interest payable date. January Two Thousand Nineteen [Member] January 2019 [Member] Refers to the principal installment plus accrued interest payable date. January Two Thousand Eighteen [Member] January 2018 [Member] Refers to the principal installment plus accrued interest payable date. June Two Thousand Nineteen [Member] June 2019 [Member] Refers to the principal installment plus accrued interest payable date. May Two Thousand Nineteen [Member] May 2019 [Member] Refers to the principal installment plus accrued interest payable date. May Two Thousand Eighteen [Member] May 2018 [Member] Refers to the first principal installment plus accrued interest payable date. October Two Thousand Eighteen [Member] October 2018 [Member] Refers to the first principal installment plus accrued interest payable date. June Two Thousand Eighteen [Member] June 2018 [Member] A written promise to pay a note to a third party. Promissory Notes [Member] 3.25% through 4.25% Notes Payable due in Next Year [Member] A table or schedule providing information pertaining to depreciation amortization impairment. Depreciation Amortization Impairment [Table] Depreciation Amortization Impairment [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Depreciation Amortization Impairment [Line Items] Depreciation Amortization Impairment [Line Items] Number of regions of the entity operates. Number of regions Number of third party facilities. Number Of Third Party Facilities Number of third party facilities Refers to the commencement period of redemption rights for redeemable non controlling interest. Redeemable Non-controlling Interest, Redemption Rights, Commencement Period Redeemable non-controlling interest, redemption rights, commencement period Percentage of limited partnership interest owned during the period. Percentage Of Limited Partnership Interest Owned Percentage of limited partnership interest owned Percentage of general partnership interest owned during the period. Percentage Of General Partnership Interest Owned Percentage of general partnership interest owned Number of clinics operated during the period. Number Of Clinics Operated Number of clinics operated Date of business acquisition. March Two Thousand Seventeen Acquisition [Member] March 2017 Acquisition [Member] Acquisition of part of a company which provides services include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. Leading Provider of Industrial Injury Prevention [Member] Industrial Injury Prevention [Member] Person who is employed by the company. Employee [Member] Disclosure of accounting policy for non-controlling interests. Non controlling Interests Policy [Policy Text Block] Non-Controlling Interests Disclosure of accounting policy for self-insurance program. Self Insurance Program Policy [Policy Text Block] Self-Insurance Program Disclosure of accounting policy for redeemable non-controlling interests. Redeemable Non Controlling Interests [Policy Text Block] Redeemable Non-Controlling Interests Disclosure of accounting policy for new accounting pronouncements that have been issued but not yet adopted. Recently Issued Accounting Guidance [Policy Text Block] Recently Issued Accounting Guidance Disclosure of accounting policy for restricted stock. Restricted Stock Policy [Policy Text Block] Restricted Stock Amount of distributions during the period on mandatorily redeemable securities net of tax. Revaluation of Redeemable Non-controlling Interest Net of Tax Revaluation of redeemable non-controlling interest, net of tax Refers to transfer of compensation liability for certain stock issued pursuant to incentive plans. Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans Transfer of compensation liability for certain stock issued pursuant to long-term incentive plans MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS [Abstract] The entire disclosure for a mandatorily redeemable non-controlling interests. Mandatorily Redeemable Noncontrolling Interests [Text Block] MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS Date of business acquisition. October Two Thousand Seventeen Acquisition [Member] October 2017 Acquisition [Member] Date of business acquisition. January Two Thousand Seventeen Acquisition [Member] January 2017 Acquisition [Member] Date of business acquisition. May Two Thousand Seventeen Acquisition [Member] May 2017 Acquisition [Member] Date of business acquisition. June Two Thousand Seventeen Acquisition [Member] June 2017 Acquisition [Member] Date of business acquisition. Two Thousand Seventeen Acquisition [Member] 2017 Acquisition [Member] Date of business acquisition. Two Thousand Eighteen Acquisition [Member] 2018 Acquisition [Member] A written promise to pay a note. Notes Payable [Member] Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred. Dividends Cash After Amendment Cash dividends after amendment The percentage points added to the reference rate to compute the variable rate on the debt instrument. Debt Instrument Basis Spread On Libor Variable Rate Spread on Libor variable rate Amount of cash and noncash consideration that could pay with respect to acquisition. Cash And Noncash Consideration With Respect To Acquisition After Amendement Cash and noncash consideration with respect to acquisition after amendment A credit agreement is a legal contract in which a bank arranges to loan a customer a certain amount of money for a specified amount of time. Credit Agreement [Member] Carrying value as of the balance sheet date of obligations incurred due to patients and payors . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Patients And Payors Related Liability Credit balances due to patients and payors Bank credit agreement to permit share repurchases of common stock during the period. Bank Credit Agreement To Permit Share Repurchases Of Common Stock Bank credit agreement to permit share repurchases of common stock Maximum percentage of repurchase of common stock during the period. Maximum Percentage Of Repurchase Of Common Stock Maximum percentage of repurchase of common stock Additional estimated repurchase of common stock during the period. Additional Estimated Repurchase Of Common Stock Additional estimated shares (in shares) Refers to the acquiree entity Therapy Practice. Therapy Practice [Member] Refers to the term of non-compete agreement under the condition if an Employed Selling Shareholders' employment is terminated (if the Selling Shareholder becomes an Employed Selling Shareholder). Non-Compete Agreement Term under Condition of Termination of Employment of Employed Selling Shareholder Non-Compete agreement term under condition of termination of employment of employed selling shareholder Refers to the term of the note issued for consideration payable for the acquisition. Business Acquisition Consideration Payable, Term of Note Business acquisition, consideration payable, term of note Refers to the required redemption term under condition of termination of an Employed Selling Shareholder's employment with subsidiary , regardless of the reason for such termination. Required Redemption Term, under Condition of Termination of Employment of Employed Selling Shareholders Required redemption term, under condition of termination of employment of employed selling shareholders Refers to the percentage of general partnership interest acquired in the business combination. Business Acquisition, Percentage of General Partnership Interest Acquired Business acquisition, percentage of general partnership interest acquired Refers to the term of employment agreement with the subsidiary entity. Term of Employment Agreement Employment agreement term Refers to the renewal term of the employment agreement with the subsidiary entity. Employment Agreement Renewal Term Employment agreement renewal term Refers to the percentage of equity interest in subsidiary contributed for acquisition. Business Acquisition Percentage Of Equity Interest In Subsidiary Contributed Percentage of equity interest of subsidiary contributed for acquisition Refers to the term of non-compete agreement regardless of whether the Selling Shareholder is employed by the subsidiary entity. Non-Compete Agreement Term under Condition Two Non-Compete agreement term regardless of whether the selling shareholder is employed Refers to the percentage of limited partnership interest acquired in the business combination. Business Acquisition, Percentage of Limited Partnership Interest Acquired Business acquisition, percentage of limited partnership acquired Medicare payment year. Year2018 [Member] Year 2018 [Member] Medicare payment year. Year2019 [Member] Year 2019 [Member] Medicare Reimbursement [Abstract] Percentage of medicare payment increase during the period. Percentage Of Medicare Payment increase Percentage of increase in medicare payment rates Combined physical therapy/speech language pathology expenses during the period. Combined Physical Therapy Speech Language Pathology Expenses Combined physical therapy/speech language pathology expenses Expected reduction in Medicare spending percentage during the period. Expected Reduction In Medicare Spending Percentage Expected reduction in Medicare spending percentage Refers to percentage of bonus payment proposed by the agency. Percentage Of Bonus Payment Percentage of bonus payment by APM Contractual Allowances [Abstract] Maximum difference between actual aggregate contractual reserve percentage as compared to estimated contractual allowance reserve percentage. Difference Between Actual Aggregate Contractual Reserve Percentages As Compared To Estimated Contractual Allowance Reserve Percentage Difference between actual aggregate contractual reserve and estimated contractual allowance reserve percentage Difference between net revenues and corresponding cash collections reflected percentage of net revenues. Difference Between Net Revenues And Corresponding Cash Collections Reflected Percentage Of Net Revenues Difference between net revenues and corresponding cash collections, approximately of net revenues Maximum contractual allowance reserve estimate. Maximum Contractual Allowance Reserve Estimate Maximum contractual allowance reserve estimate Annual Limit occupational therapy services during the period. Annual Limit Occupational Therapy Services Annual limit occupational therapy services Reduction in Combined physical therapy/speech language pathology expenses during the period. Reduction In Combined Physical Therapy Speech Language Pathology Expenses Reduction in combined physical therapy/speech language pathology expenses Reduction in Medicare spending percentage during the period. Reduction In Medicare Spending Percentage Medicare spending cut percentage Annual Limit on physical therapy and speech language pathology services during the period. Annual Limit On Physical Therapy And Speech Language Pathology Services Annual limit on physical therapy and speech language pathology services Percentage reduction for service in office or other non institutional settings during the period. Percentage Reduction For Service In Office Or Other Non Institutional Settings Percentage reduction for service Medicare payment year. Year 2017 [Member] This element represents the period of federal debt ceiling in connection with deficit reductions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period Of Federal Debt Ceiling In Connection With Deficit Reductions Federal debt ceiling in connection with deficit reductions Refers to the percentage of payment for outpatient therapy services to the therapy assistant. Percentage of Payment for Outpatient Therapy Services Percentage of payment for outpatient therapy services Amount of reductions in federal spending during the period. Amount Of Reductions In Federal Spending Reductions in federal spending Net revenue from Medicare. Net revenue from Medicare Net patient revenue from Medicare accounts Percentage of practice expense component of relative value unit during the period. Percentage Of Practice Expense Component Of Relative Value Unit Percentage of practice expense component Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. Revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Management Contract Revenues [Member] Insurance products service years. From Two Thousand Twenty Through Two Thousand Twenty Five [Member] From 2020 through 2025 [Member] Other revenues include services provided on-site, such as schools and industrial worksites, for physical or occupational therapy services, and athletic trainers and gym membership fees. Contract terms and rates are agreed to in advance between the Company and the third parties. Services are typically performed over the contract period and revenue is recorded in accordance with the contract terms. If the services are paid in advance, revenue is deferred over the period of the agreement and recognized when the services are performed. Other Revenues [Member] Insurance products service years. From Two Thousand Nineteen Through Two Thousand Twenty Four [Member] From 2019 through 2024 [Member] Revenues from the industrial injury prevention business are derived from onsite services provided to clients' employees including injury prevention, rehabilitation, ergonomic assessments and performance optimization. Revenues are determined based on the number of hours and respective rate for services provided. The Company has agreements with third-party payers that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payer contracts and historical collection and write-off experience. Industrial Injury Prevention Services Revenues [Member] Industrial Injury Prevention Services Revenues [Member] REDEEMABLE NON-CONTROLLING INTERESTS [Abstract] The entire disclosure for a redeemable non-controlling interests. REDEEMABLE NON-CONTROLLING INTERESTS [Text Block] REDEEMABLE NON-CONTROLLING INTERESTS Represents the upper bound of a range for the estimate of fair value as of the reporting date of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. Redeemable Non-Controlling Interest [Member] Carrying Amount of Redeemable Non-Controlling Interest [Abstract] Carrying Amount (Fair Value) of Redeemable Non-Controlling Interest [Abstract] Refers to amount of contractual time period had lapsed but holder's employment had not been terminated as of balance sheet date. Contractual Time Period Has Lapsed But Holders Employment Has Not Been Terminated Contractual time period has lapsed but holder's employment has not been terminated Refers to amount of contractual time period had not lapsed and holder's employment had not been terminated as of balance sheet date. Contractual Time Period Has Not Lapsed And Holders Employment Has Not Been Terminated Contractual time period has not lapsed and holder's employment has not been terminated The distributions during the period for redemption of mandatorily redeemable noncontrolling interests. Distributions to Limited Partners and Redeemable Noncontrolling Interests Distributions to redeemable non-controlling interest partners Tabular disclosure of carrying amount of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. Carrying Amount of Redeemable Non-Controlling Interest [Table Text Block] Carrying Amount of (Fair Value) Redeemable Non-Controlling Interest EX-101.PRE 11 usph-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2018
May 07, 2018
Document And Entity Information [Abstract]    
Entity Registrant Name U S PHYSICAL THERAPY INC /NV  
Entity Central Index Key 0000885978  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   12,669,538
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2018  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 19,813 $ 21,933
Patient accounts receivable, less allowance for doubtful accounts of $2,517 and $2,273, respectively 46,228 44,707
Accounts receivable - other 6,504 5,655
Other current assets 3,050 4,786
Total current assets 75,595 77,081
Fixed assets:    
Furniture and equipment 51,569 51,100
Leasehold improvements 29,981 29,760
Fixed assets, gross 81,550 80,860
Less accumulated depreciation and amortization 61,742 60,475
Fixed assets, net 19,808 20,385
Goodwill 273,770 271,338
Other identifiable intangible assets, net 47,092 48,954
Other assets 1,357 1,224
Total assets 417,622 418,982
Current liabilities:    
Accounts payable - trade 1,722 2,165
Accrued expenses 38,342 33,342
Current portion of notes payable 5,317 4,044
Total current liabilities 45,381 39,551
Notes payable, net of current portion 782 2,728
Revolving line of credit 42,000 54,000
Mandatorily redeemable non-controlling interests 0 327
Deferred taxes 10,151 10,875
Deferred rent 2,005 2,116
Other long-term liabilities 733 743
Total liabilities 101,052 110,340
Redeemable non-controlling interests 108,085 102,572
Commitments and contingencies
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity:    
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding 0 0
Common stock, $.01 par value, 20,000,000 shares authorized, 14,884,676 and 14,809,299 shares issued, respectively 149 148
Additional paid-in capital 75,543 73,940
Retained earnings 162,907 162,406
Treasury stock at cost, 2,214,737 shares (31,628) (31,628)
Total USPH shareholders' equity 206,971 204,866
Non-controlling interests 1,514 1,204
Total USPH shareholders' equity and non-controlling interests 208,485 206,070
Total liabilities, redeemable non-controlling interests, USPH shareholders' equity and non-controlling interests $ 417,622 $ 418,982
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Allowance for doubtful accounts, patient accounts receivable $ 2,517 $ 2,273
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 500,000 500,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, shares issued (in shares) 14,884,676 14,809,299
Treasury stock (in shares) 2,214,737 2,214,737
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF NET INCOME (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Net revenues $ 108,342 $ 97,565
Operating costs:    
Salaries and related costs 62,279 55,827
Rent, supplies, contract labor and other 21,776 20,087
Provision for doubtful accounts 1,061 898
Closure costs 12 6
Total operating costs 85,128 76,818
Gross Profit 23,214 20,747
Corporate office costs 10,163 8,547
Operating income 13,051 12,200
Interest and other income, net 32 24
Interest expense:    
Mandatorily redeemable non-controlling interests - change in redemption value 0 (2,669)
Mandatorily redeemable non-controlling interests - earnings allocable 0 (1,294)
Debt and other (553) (415)
Total interest expense (553) (4,378)
Income before taxes 12,530 7,846
Provision for income taxes 2,476 1,812
Net income 10,054 6,034
Less: net income attributable to non-controlling interests (2,937) (1,218)
Net income attributable to USPH shareholders $ 7,117 $ 4,816
Basic and diluted earnings per share attributable to USPH shareholders (in dollars per share) $ 0.27 $ 0.38
Shares used in computation - basic and diluted (in shares) 12,616 12,528
Dividends declared per common share (in dollars per share) $ 0.23 $ 0.20
Net Patient Revenues [Member]    
Net revenues $ 100,552 $ 93,654
Other Revenues [Member]    
Net revenues $ 7,790 $ 3,911
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
OPERATING ACTIVITIES    
Net income including non-controlling interests $ 10,054 $ 6,034
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities:    
Depreciation and amortization 2,468 2,356
Provision for doubtful accounts 1,061 898
Equity-based awards compensation expense 1,381 1,280
Loss on sale of fixed assets 54 33
Deferred income taxes (1,162) (250)
Changes in operating assets and liabilities:    
Increase in patient accounts receivable (2,782) (1,542)
Increase in accounts receivable - other (849) (3,697)
(Increase) decrease in other assets (1,238) 757
Increase in accounts payable and accrued expenses 7,389 5,315
Increase in mandatorily redeemable non-controlling interests 0 2,911
(Decrease) increase in other liabilities (845) 76
Net cash provided by operating activities 15,531 14,171
INVESTING ACTIVITIES    
Purchase of fixed assets (1,404) (1,587)
Purchase of businesses, net of cash acquired (761) (15,670)
Purchase of non-controlling interest (246) 0
Proceeds on sale of fixed assets 0 62
Net cash used in investing activities (2,411) (17,195)
FINANCING ACTIVITIES    
Distributions to non-controlling interests (2,208) (937)
Proceeds from revolving line of credit 19,000 32,000
Payments on revolving line of credit (31,000) (20,000)
Payments to settle mandatorily redeemable non-controlling interests (265) (2,230)
Principal payments on notes payable (823) (702)
Other 56 0
Net (cash used in) provided by financing activities (15,240) 8,131
Net increase in cash and cash equivalents (2,120) 5,107
Cash and cash equivalents - beginning of period 21,933 20,047
Cash and cash equivalents - end of period 19,813 25,154
Cash paid during the period for:    
Income taxes 2,941 86
Interest 526 599
Non-cash investing and financing transactions during the period:    
Purchase of business - seller financing portion $ 150 $ 900
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (unaudited) - 3 months ended Mar. 31, 2018 - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Treasury Stock [Member]
Total Shareholders' Equity [Member]
Non-controlling Interests [Member]
Total
Beginning balance at Dec. 31, 2017 $ 148 $ 73,940 $ 162,406 $ (31,628) $ 204,866 $ 1,204 $ 206,070
Beginning balance (in shares) at Dec. 31, 2017 14,809     (2,215)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of restricted stock, net of cancellation $ 1 0 0 $ 0 1 0 1
Issuance of restricted stock, net of cancellation (in shares) 76     0      
Revaluation of redeemable non-controlling interest, net of tax $ 0 0 (3,747) $ 0 (3,747) 0 (3,747)
Compensation expense - equity-based awards 0 1,381 0 0 1,381 0 1,381
Transfer of compensation liability for certain stock issued pursuant to long-term incentive plans 0 373 0 0 373 0 373
Purchase of non-controlling interest 0 (151) 0 0 (151) (42) (193)
Dividends payable to USPT shareholders 0 0 (2,914) 0 (2,914) 0 (2,914)
Distributions to non-controlling interest partners 0 0 0 0 0 (849) (849)
Other 0 0 45 0 45 0 45
Net income 0 0 7,117 0 7,117 1,201 8,318
Ending balance at Mar. 31, 2018 $ 149 $ 75,543 $ 162,907 $ (31,628) $ 206,971 $ 1,514 $ 208,485
Ending balance (in shares) at Mar. 31, 2018 14,885     (2,215)      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2018
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries (the “Company”). All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest in all the Clinic Partnerships. Our limited partnership interests range from 49% to 99% in the Clinic Partnerships.  The managing therapist of each clinic owns, directly or indirectly, the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as “Clinic Partnerships”). To a lesser extent, the Company operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with therapists (hereinafter referred to as “Wholly-Owned Facilities”).

In March 2017, the Company acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. Services provided include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers including a number of Fortune 500 companies. Other clients include large insurers and their contractors.

The Company continues to seek to attract for employment physical therapists who have established relationships with physicians and other referral sources by offering these therapists a competitive salary and incentives based on the profitability of the clinic that they manage. The Company also looks for therapists with whom to establish new, de novo clinics to be owned jointly by the Company and such therapists; in these situations, the therapist is offered the opportunity to co-invest in the new clinic and also receives a competitive salary for managing the clinic. For multi-site clinic practices in which a controlling interest is acquired by the Company, the prior owners typically continue on as employees to manage the clinic operations, retaining a non-controlling ownership interest in the clinics and receiving a competitive salary for managing the clinic operations. In addition, the Company has developed satellite clinic facilities as part of existing Clinic Partnerships and Wholly-Owned facilities, with the result that a substantial number of Clinic Partnerships and Wholly-Owned facilities operate more than one clinic location. In 2018, we intend to continue to acquire clinic practices and continue to focus on developing new clinics and opening satellite clinics where appropriate, along with increasing our patient volume through marketing and new programs.

On February 28, 2018, the Company, through one of its majority owned Clinic Partnerships, acquired two clinic practices.  These practices will operate as satellites of the existing Clinic Partnership.

During the year ended December 31, 2017, the Company acquired an interest in the following clinic groups:

 
Date 
% Interest Acquired
  
Number of Clinics
 
 
 
      
January 2017 Acquisition
January 1
 
70%
 
  
17
 
May 2017 Acquisition
May 31
 
70%
 
  
4
 
June 2017 Acquisition
June 30
 
60%
 
  
9
 
October 2017 Acquisition
October 31
 
70%
 
  
9
 

Also, during the 2017 year, the Company purchased the assets and business of two physical therapy clinics in separate transactions.  One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing Clinic Partnerships.

As of March 31, 2018, the Company operated 580 clinics in 42 states as well as the industrial injury prevention business.  The Company also manages physical therapy facilities for third parties, primarily physicians, with 28 third-party facilities under management as of March 31, 2018.

The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.  The Company intends to continue to pursue additional acquisition opportunities, develop new clinics and open satellite clinics.
 
The accompanying unaudited consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions for Form 10-Q. However, the statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. Management believes this report contains all necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. For further information regarding the Company’s accounting policies, please read the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate Controller have certified, that the financial statements included in this report present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented.

Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results the Company expects for the entire year.  Please also review the Risk Factors section included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Clinic Partnerships

For non-acquired Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interests, typically owned by the managing therapist, directly or indirectly, are recorded within the balance sheets and income statements as non-controlling interests.  For acquired Clinic Partnerships with mandatorily redeemable non-controlling interests, the earnings and liabilities attributable to the non-controlling interest were recorded within the consolidated statements of income line item: Interest expense – mandatorily redeemable non-controlling interests – earnings allocable and in the consolidated balance sheet line item: Mandatorily redeemable non-controlling interests.  For acquired Clinic Partnerships with redeemable non-controlling interests, the earnings attributable to the redeemable non-controlling interests are recorded within the consolidated statements of income line item – net income attributable to non-controlling interests and the equity interests are recorded on the consolidated balance sheet as redeemable non-controlling interests.

Effective December 31, 2017, the Company entered into amendments to its acquired limited partnership agreements replacing the mandatory redemption feature. No monetary consideration was paid to the partners to amend the agreements.   The amended limited partnership agreements provide that, upon certain events, the Company has a call right (the “Call Right”) and the selling entity has a put right (the “Put Right”) for the purchase and sale of the limited partnership interest held by the partner.  Once triggered, the Put Right and the Call Right do not expire, even upon an individual partner’s death, and contain no mandatory redemption feature.  The purchase price of the partner’s limited partnership interest upon the exercise of either the Put Right or the Call Right is calculated per the terms of the respective agreements.  The Company accounted for the amendment of its limited partnership agreements as an extinguishment of the outstanding Seller Entity Interests, as defined in Footnote 5, classified as liabilities through the issuance of new Seller Entity Interests classified in temporary equity. Pursuant to ASC 470-50-40-2, the Company removed the outstanding liability-classified Seller Entity Interests at their carrying amounts, recognized the new temporary-equity-classified Seller Entity Interests at their fair value, and recorded  no gain or loss on extinguishment, as management believes the redemption value (i.e. the carrying amount) and fair value are the same.  In summary, the redemption values of the mandatorily redeemable non-controlling interest (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet. The remaining balance of $327,000 in the line item – Mandatorily redeemable non-controlling interests – relates to one limited partnership agreement that was not amended, as the non-controlling interest was purchased by the Company in January 2018.  See Footnote 5 - Mandatorily redeemable non-controlling interests – and Footnote 6 - Redeemable non-controlling interests – for further discussion.

Wholly-Owned Facilities

For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due to the profit sharing therapists. The amount is expensed as compensation and included in operating costs – salaries and related costs. The respective liability is included in current liabilities – accrued expenses on the balance sheets.
 
Significant Accounting Policies

Cash Equivalents

The Company maintains its cash and cash equivalents at financial institutions.  The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.  The combined account balances at several institutions typically exceed Federal Deposit Insurance Corporation (“FDIC”) insurance coverage and, as a result, there is a concentration of credit risk related on deposits in excess of FDIC insurance coverage. Management believes that the risk is not significant.

Long-Lived Assets

Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for purchased software from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.

Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Goodwill

Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain identifiable intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital.

The fair value of goodwill and other identifiable intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company evaluates indefinite lived tradenames using the relief from royalty method in conjunction with its annual goodwill impairment test.  The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining the Company’s reporting units when performing its annual goodwill impairment test. In the first quarter of 2018, there were six regions.  In addition to the six regions, in 2017, the impairment test included a separate analysis for the industrial injury prevention business, a separate reporting unit.

An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other identifiable intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2017, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation of goodwill in 2017, 2016 and 2015 did not result in any goodwill amounts that were deemed impaired.

The Company has not identified any triggering events occurring after the testing date that would impact the impairment testing results obtained.  The Company will continue to monitor for any triggering events or other indicators of impairment.
 
Redeemable Non-Controlling Interests

The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those that the owners and the Company have certain redemption rights, whether currently exercisable or not, and which currently, or in the future, require that the Company purchase or the owner sell the non-controlling interest held by the owner, if certain conditions are met.  The purchase price is derived at a predetermined formula based on a multiple of trailing twelve months earnings performance as defined in the respective limited partnership agreements.  The redemption rights can be triggered by the owner or the Company at such time as both of the following events have occurred: 1) termination of the owner’s employment, regardless of the reason for such termination, and 2) the passage of specified number of years after the closing of the transaction, typically three to five years, as defined in the limited partnership agreement.  The redemption rights are not automatic or mandatory (even upon death) and require either the owner or the Company to exercise its rights when the conditions triggering the redemption rights have been satisfied.

On the date the Company acquires a controlling interest in a partnership, and the limited partnership agreement for such partnership contains redemption rights not under the control of the Company, the fair value of the non-controlling interest is recorded in the consolidated balance sheet under the caption – Redeemable non-controlling interests.  Then, in each reporting period thereafter until it is purchased by the Company, the redeemable non-controlling interest is adjusted to the greater of its then current redemption value or initial value, based on the predetermined formula defined in the respective limited partnership agreement.  As a result, the value of the non-controlling interest is not adjusted below its initial value.  The Company records any adjustment in the redemption value, net of tax, directly to retained earnings and are not reflected in the consolidated statements of income.  Although the adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects the adjustments, net of tax, in the earnings per share calculation.  The amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income. Management believes the redemption value (i.e. the carrying amount) and fair value are the same.

Non-Controlling Interests

The Company recognizes non-controlling interests, in which the Company has no obligation but the right to purchase the non-controlling interests, as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the statements of net income. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling equity investment on the deconsolidation date.

When the purchase price of a non-controlling interest by the Company exceeds the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.

Revenue Recognition

Revenues are recognized in the period in which services are rendered. See Footnote 3 for further discussion of revenue recognition.

Allowance for Doubtful Accounts

The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.
 
Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Tax Cuts and Jobs Act of 2017 (the “TCJA”) was passed by Congress on December 20, 2017 and signed into law by President Trump on December 22, 2017. The TCJA makes significant changes to U.S. corporate income tax laws including a decrease in the corporate income tax rate to 21% effective January 1, 2018.

The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the twelve months ended March 31, 2018. The Company will book any interest or penalties, if required, in interest and other expense, as appropriate.

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount under the Amended Credit Agreement approximates its fair value. The interest rate on the Amended Credit Agreement, which is tied to the Eurodollar Rate, is set at various short-term intervals, as detailed in the Amended Credit Agreement.

Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance.  The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.

Use of Estimates

In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.

Self-Insurance Program

The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through March 31, 2018.

Restricted Stock

Restricted stock issued to employees and directors is subject to continued employment or continued service on the board, respectively. Generally, restrictions on the stock granted to employees, other than officers, lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the vesting period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.
 
Recently Adopted Accounting Guidance

In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The original standards were effective for fiscal years beginning after December 15, 2016; however, in July 2015, the FASB approved a one-year deferral of these standards, with a new effective date for fiscal years beginning after December 15, 2017. The standards require the selection of a retrospective or cumulative effect transition method.

The Company implemented the new standard beginning January 1, 2018 using a modified retrospective transition method.  Adoption of the new standard did not result in material changes to the presentation of net revenues and bad debt expense in the consolidated statements of income, and the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change relates to how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common forms of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company’s estimate for unrealizable amounts is recorded as a reduction of revenue. Under the new standards, the Company’s estimate for unrealizable amounts will continue to be recognized as a reduction to revenue. The bad debt expense historically reported will not materially change.

Recently Issued Accounting Guidance

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350), which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment change. ASU 2017-04 is effective prospectively for fiscal years, and the interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact.

In February 2016, the FASB issued amended accounting guidance (ASU 2016-02, Leases) which replaced most existing lease accounting guidance under U. S. generally accepted accounting principles. Among other changes, the amended guidance requires that a right-to-use asset, which is an asset that represents the lessee’s right to use, and a lease liability, which is a lessee’s obligation to make lease payments arising for a lease measured on a discounted basis, be recognized on the balance sheet by lessees for those leases with a term of greater than 12 months. The amended guidance is effective for reporting periods beginning after December 15, 2018; however, early adoption is permitted. Entities can use to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements or recognize the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings.

Since the Company leases all but one of its clinic facilities, upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will continue to be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of income.
 
The Company will implement the new standard beginning January 1, 2019. The Company’s implementation efforts are focused on populating the data in a lease accounting software package and developing internal controls in order to account for its leases under the new standard.
 
Subsequent Event

The Company has evaluated events occurring after the balance sheet date for possible disclosure as a subsequent event through the date that these consolidated financial statements were issued. On April 30, 2018, the Company acquired a 65% interest in a leading provider of industrial injury prevention for $9.0 million.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACQUISITIONS OF BUSINESSES
3 Months Ended
Mar. 31, 2018
ACQUISITIONS OF BUSINESSES [Abstract]  
ACQUISITIONS OF BUSINESSES
2. ACQUISITIONS OF BUSINESSES

On February 28, 2018, the Company purchased the assets and business of two physical therapy clinics, for an aggregate purchase price of $760,000 in cash and $150,000 in seller note that is payable, plus accrued interest, on August 31, 2019.

The purchase price for this acquisition has been preliminarily allocated as follows (in thousands):

Cash paid
 
$
760
 
Seller note
  
150
 
Total consideration
 
$
910
 
     
Referral relationships
  
36
 
Non-compete
  
18
 
Goodwill
  
856
 
  
$
910
 

On January 1, 2017, the Company acquired a 70% interest in a seventeen-clinic physical therapy practice.  The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that was payable in two principal installments totaling $250,000 each, plus accrued interest.  The first installment was paid in January 2018 and the second installment is due in January 2019.

On May 31, 2017, the Company acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, in May 2018 and 2019.

On June 30, 2017, the Company acquired a 60% interest in a nine-clinic physical therapy practice.  The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in June 2018 and 2019.

On October 31, 2017, the Company acquired a 70% interest in a nine-clinic physical therapy practice and two management contracts with third party providers.  The purchase price for the 70% interest was $4.0 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in October 2018 and 2019.

In addition to the above, as previously mentioned in March 2017, the Company acquired a 55% interest in a company which is a leading provider of industrial injury prevention services. The purchase price for the 55% interest was $6.2 million in cash and $0.4 million in a seller note that is payable, principal plus accrued interest, in September 2018. Also, in 2017, the Company purchased the assets and business of two physical therapy clinics in separate transactions. One clinic was consolidated with an existing clinic and the other operates as a satellite clinic of one of the existing partnerships.

The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.
 
The purchase price for the 2017 acquisitions has been preliminarily allocated as follows (in thousands):

Cash paid, net of cash acquired
 
$
36,682
 
Seller notes
  
2,150
 
Total consideration
 
$
38,832
 
Estimated fair value of net tangible assets acquired:
    
Total current assets
 
$
6,048
 
Total non-current assets
  
1,642
 
Total liabilities
  
(2,909
)
Net tangible assets acquired
 
$
4,781
 
Referral relationships
  
4,085
 
Non-compete
  
1,224
 
Tradename
  
7,039
 
Goodwill
  
45,868
 
Fair value of non-controlling interest (classified as redeemable non-controlling interests)
  
(13,883
)
Fair value of non-controlling interest (originally classified as mandatorily redeemable non-controlling interests)
  
(10,282
)
  
$
38,832
 

The purchase prices plus the fair value of the non-controlling interests for the acquisitions in first quarter of 2017 were allocated to the fair value of the assets acquired, inclusive of identifiable intangible assets, i.e. trade names, referral relationships and non-compete agreements, and liabilities assumed based on the fair values at the acquisition date, with the amount exceeding the fair values being recorded as goodwill are finalized. For the acquisitions occurring on or after April 1, 2017, the Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and identifiable intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used at March 31, 2018 based on additional information obtained and completion of the valuation of the identifiable intangible assets. Changes in the estimated valuation of the tangible assets acquired, the completion of the valuation of identifiable intangible assets and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill.

For the acquisitions in 2017, the values assigned to the referral relationships and non-compete agreements are being amortized to expense equally over the respective estimated lives. For referral relationships, the range of the estimated lives was 7½ to 11 years, and for non-compete agreements the estimated lives were five to six years. Generally, the values assigned to tradenames are tested annually for impairment,

For the 2017 acquisitions, total current assets primarily represent patient accounts receivable. Total non-current assets are fixed assets, primarily equipment, used in the practices.

The consideration paid for each of the acquisitions was derived through arm’s length negotiations. Funding for the cash portions was derived from proceeds from the Company’s revolving credit facility. The results of operations of the acquisitions have been included in the Company’s consolidated financial statements since their respective date of acquisition. Unaudited proforma consolidated financial information for the acquisitions in 2018, and 2017 acquisitions have not been included as the results, individually and in the aggregate, were not material to current operations.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE RECOGNITION
3 Months Ended
Mar. 31, 2018
REVENUE RECOGNITION [Abstract]  
REVENUE RECOGNITION
3.  REVENUE RECOGNITION

Categories

Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.

Management contract revenues, which are included in other revenues in the consolidated statements of net income, are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred.
 
Revenues from the industrial injury prevention business, which are also included in other revenues in the consolidated statements of net income, are derived from onsite services provided to clients’ employees including injury prevention, rehabilitation, ergonomic assessments and performance optimization. Revenues are determined based on the number of hours and respective rate for services provided.

Additionally, other revenues include services provided on-site, such as schools and industrial worksites, for physical or occupational therapy services, and athletic trainers and gym membership fees.  Contract terms and rates are agreed to in advance between the Company and the third parties. Services are typically performed over the contract period and revenue is recorded in accordance with the contract terms. If the services are paid in advance, revenue is deferred over the period of the agreement and recognized when the services are performed.

The following table details the revenue related to the various categories:

  
Three Months Ended
  
Three Months Ended
 
  
March 31, 2018
  
March 31, 2017
 
Net patient revenues
 
$
100,552
  
$
93,654
 
Management contract revenues
  
2,236
   
1,857
 
Industrial injury prevention services revenues
  
4,852
   
1,506
 
Other revenues
  
702
   
548
 
  
$
108,342
  
$
97,565
 

Net Patient Revenues - Physical / Occupational Therapy Revenue

Net patient revenues consists of revenues for physical therapy and occupational therapy clinics that provide pre-and post-operative care and treatment for orthopedic related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.

For ASC 606, there is an implied contract between the Company and the patient upon each patient visit.  Separate contractual arrangements exist between the Company and third party payors (e.g. insurers, managed care programs, government programs, workers' compensation) which establish the amounts the third parties pay on behalf of the patients for covered services rendered.   While these agreements are not considered contracts with the customer, they are used for determining the transaction price for services provided to the patients covered by the third party payors.  The payor contracts do not indicate performance obligations of the Company, but indicate reimbursement rates for patients who are covered by those payors when the services are provided.  At that time, the Company is obligated to provide services for the reimbursement rates stipulated in the payor contracts.  The execution of the contract alone does not indicate a performance obligation. For self-paying customers, the performance obligation exists when the Company provides the services at established rates. The difference between the Company’s established rate and the anticipated reimbursement rate is accounted for an as offset to revenue – contractual allowance.

Contractual Allowances

Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements by both insurance companies and government sponsored healthcare programs for such services. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow the Company to provide the necessary detail and accuracy with its collectability estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing system does not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, the need for a manual process for determining its contractual allowance reserve. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, historically the difference between net revenues and corresponding cash collections has generally reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent periods’ contractual write-offs on a payor basis reflects a difference within approximately 1% between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at March 31, 2018.
 
A contract’s transaction price is allocated to each distinct performance obligation and recognized when, or as, the performance obligation is satisfied. To determine the transaction price, the Company includes the effects of any variable consideration, such as the probability of collecting that amount.  The Company applies established rates to the services provided, and adjusts for the terms of payor contracts, as applicable.  These contracted amounts are different from the Company’s established rates.  The Company has established a “contractual allowance” for this difference. The allowance is based on the terms of payor contracts, historical and current reimbursement information and current experience with the clinic and partners. The Company’s established rates less the contractual allowance is the revenue that is recognized in the period in which the service is rendered. This revenue is deemed the transaction price and stated as “Net Patient Revenue” on the Company’s income statement.

The majority of the Company’s performance obligations are satisfied at one point in time. After the clinic has provided services and satisfied its obligation to the customer for the reimbursement rates stipulated in the payor contracts (i.e the transaction price), the Company recognizes the revenue, net of contractual allowances, in the period in which the services are rendered. The Company recognizes the full amount of revenue and reports the contractual allowances as a contra (or offset) revenue account to report a net revenue number based on the expected collections.

Medicare Reimbursement

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (‘‘MPFS’’). For services provided in 2018, a 0.5% increase has been applied to the fee schedule payment rates; for services provided in 2019, a 0.25% increase will be applied to the fee schedule payment rates, subject to an adjustment beginning in 2019 under the Merit-Based Incentive Payment System (“MIPS”).    For services provided in 2020 through 2025, a 0.0% percent update will be applied each year to the fee schedule payment rates, subject to adjustments under MIPS and any alternative payment models (“APMs”).   Beginning in 2019, payments to individual therapists (Physical/Occupational Therapist in Private Practice) under the fee schedule may be subject to adjustment based on performance in MIPS, which measures performance based on certain quality metrics, resource use, and meaningful use of electronic health records. Under the MIPS requirements, a provider's performance is assessed according to established performance standards and used to determine an adjustment factor that is then applied to the professional's payment for a year. Each year from 2019 through 2024, professionals who receive a significant share of their revenues through an APM (such as accountable care organizations or bundled payment arrangements) that involves risk of financial losses and a quality measurement component will receive a 5% bonus. The bonus payment for APM participation is intended to encourage participation and testing of new APMs and to promote the alignment of incentives across payors. The specifics of the MIPS and APM adjustments beginning in 2019 and 2020, respectively, will be subject to future notice and comment rule-making.

The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap. On April 1, 2013, a 2% reduction to Medicare payments was implemented. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, extended the 2% reductions to Medicare payments through fiscal year 2025. The Bipartisan Budget Act of 2018, enacted on February 9, 2018, extends the 2% reductions to Medicare payments through fiscal year 2027.

Historically, the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary was subject to an annual dollar limit (i.e., the ‘‘Therapy Cap’’ or ‘‘Limit’’). For 2017, the annual Limit on outpatient therapy services was $1,980 for combined Physical Therapy and Speech Language Pathology services and $1,980 for Occupational Therapy services. As a result of Bipartisan Budget Act of 2018, the Therapy Caps have been eliminated, effective as of January 1, 2018.
 
Under the Middle Class Tax Relief and Job Creation Act of 2012 (‘‘MCTRA’’), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The MACRA directed CMS to modify the manual medical review process such that those reviews will no longer apply to all claims exceeding the $3,700 threshold and instead will be determined on a targeted basis based on a variety of factors that CMS considers appropriate. The Bipartisan Budget Act of 2018 extends the targeted medical review indefinitely, but reduces the threshold to $3,000 through December 31, 2027.  For 2028, the threshold amount will be increased by the percentage increase in the Medicare Economic Index (“MEI”) for 2028 and in subsequent years the threshold amount will increase based on the corresponding percentage increase in the MEI for such subsequent year.

CMS adopted a multiple procedure payment reduction (‘‘MPPR’’) for therapy services in the final update to the MPFS for calendar year 2011. The MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (‘‘RVU’’) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. Since 2013, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 50%. In addition, the MCTRA directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. Reporting of these functional limitation codes and modifiers are required on the claim for payment.

Medicare claims for outpatient therapy services furnished by therapy assistants on or after January 1, 2022 must include a modifier indicating the service was furnished by a therapy assistant. CMS is required to develop a modifier to mark services provided by a therapy assistant by January 1, 2019, and then submitted claims must report the modifier mark starting January 1, 2020. Outpatient therapy services furnished on or after January 1, 2022 in whole or part by a therapy assistant will be paid at an amount equal to 85% of the payment amount otherwise applicable for the service.

Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. We believe that we are in compliance, in all material respects, with all applicable laws and regulations and are not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of March 31, 2018. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program. For three months ended March 31, 2018, net patient revenue from Medicare were approximately $24.6 million.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
EARNINGS PER SHARE
3 Months Ended
Mar. 31, 2018
EARNINGS PER SHARE [Abstract]  
EARNINGS PER SHARE
4. EARNINGS PER SHARE

The following tables provide a detail of the basic and diluted earnings per share computation.  In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest (see Footnote 6), net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation.

  
Three Months Ended March 31,
 
  
2018
  
2017
 
Computation of earnings per share - USPH shareholders
      
Net income attributable to USPH shareholders
 
$
7,117
  
$
4,816
 
Charges to retained earnings:
        
Revaluation of redeemable non-controlling interest
 
$
(5,081
)
 
$
-
 
Tax effect at statutory rate (federal and state) of 26.25%
  
1,334
   
-
 
  
$
3,370
  
$
4,816
 
         
Basic and diluted per share
 
$
0.27
  
$
0.38
 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS
3 Months Ended
Mar. 31, 2018
MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS [Abstract]  
MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS
5. MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS

Prior to the second quarter of 2017, when the Company acquired a majority interest (the “Acquisition”) in a physical therapy clinic business (referred to as “Therapy Practice”), these Acquisitions occurred in a series of steps which are described below.

1.
Prior to the Acquisition, the Therapy Practice exists as a separate legal entity (the “Seller Entity”). The Seller Entity is owned by one or more individuals (the “Selling Shareholders”) most of whom are physical therapists that work in the Therapy Practice and provide physical therapy services to patients.
2.
In conjunction with the Acquisition, the Seller Entity contributes the Therapy Practice into a newly-formed limited partnership (“NewCo”), in exchange for one hundred percent (100%) of the limited and general partnership interests in NewCo. Therefore, in this step, NewCo becomes a wholly-owned subsidiary of the Seller Entity.
3.
The Company enters into an agreement (the “Purchase Agreement”) to acquire from the Seller Entity a majority (ranges from 50% to 90%) of the limited partnership interest and, in all cases, 100% of the general partnership interest in NewCo. The Company does not purchase 100% of the limited partnership interest because the Selling Shareholders, through the Seller Entity, want to maintain an ownership percentage. The consideration for the Acquisition is primarily payable in the form of cash at closing and a small two-year note in lieu of an escrow (the “Purchase Price”). The Purchase Agreement does not contain any future earn-out or other contingent consideration that is payable to the Seller Entity or the Selling Shareholders.
4.
The Company and the Seller Entity also execute a partnership agreement (the “Partnership Agreement”) for NewCo that sets forth the rights and obligations of the limited and general partners of NewCo. After the Acquisition, the Company is the general partner of NewCo.
5.
As noted above, the Company does not purchase 100% of the limited partnership interests in NewCo and the Seller Entity retains a portion of the limited partnership interest in NewCo (“Seller Entity Interest”).
6.
In most cases, some or all of the Selling Shareholders enter into an employment agreement (the  “Employment Agreement”) with NewCo with an initial term that ranges from three to five years (the “Employment Term”), with automatic one-year renewals, unless employment is terminated prior to the end of the Employment Term. As a result, a Selling Shareholder becomes an employee (“Employed Selling Shareholder”) of NewCo. The employment of an Employed Selling Shareholder can be terminated by the Employed Selling Shareholder or NewCo, with or without cause, at any time. In a few situations, a Selling Shareholder does not become employed by NewCo and is not involved with NewCo following the closing; in those situations, such Selling Shareholders sell their entire ownership interest in the Seller Entity as of the closing of the Acquisition.
7.
The compensation of each Employed Selling Shareholder is specified in the Employment Agreement and is customary and commensurate with his or her responsibilities based on other employees in similar capacities within NewCo, the Company and the industry.
 
8.
The Company and the Selling Shareholder (including both Employed Selling Shareholders and Selling Shareholders not employed by NewCo) execute a non-compete agreement (the “Non- Compete Agreement”) which restricts the Selling Shareholder from engaging in competing business activities for a specified period of time (the “Non-Compete Term”). A Non-Compete Agreement is executed with the Selling Shareholders in all cases. That is, even if the Selling Shareholder does not become an Employed Selling Shareholder, the Selling Shareholder is restricted from engaging in a competing business during the Non-Compete Term.
9.
The Non-Compete Term commences as of the date of the Acquisition and expires on the later of:
a.
Two years after the date an Employed Selling Shareholders’ employment is terminated (if the Selling Shareholder becomes an Employed Selling Shareholder) or
b.
Five to six years from the date of the Acquisition, as defined in the Non-Compete Agreement, regardless of whether the Selling Shareholder is employed by NewCo.
10.
The Non-Compete Agreement applies to a restricted region which is defined as a 15-mile radius from the Therapy Practice. That is, an Employed Selling Shareholder is permitted to engage in competing businesses or activities outside the 15-mile radius (after such Employed Selling Shareholder no longer is employed by NewCo) and a Selling Shareholder who is not employed by NewCo immediately is permitted to engage in the competing business or activities outside the 15-mile radius.
11.
The Partnership Agreement contains provisions for the redemption of the Seller Entity Interest, either at the option of the Company (the “Call Option”) or on a required basis (the “Required Redemption”):
a.
Required Redemption
i.
Once the Required Redemption is triggered, the Company is obligated to purchase from the Seller Entity and the Seller Entity is obligated to sell to the Company, the allocable portion of the Seller Entity Interest based on the terminated Selling Shareholder’s pro rata ownership interest in the Seller Entity (the “Allocable Portion”). Required Redemption is
triggered when both of the following events have occurred:
1.
Termination of an Employed Selling Shareholder’s employment with NewCo, regardless of the reason for such termination, and
2.
The expiration of an agreed upon period of time, typically three to five years, as set forth in the relevant Partnership Agreement (the “Holding Period”).
ii.
In the event an Employed Selling Shareholder’s employment terminates prior to the expiration of the Holding Period, the Required Redemption would occur only upon expiration of the Holding Period.
b.
Call Option
i.
In the event that an Employed Selling Shareholder’s employment terminates prior to expiration of the Holding Period, the Company has the contractual right, but not the obligation, to acquire the Employed Selling Shareholder’s Allocable Portion of the Seller Entity Interest from the Seller Entity through exercise of the Call Option.
c.
For the Required Redemption and the Call Option, the purchase price is derived from a formula based on a specified multiple of NewCo’s trailing twelve months of earnings before interest, taxes, depreciation, amortization, and the Company’s internal management fee, plus an Allocable Portion of any undistributed earnings of NewCo (the “Redemption Amount”). NewCo’s earnings are distributed monthly based on available cash within NewCo; therefore, the undistributed earnings amount is small, if any.
d.
The Purchase Price for the initial equity interest purchased by the Company is also based on the same specified multiple of the trailing twelve-month earnings that is used in the Required Redemption noted above.
e.
Although, the Required Redemption and the Call Option do not have an expiration date, the Seller Entity Interest eventually will be purchased by the Company.
f.
The Required Redemption and the Call Option never apply to Selling Shareholders who do not become employed by NewCo, since the Company requires that such Selling Shareholders sell their entire ownership interest in the Seller Entity at the closing of the Acquisition.
12.
An Employed Selling Shareholder’s ownership of his or her equity interest in the Seller Entity predates the Acquisition and the Company’s purchase of its partnership interest in NewCo. The Employment Agreement and the Non-Compete Agreement do not contain any provision to escrow or “claw back” the equity interest in the Seller Entity held by such Employed Selling Shareholder, nor the Seller Entity Interest in NewCo, in the event of a breach of the employment or non-compete terms. More specifically, even if the Employed Selling Shareholder is terminated for “cause” by NewCo, such Employed Selling Shareholder does not forfeit his or her right to his or her full equity interest in the Seller Entity and the Seller Entity does not forfeit its right to any portion of the Seller Entity Interest. The Company’s only recourse against the Employed Selling Shareholder for breach of either the Employment Agreement or the Non-Compete Agreement is to seek damages and other legal remedies under such agreements. There are no conditions in any of the arrangements with an Employed Selling Shareholder that would result in a forfeiture of the equity interest held in the Seller Entity or of the Seller Entity Interest.
 
As previously mentioned, due to the amendments that were made to partnerships agreements, the Call Option and Required Redemption provisions described in number 11 of Footnote 5 have been modified to be consistent with the provisions described in Footnote 6 below.  As a result, the redemption values of the mandatorily redeemable non-controlling interest (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) at fair value on the December 31, 2017 consolidated balance sheet.  For 2017, the earnings and liabilities attributable to mandatorily redeemable non-controlling interests were recorded within the consolidated statements of income line item: Interest expense – mandatorily redeemable non-controlling interests – earnings allocable and in the consolidated balance sheet line item: Mandatorily redeemable non-controlling interests.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
REDEEMABLE NON-CONTROLLING INTERESTS
3 Months Ended
Mar. 31, 2018
REDEEMABLE NON-CONTROLLING INTERESTS [Abstract]  
REDEEMABLE NON-CONTROLLING INTERESTS
6. REDEEMABLE NON-CONTROLLING INTERESTS

When the Company acquires a majority interest in a Therapy Practice, those Acquisitions occur in a series of steps as described in numbers 1 through 10 of footnote 5 – Mandatorily Redeemable Non-Controlling Interests.  For the Acquisitions that occurred after the first quarter of 2017, and for the acquisitions that occurred during and prior to the first quarter of 2017 but for which the partnership agreements were amended, the applicable Partnership Agreement contains provisions for the redemption of the Seller Entity Interest, either at the option of the Company (the “Call Right”) or at the option of the Seller Entity (the “Put Right”) as follows:
1.
Put Right
a.
In the event that any Selling Shareholder’s employment is terminated involuntarily by the Company without “Cause” pursuant to Section 7(d) of such Selling Shareholder’s Employment Agreement prior to the fifth anniversary of the Closing Date, the Seller Entity thereafter shall have an irrevocable right to cause the Company to purchase from Seller Entity the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest at the purchase price described in “3” below.
b.
In the event that any Selling Shareholder is not employed by NewCo as of the fifth anniversary of the Closing Date and the Company has not exercised its Call Right with respect to the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest, Seller Entity thereafter shall have the Put Right to cause the Company to purchase from Seller Entity the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest at the purchase price described in “3” below.
c.
In the event that any Selling Shareholder’s employment with NewCo is terminated for any reason on or after the fifth anniversary of the Closing Date, the Seller Entity shall have the Put Right, and upon the exercise of the Put Right, the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest shall be redeemed by the Company at the purchase price described in “3” below.
2.
Call Right
a.
If any Selling Shareholder’s employment by NewCo is terminated (i) pursuant to a voluntary termination by the Selling Shareholder or (ii) by NewCo with “Cause” (as defined in the Selling Shareholder’s Employment Agreement), prior to the fifth anniversary of the Closing Date, the Company thereafter shall have an irrevocable right to purchase from Seller Entity the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest, in each case at the purchase price described in “3” below.
b.
In the event that any Selling Shareholder’s employment with NewCo is terminated for any reason on or after the fifth anniversary of the Closing Date, the Company shall have the Call Right, and upon the exercise of the Call Right, the Terminated Selling Shareholder’s Allocable Percentage of Seller Entity’s Interest shall be redeemed by the Company at the purchase price described in “3” below.
3.
For the Put Right and the Call Right, the purchase price is derived from a formula based on a specified multiple of NewCo’s trailing twelve months of earnings before interest, taxes, depreciation, amortization, and the Company’s internal management fee, plus an Allocable Percentage of any undistributed earnings of NewCo (the “Redemption Amount”). NewCo’s earnings are distributed monthly based on available cash within NewCo; therefore, the undistributed earnings amount is small, if any.
 
4.
The Purchase Price for the initial equity interest purchased by the Company is also based on the same specified multiple of the trailing twelve-month earnings that is used in the Put Right and the Call Right noted above.
5.
The Put Right and the Call Right do not have an expiration date, but the Seller Entity Interest is not required to be purchased by the Company or sold by the Seller Entity.
6.
The Put Right and the Call Right never apply to Selling Shareholders who do not become employed by NewCo, since the Company requires that such Selling Shareholders sell their entire ownership interest in the Seller Entity at the closing of the Acquisition.

An Employed Selling Shareholder’s ownership of his or her equity interest in the Seller Entity predates the Acquisition and the Company’s purchase of its partnership interest in NewCo. The Employment Agreement and the Non-Compete Agreement do not contain any provision to escrow or “claw back” the equity interest in the Seller Entity held by such Employed Selling Shareholder, nor the Seller Entity Interest in NewCo, in the event of a breach of the employment or non-compete terms. More specifically, even if the Employed Selling Shareholder is terminated for “cause” by NewCo, such Employed Selling Shareholder does not forfeit his or her right to his or her full equity interest in the Seller Entity and the Seller Entity does not forfeit its right to any portion of the Seller Entity Interest. The Company’s only recourse against the Employed Selling Shareholder for breach of either the Employment Agreement or the Non-Compete Agreement is to seek damages and other legal remedies under such agreements. There are no conditions in any of the arrangements with an Employed Selling Shareholder that would result in a forfeiture of the equity interest held in the Seller Entity or of the Seller Entity Interest.

For the three months ended March 31, 2018, the following table details the changes in the carrying amount of redeemable non-controlling interest (in thousands):

Three Months Ended
March 31, 2018
    
Beginning balance
 
$
102,572
 
Operating results allocated to redeemable non-controlling interest partners
  
1,736
 
Distributions to redeemable non-controlling interest partners
  
(1,359
)
Changes in the fair value of redeemable non-controlling interest
  
5,081
 
Other
  
55
 
Ending balance
 
$
108,085
 

The following table categorizes the carrying amount (fair value) of the redeemable non-controlling interests (in thousands):

  
March 31, 2018
 
    
Contractual time period has lapsed but holder's employment has not been terminated
 
$
34,127
 
Contractual time period has not lapsed and holder's employment has not been terminated
  
73,958
 
Fair value
 
$
108,085
 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
GOODWILL
3 Months Ended
Mar. 31, 2018
GOODWILL [Abstract]  
GOODWILL
7. GOODWILL

The changes in the carrying amount of goodwill consisted of the following (in thousands):

Beginning balance
 
$
271,338
 
Goodwill acquired during the year
  
856
 
Goodwill adjustments for purchase price allocation of businesses acquired in prior year
  
1,576
 
Ending balance
 
$
273,770
 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTANGIBLE ASSETS, NET
3 Months Ended
Mar. 31, 2018
INTANGIBLE ASSETS, NET [Abstract]  
INTANGIBLE ASSETS, NET
8. INTANGIBLE ASSETS, NET

Intangible assets, net as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

  
March 31, 2018
  
December 31, 2017
 
Tradenames
 
$
28,273
  
$
29,673
 
Referral relationships, net of accumulated amortization of $7,729 and $7,209, respectively
  
16,527
   
16,811
 
Non-compete agreements, net of accumulated amortization of $4,297 and $4,100, respectively
  
2,292
   
2,470
 
  
$
47,092
  
$
48,954
 

Tradenames, referral relationships and non-compete agreements are related to the businesses acquired. Typically, the value assigned to tradenames has an indefinite life and is tested at least annually for impairment using the relief from royalty method in conjunction with the Company’s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non-compete agreements are amortized over the respective term of the agreements which range from five to six years.

The following table details the amount of amortization expense recorded for intangible assets for the three months ended March 31, 2018 and 2017 (in thousands):

  
Three Months Ended
  
Three Months Ended
 
  
March 31, 2018
  
March 31, 2017
 
Referral relationships
 
$
520
  
$
458
 
Non-compete agreements
  
197
   
195
 
  
$
717
  
$
653
 

Based on the balance of referral relationships and non-compete agreements as of March 31, 2018, the expected amount to be amortized in 2018 and thereafter by year is as follows (in thousands):

Referral Relationships
  
Non-Compete Agreements
 
Years
 
Annual Amount
  
Years
  
Annual Amount
 
Ending December 31,
    
Ending December 31,
    
2018
 
$
2,068
   
2018
  
$
766
 
2019
 
$
1,965
   
2019
  
$
693
 
2020
 
$
1,965
   
2020
  
$
481
 
2021
 
$
1,965
   
2021
  
$
403
 
2022
 
$
1,917
   
2022
  
$
143
 
2023
 
$
1,809
   
2023
  
$
3
 
Thereafter
 
$
5,358
         
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCRUED EXPENSES
3 Months Ended
Mar. 31, 2018
ACCRUED EXPENSES [Abstract]  
ACCRUED EXPENSES
9. ACCRUED EXPENSES

Accrued expenses as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

  
March 31, 2018
  
December 31, 2017
 
Salaries and related costs
 
$
22,677
  
$
16,828
 
Credit balances due to patients and payors
  
3,841
   
4,158
 
Group health insurance claims
  
2,637
   
2,929
 
Income taxes payable
  
2,139
   
2,833
 
Dividend payable to USPH shareholders
  
2,914
   
-
 
Other
  
4,134
   
6,594
 
Total
 
$
38,342
  
$
33,342
 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT
3 Months Ended
Mar. 31, 2018
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT [Abstract]  
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT
10. NOTES PAYABLE AND AMENDED CREDIT AGREEMENT

Amounts outstanding under the Amended Credit Agreement and notes payable as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

  
March 31, 2018
  
December 31, 2017
 
Credit Agreement average effective interest rate of 3.8% inclusive of unused fee
 
$
42,000
  
$
54,000
 
Various notes payable with $5,317 plus accrued interest due in the next year, interest accrues in the range of 3.25% through 4.25% per annum
  
6,099
   
6,772
 
   
48,099
   
60,772
 
Less current portion
  
(5,317
)
  
(4,044
)
Long term portion
 
$
42,782
  
$
56,728
 

Effective December 5, 2013, the Company entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility. This agreement was amended in August 2015, January 2016, March 2017 and November 2017 (hereafter referred to as “Amended Credit Agreement”). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common stockholders, capital expenditures and other corporate purposes. The pricing grid which is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.25% to 2.0% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.25% to 0.3% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement.

The January 2016 amendment to the Amended Credit Agreement increased the cash and noncash consideration that the Company could pay with respect to acquisitions permitted under the Amended Credit Agreement to $50,000,000 for any fiscal year, and increased the amount the Company may pay in cash dividends to its shareholders in an aggregate amount not to exceed $10,000,000 in any fiscal year.  The March 2017 amendment, among other items, increased the amount the Company may pay in cash dividends to its shareholders in an aggregate amount not to exceed $15,000,000 in any fiscal year. The November 2017 amendment, among other items, adjusted the pricing grid as described above, increased the aggregate amount the Company may pay in cash dividends to its shareholders to an amount not to exceed $20,000,000 and extended the maturity date to November 30, 2021.

On March 31, 2018, $42.0 million was outstanding on the Amended Credit Agreement resulting in $83.0 million of availability. As of March 31, 2018 and the date of this report, the Company was in compliance with all of the covenants thereunder.

The Company generally enters into various notes payable as a means of financing a portion of its acquisitions and purchases of non-controlling interests. In conjunction with the acquisition of the two clinic practices on February 28, 2018, the Company entered into a note payable in the amount of $150,000, which is payable on August 31, 2019.  Interest accrues at the rate of 4.5% per annum and is payable on August 31, 2019.  In conjunction with the acquisitions in 2017, the Company entered into notes payable in the aggregate amount of $2.2 million of which an aggregate principal payment of $1.3 million is due in 2018 (of which $250,000 was paid in January 2018) and $0.9 million in 2019.   Interest accrues in the range of 3.25% to 4.0% per annum and is payable with each principal installment.
 
Aggregate annual payments of principal required pursuant to the Amended Credit Agreement and the above notes payable subsequent to March 31, 2018 are as follows (in thousands):

During the twelve months ended March 31, 2019
 
$
5,317
 
During the twelve months ended March 31, 2020
  
782
 
During the twelve months ended March 31, 2021
  
-
 
During the twelve months ended March 31, 2022
  
42,000
 
  
$
48,099
 

The revolving credit facility (balance at March 31, 2018 of $42.0 million) matures on November 30, 2021.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMON STOCK
3 Months Ended
Mar. 31, 2018
COMMON STOCK [Abstract]  
COMMON STOCK
11. COMMON STOCK

From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company’s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (“March 2009 Authorization”). The Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. The Company is required to retire shares purchased under the March 2009 Authorization.

Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. There are currently an additional estimated 184,502 shares (based on the closing price of $81.30 on March 31, 2018) that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company’s cash position. The Company did not purchase any shares of its common stock during the three months ended March 31, 2018.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2018
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Cash Equivalents
Cash Equivalents

The Company maintains its cash and cash equivalents at financial institutions.  The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.  The combined account balances at several institutions typically exceed Federal Deposit Insurance Corporation (“FDIC”) insurance coverage and, as a result, there is a concentration of credit risk related on deposits in excess of FDIC insurance coverage. Management believes that the risk is not significant.
Long-Lived Assets
Long-Lived Assets

Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for purchased software from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.
Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of
Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Goodwill
Goodwill

Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain identifiable intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital.

The fair value of goodwill and other identifiable intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company evaluates indefinite lived tradenames using the relief from royalty method in conjunction with its annual goodwill impairment test.  The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to the operating segment level for the purpose of determining the Company’s reporting units when performing its annual goodwill impairment test. In the first quarter of 2018, there were six regions.  In addition to the six regions, in 2017, the impairment test included a separate analysis for the industrial injury prevention business, a separate reporting unit.

An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other identifiable intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two factors: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each factor and the sum of each weight times the factor is considered the estimated fair value. For 2017, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluation of goodwill in 2017, 2016 and 2015 did not result in any goodwill amounts that were deemed impaired.

The Company has not identified any triggering events occurring after the testing date that would impact the impairment testing results obtained.  The Company will continue to monitor for any triggering events or other indicators of impairment.
Redeemable Non-Controlling Interests
Redeemable Non-Controlling Interests

The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those that the owners and the Company have certain redemption rights, whether currently exercisable or not, and which currently, or in the future, require that the Company purchase or the owner sell the non-controlling interest held by the owner, if certain conditions are met.  The purchase price is derived at a predetermined formula based on a multiple of trailing twelve months earnings performance as defined in the respective limited partnership agreements.  The redemption rights can be triggered by the owner or the Company at such time as both of the following events have occurred: 1) termination of the owner’s employment, regardless of the reason for such termination, and 2) the passage of specified number of years after the closing of the transaction, typically three to five years, as defined in the limited partnership agreement.  The redemption rights are not automatic or mandatory (even upon death) and require either the owner or the Company to exercise its rights when the conditions triggering the redemption rights have been satisfied.

On the date the Company acquires a controlling interest in a partnership, and the limited partnership agreement for such partnership contains redemption rights not under the control of the Company, the fair value of the non-controlling interest is recorded in the consolidated balance sheet under the caption – Redeemable non-controlling interests.  Then, in each reporting period thereafter until it is purchased by the Company, the redeemable non-controlling interest is adjusted to the greater of its then current redemption value or initial value, based on the predetermined formula defined in the respective limited partnership agreement.  As a result, the value of the non-controlling interest is not adjusted below its initial value.  The Company records any adjustment in the redemption value, net of tax, directly to retained earnings and are not reflected in the consolidated statements of income.  Although the adjustments are not reflected in the consolidated statements of income, current accounting rules require that the Company reflects the adjustments, net of tax, in the earnings per share calculation.  The amount of net income attributable to redeemable non-controlling interest owners is included in consolidated net income on the face of the consolidated statement of income. Management believes the redemption value (i.e. the carrying amount) and fair value are the same.
Non-Controlling Interests
Non-Controlling Interests

The Company recognizes non-controlling interests, in which the Company has no obligation but the right to purchase the non-controlling interests, as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the statements of net income. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling equity investment on the deconsolidation date.

When the purchase price of a non-controlling interest by the Company exceeds the book value at the time of purchase, any excess or shortfall is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.
Revenue Recognition
Revenue Recognition

Revenues are recognized in the period in which services are rendered. See Footnote 3 for further discussion of revenue recognition.
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts

The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.
Income Taxes
Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Tax Cuts and Jobs Act of 2017 (the “TCJA”) was passed by Congress on December 20, 2017 and signed into law by President Trump on December 22, 2017. The TCJA makes significant changes to U.S. corporate income tax laws including a decrease in the corporate income tax rate to 21% effective January 1, 2018.

The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the twelve months ended March 31, 2018. The Company will book any interest or penalties, if required, in interest and other expense, as appropriate.
Fair Value of Financial Instruments
Fair Value of Financial Instruments

The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount under the Amended Credit Agreement approximates its fair value. The interest rate on the Amended Credit Agreement, which is tied to the Eurodollar Rate, is set at various short-term intervals, as detailed in the Amended Credit Agreement.
Segment Reporting
Segment Reporting

Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance.  The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.
Use of Estimates
Use of Estimates

In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.
Self-Insurance Program
Self-Insurance Program

The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through March 31, 2018.
Restricted Stock
Restricted Stock

Restricted stock issued to employees and directors is subject to continued employment or continued service on the board, respectively. Generally, restrictions on the stock granted to employees, other than officers, lapse in equal annual installments on the following four anniversaries of the date of grant. For those shares granted to directors, the restrictions will lapse in equal quarterly installments during the first year after the date of grant. For those granted to officers, the restriction will lapse in equal quarterly installments during the four years following the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the vesting period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.
Recently Adopted Accounting Guidance
Recently Adopted Accounting Guidance

In May 2014, March 2016, April 2016, and December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The original standards were effective for fiscal years beginning after December 15, 2016; however, in July 2015, the FASB approved a one-year deferral of these standards, with a new effective date for fiscal years beginning after December 15, 2017. The standards require the selection of a retrospective or cumulative effect transition method.

The Company implemented the new standard beginning January 1, 2018 using a modified retrospective transition method.  Adoption of the new standard did not result in material changes to the presentation of net revenues and bad debt expense in the consolidated statements of income, and the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change relates to how the new standard requires healthcare providers to estimate the amount of variable consideration to be included in the transaction price up to an amount which is probable that a significant reversal will not occur. The most common forms of variable consideration the Company experiences are amounts for services provided that are ultimately not realizable from a customer. Under the current standards, the Company’s estimate for unrealizable amounts is recorded as a reduction of revenue. Under the new standards, the Company’s estimate for unrealizable amounts will continue to be recognized as a reduction to revenue. The bad debt expense historically reported will not materially change.
Recently Issued Accounting Guidance
Recently Issued Accounting Guidance

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment (Topic 350), which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment change. ASU 2017-04 is effective prospectively for fiscal years, and the interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact.

In February 2016, the FASB issued amended accounting guidance (ASU 2016-02, Leases) which replaced most existing lease accounting guidance under U. S. generally accepted accounting principles. Among other changes, the amended guidance requires that a right-to-use asset, which is an asset that represents the lessee’s right to use, and a lease liability, which is a lessee’s obligation to make lease payments arising for a lease measured on a discounted basis, be recognized on the balance sheet by lessees for those leases with a term of greater than 12 months. The amended guidance is effective for reporting periods beginning after December 15, 2018; however, early adoption is permitted. Entities can use to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements or recognize the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings.

Since the Company leases all but one of its clinic facilities, upon adoption, the Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of the operating lease obligations of the Company. Operating lease expense will continue to be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of income.
 
The Company will implement the new standard beginning January 1, 2019. The Company’s implementation efforts are focused on populating the data in a lease accounting software package and developing internal controls in order to account for its leases under the new standard.
Subsequent Event
Subsequent Event

The Company has evaluated events occurring after the balance sheet date for possible disclosure as a subsequent event through the date that these consolidated financial statements were issued. On April 30, 2018, the Company acquired a 65% interest in a leading provider of industrial injury prevention for $9.0 million.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2018
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Schedule of Clinic Acquisition
During the year ended December 31, 2017, the Company acquired an interest in the following clinic groups:

 
Date 
% Interest Acquired
  
Number of Clinics
 
 
 
      
January 2017 Acquisition
January 1
 
70%
 
  
17
 
May 2017 Acquisition
May 31
 
70%
 
  
4
 
June 2017 Acquisition
June 30
 
60%
 
  
9
 
October 2017 Acquisition
October 31
 
70%
 
  
9
 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACQUISITIONS OF BUSINESSES (Tables)
3 Months Ended
Mar. 31, 2018
ACQUISITIONS OF BUSINESSES [Abstract]  
Schedule of Preliminary Purchase Prices Allocation
The purchase price for this acquisition has been preliminarily allocated as follows (in thousands):

Cash paid
 
$
760
 
Seller note
  
150
 
Total consideration
 
$
910
 
     
Referral relationships
  
36
 
Non-compete
  
18
 
Goodwill
  
856
 
  
$
910
 

The purchase price for the 2017 acquisitions has been preliminarily allocated as follows (in thousands):

Cash paid, net of cash acquired
 
$
36,682
 
Seller notes
  
2,150
 
Total consideration
 
$
38,832
 
Estimated fair value of net tangible assets acquired:
    
Total current assets
 
$
6,048
 
Total non-current assets
  
1,642
 
Total liabilities
  
(2,909
)
Net tangible assets acquired
 
$
4,781
 
Referral relationships
  
4,085
 
Non-compete
  
1,224
 
Tradename
  
7,039
 
Goodwill
  
45,868
 
Fair value of non-controlling interest (classified as redeemable non-controlling interests)
  
(13,883
)
Fair value of non-controlling interest (originally classified as mandatorily redeemable non-controlling interests)
  
(10,282
)
  
$
38,832
 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE RECOGNITION (Tables)
3 Months Ended
Mar. 31, 2018
REVENUE RECOGNITION [Abstract]  
Disaggregation of Revenue, Categories
The following table details the revenue related to the various categories:

  
Three Months Ended
  
Three Months Ended
 
  
March 31, 2018
  
March 31, 2017
 
Net patient revenues
 
$
100,552
  
$
93,654
 
Management contract revenues
  
2,236
   
1,857
 
Industrial injury prevention services revenues
  
4,852
   
1,506
 
Other revenues
  
702
   
548
 
  
$
108,342
  
$
97,565
 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
EARNINGS PER SHARE (Tables)
3 Months Ended
Mar. 31, 2018
EARNINGS PER SHARE [Abstract]  
Computations of Basic and Diluted Earnings Per Share
The following tables provide a detail of the basic and diluted earnings per share computation.  In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest (see Footnote 6), net of tax, charged directly to retained earnings is included in the earnings per basic and diluted share calculation.

  
Three Months Ended March 31,
 
  
2018
  
2017
 
Computation of earnings per share - USPH shareholders
      
Net income attributable to USPH shareholders
 
$
7,117
  
$
4,816
 
Charges to retained earnings:
        
Revaluation of redeemable non-controlling interest
 
$
(5,081
)
 
$
-
 
Tax effect at statutory rate (federal and state) of 26.25%
  
1,334
   
-
 
  
$
3,370
  
$
4,816
 
         
Basic and diluted per share
 
$
0.27
  
$
0.38
 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
REDEEMABLE NON-CONTROLLING INTERESTS (Tables)
3 Months Ended
Mar. 31, 2018
REDEEMABLE NON-CONTROLLING INTERESTS [Abstract]  
Changes in Carrying Amount of Redeemable Non-Controlling Interest
For the three months ended March 31, 2018, the following table details the changes in the carrying amount of redeemable non-controlling interest (in thousands):

Three Months Ended
March 31, 2018
    
Beginning balance
 
$
102,572
 
Operating results allocated to redeemable non-controlling interest partners
  
1,736
 
Distributions to redeemable non-controlling interest partners
  
(1,359
)
Changes in the fair value of redeemable non-controlling interest
  
5,081
 
Other
  
55
 
Ending balance
 
$
108,085
 
Carrying Amount of (Fair Value) Redeemable Non-Controlling Interest
The following table categorizes the carrying amount (fair value) of the redeemable non-controlling interests (in thousands):

  
March 31, 2018
 
    
Contractual time period has lapsed but holder's employment has not been terminated
 
$
34,127
 
Contractual time period has not lapsed and holder's employment has not been terminated
  
73,958
 
Fair value
 
$
108,085
 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
GOODWILL (Tables)
3 Months Ended
Mar. 31, 2018
GOODWILL [Abstract]  
Summary of Changes in Carrying Amount of Goodwill
The changes in the carrying amount of goodwill consisted of the following (in thousands):

Beginning balance
 
$
271,338
 
Goodwill acquired during the year
  
856
 
Goodwill adjustments for purchase price allocation of businesses acquired in prior year
  
1,576
 
Ending balance
 
$
273,770
 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTANGIBLE ASSETS, NET (Tables)
3 Months Ended
Mar. 31, 2018
INTANGIBLE ASSETS, NET [Abstract]  
Intangible Assets, Net
Intangible assets, net as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

  
March 31, 2018
  
December 31, 2017
 
Tradenames
 
$
28,273
  
$
29,673
 
Referral relationships, net of accumulated amortization of $7,729 and $7,209, respectively
  
16,527
   
16,811
 
Non-compete agreements, net of accumulated amortization of $4,297 and $4,100, respectively
  
2,292
   
2,470
 
  
$
47,092
  
$
48,954
 
Amortization Expenses
The following table details the amount of amortization expense recorded for intangible assets for the three months ended March 31, 2018 and 2017 (in thousands):

  
Three Months Ended
  
Three Months Ended
 
  
March 31, 2018
  
March 31, 2017
 
Referral relationships
 
$
520
  
$
458
 
Non-compete agreements
  
197
   
195
 
  
$
717
  
$
653
 
Amortization of Tradename, Referral Relationships and Non-Competition Agreements
Based on the balance of referral relationships and non-compete agreements as of March 31, 2018, the expected amount to be amortized in 2018 and thereafter by year is as follows (in thousands):

Referral Relationships
  
Non-Compete Agreements
 
Years
 
Annual Amount
  
Years
  
Annual Amount
 
Ending December 31,
    
Ending December 31,
    
2018
 
$
2,068
   
2018
  
$
766
 
2019
 
$
1,965
   
2019
  
$
693
 
2020
 
$
1,965
   
2020
  
$
481
 
2021
 
$
1,965
   
2021
  
$
403
 
2022
 
$
1,917
   
2022
  
$
143
 
2023
 
$
1,809
   
2023
  
$
3
 
Thereafter
 
$
5,358
         
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCRUED EXPENSES (Tables)
3 Months Ended
Mar. 31, 2018
ACCRUED EXPENSES [Abstract]  
Summary of Accrued Expenses
Accrued expenses as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

  
March 31, 2018
  
December 31, 2017
 
Salaries and related costs
 
$
22,677
  
$
16,828
 
Credit balances due to patients and payors
  
3,841
   
4,158
 
Group health insurance claims
  
2,637
   
2,929
 
Income taxes payable
  
2,139
   
2,833
 
Dividend payable to USPH shareholders
  
2,914
   
-
 
Other
  
4,134
   
6,594
 
Total
 
$
38,342
  
$
33,342
 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Tables)
3 Months Ended
Mar. 31, 2018
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT [Abstract]  
Summary of Credit Agreement and Notes Payable
Amounts outstanding under the Amended Credit Agreement and notes payable as of March 31, 2018 and December 31, 2017 consisted of the following (in thousands):

  
March 31, 2018
  
December 31, 2017
 
Credit Agreement average effective interest rate of 3.8% inclusive of unused fee
 
$
42,000
  
$
54,000
 
Various notes payable with $5,317 plus accrued interest due in the next year, interest accrues in the range of 3.25% through 4.25% per annum
  
6,099
   
6,772
 
   
48,099
   
60,772
 
Less current portion
  
(5,317
)
  
(4,044
)
Long term portion
 
$
42,782
  
$
56,728
 
Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility
Aggregate annual payments of principal required pursuant to the Amended Credit Agreement and the above notes payable subsequent to March 31, 2018 are as follows (in thousands):

During the twelve months ended March 31, 2019
 
$
5,317
 
During the twelve months ended March 31, 2020
  
782
 
During the twelve months ended March 31, 2021
  
-
 
During the twelve months ended March 31, 2022
  
42,000
 
  
$
48,099
 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)
3 Months Ended 12 Months Ended
Apr. 30, 2018
USD ($)
Feb. 28, 2018
Clinic
Mar. 31, 2018
USD ($)
Clinic
State
Facility
Segment
Region
Dec. 31, 2017
USD ($)
Clinic
Depreciation Amortization Impairment [Line Items]        
Percentage of general partnership interest owned     1.00%  
Number of clinic practices acquired | Clinic   2 2 2
Number of clinics consolidated with an existing clinic | Clinic       1
Number of clinics that operate as a satellite clinic with existing partnerships | Clinic       1
Number of clinics operated | Clinic     580  
Number of states where clinics are operated | State     42  
Number of third party facilities | Facility     28  
Mandatorily redeemable non-controlling interests     $ 0 $ 327,000
Number of business segments | Segment     1  
Number of regions | Region     6  
Corporate income tax rate     21.00%  
Unrecognized tax benefit     $ 0  
Accrued interest and penalties associated with any unrecognized tax benefits     0  
Interest expense recognized     $ 0  
March 2017 Acquisition [Member]        
Depreciation Amortization Impairment [Line Items]        
Percentage of interest acquired     55.00%  
Industrial Injury Prevention [Member] | Subsequent Event [Member]        
Depreciation Amortization Impairment [Line Items]        
Percentage of interest acquired 65.00%      
Value of interest acquired $ 9,000,000      
Employee [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]        
Period in which restrictions lapse on stock granted     4 years  
Director [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]        
Period in which restrictions lapse on stock granted     1 year  
Officer [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]        
Period in which restrictions lapse on stock granted     4 years  
Minimum [Member]        
Depreciation Amortization Impairment [Line Items]        
Percentage of limited partnership interest owned     49.00%  
Redeemable non-controlling interest, redemption rights, commencement period     3 years  
Minimum [Member] | Furniture & Equipment [Member]        
Depreciation Amortization Impairment [Line Items]        
Estimated useful lives     3 years  
Minimum [Member] | Software [Member]        
Depreciation Amortization Impairment [Line Items]        
Estimated useful lives     3 years  
Minimum [Member] | Leasehold Improvements [Member]        
Depreciation Amortization Impairment [Line Items]        
Estimated useful lives     3 years  
Maximum [Member]        
Depreciation Amortization Impairment [Line Items]        
Percentage of limited partnership interest owned     99.00%  
Redeemable non-controlling interest, redemption rights, commencement period     5 years  
Maximum [Member] | Furniture & Equipment [Member]        
Depreciation Amortization Impairment [Line Items]        
Estimated useful lives     8 years  
Maximum [Member] | Software [Member]        
Depreciation Amortization Impairment [Line Items]        
Estimated useful lives     7 years  
Maximum [Member] | Leasehold Improvements [Member]        
Depreciation Amortization Impairment [Line Items]        
Estimated useful lives     5 years  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Clinic Acquisition (Details) - Clinic
3 Months Ended 12 Months Ended
Feb. 28, 2018
Mar. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]      
Number of clinics 2 2 2
January 2017 Acquisition [Member]      
Business Acquisition [Line Items]      
Acquisition date     Jan. 01, 2017
Percentage of interest acquired     70.00%
Number of clinics     17
May 2017 Acquisition [Member]      
Business Acquisition [Line Items]      
Acquisition date     May 31, 2017
Percentage of interest acquired     70.00%
Number of clinics     4
June 2017 Acquisition [Member]      
Business Acquisition [Line Items]      
Acquisition date     Jun. 30, 2017
Percentage of interest acquired     60.00%
Number of clinics     9
October 2017 Acquisition [Member]      
Business Acquisition [Line Items]      
Acquisition date     Oct. 31, 2017
Percentage of interest acquired     70.00%
Number of clinics     9
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACQUISITIONS OF BUSINESSES (Details)
3 Months Ended 12 Months Ended
Feb. 28, 2018
USD ($)
Clinic
Oct. 31, 2017
USD ($)
Clinic
Contract
Installment
Jun. 30, 2017
USD ($)
Clinic
Installment
May 31, 2017
USD ($)
Clinic
Installment
Mar. 23, 2017
USD ($)
Jan. 01, 2017
USD ($)
Clinic
Installment
Mar. 31, 2018
USD ($)
Clinic
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Clinic
Dec. 31, 2016
USD ($)
Business Acquisition [Line Items]                    
Number of clinics | Clinic 2           2   2  
Number of clinics consolidated with an existing clinic | Clinic                 1  
Number of clinics that operate as a satellite clinic with existing partnerships | Clinic                 1  
Seller notes issued for acquisition of interest in clinic $ 150,000               $ 2,150,000  
Cash paid, net of cash acquired 760,000           $ 761,000 $ 15,670,000 36,682,000  
Seller notes 150,000               2,150,000  
Total consideration 910,000               38,832,000  
Estimated fair value of net tangible assets acquired [Abstract]                    
Total current assets                 6,048,000  
Total non-current assets                 1,642,000  
Total liabilities                 (2,909,000)  
Net tangible assets acquired                 4,781,000  
Referral relationships 36,000               4,085,000  
Non-compete 18,000               1,224,000  
Tradename                 7,039,000  
Goodwill 856,000               45,868,000  
Fair value of non-controlling interest (classified as redeemable non-controlling interests)                 (13,883,000)  
Fair value of non-controlling interest (originally classified as mandatorily redeemable non-controlling interests)                 (10,282,000)  
Total consideration $ 910,000               $ 38,832,000  
Referral Relationships [Member] | Minimum [Member]                    
Business Acquisition [Line Items]                    
Estimated useful lives of acquired intangibles             7 years 6 months      
Referral Relationships [Member] | Maximum [Member]                    
Business Acquisition [Line Items]                    
Estimated useful lives of acquired intangibles             11 years      
Non-compete Agreements [Member] | Minimum [Member]                    
Business Acquisition [Line Items]                    
Estimated useful lives of acquired intangibles             5 years      
Non-compete Agreements [Member] | Maximum [Member]                    
Business Acquisition [Line Items]                    
Estimated useful lives of acquired intangibles             6 years      
Acquisition Of Two Clinic Practices [Member]                    
Business Acquisition [Line Items]                    
Number of clinics | Clinic 2                  
Acquisition of Seventeen Clinic Practices [Member]                    
Business Acquisition [Line Items]                    
Number of clinics | Clinic           17        
Percentage of interest acquired                   70.00%
Cash paid for acquisition of interest in clinic           $ 10,700,000        
Seller notes issued for acquisition of interest in clinic                   $ 500,000
Business acquisition number of installments to payment of purchase consideration | Installment           2        
Seller notes                   $ 500,000
Acquisition of Seventeen Clinic Practices [Member] | January 2018 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest           $ 250,000        
Acquisition of Seventeen Clinic Practices [Member] | January 2019 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest           $ 250,000        
Workforce Performance Solutions [Member]                    
Business Acquisition [Line Items]                    
Percentage of interest acquired         55.00%          
Cash paid for acquisition of interest in clinic         $ 6,200,000          
Seller notes issued for acquisition of interest in clinic         400,000          
Seller notes         $ 400,000          
Acquisition Of Four Clinic Practices [Member]                    
Business Acquisition [Line Items]                    
Number of clinics | Clinic       4            
Percentage of interest acquired       70.00%            
Cash paid for acquisition of interest in clinic       $ 2,300,000            
Seller notes issued for acquisition of interest in clinic       $ 250,000            
Business acquisition number of installments to payment of purchase consideration | Installment       2            
Seller notes       $ 250,000            
Acquisition Of Four Clinic Practices [Member] | May 2018 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest       125,000            
Acquisition Of Four Clinic Practices [Member] | May 2019 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest       $ 125,000            
Acquisition Of Nine Clinic Practices [Member]                    
Business Acquisition [Line Items]                    
Number of clinics | Clinic   9 9              
Number of management contracts | Contract   2                
Percentage of interest acquired   70.00% 60.00%              
Cash paid for acquisition of interest in clinic   $ 4,000,000 $ 15,800,000              
Seller notes issued for acquisition of interest in clinic   $ 500,000 $ 500,000              
Business acquisition number of installments to payment of purchase consideration | Installment   2 2              
Seller notes   $ 500,000 $ 500,000              
Acquisition Of Nine Clinic Practices [Member] | June 2018 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest     250,000              
Acquisition Of Nine Clinic Practices [Member] | June 2019 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest     $ 250,000              
Acquisition Of Nine Clinic Practices [Member] | October 2018 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest   250,000                
Acquisition Of Nine Clinic Practices [Member] | October 2019 [Member]                    
Business Acquisition [Line Items]                    
Acquisition cost payable in two principal installments including accrued interest   $ 250,000                
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE RECOGNITION (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Feb. 09, 2018
Nov. 02, 2015
Apr. 01, 2013
Revenue from Contract with Customer, Excluding Assessed Tax [Abstract]          
Revenue related to the various categories $ 108,342,000 $ 97,565,000      
Contractual Allowances [Abstract]          
Difference between net revenues and corresponding cash collections, approximately of net revenues 1.00%        
Difference between actual aggregate contractual reserve and estimated contractual allowance reserve percentage 1.00%        
Maximum contractual allowance reserve estimate 1.00%        
Medicare Reimbursement [Abstract]          
Federal debt ceiling in connection with deficit reductions 10 years        
Reductions in federal spending $ 1,200,000,000,000        
Medicare spending cut percentage 2.00%        
Expected reduction in Medicare spending percentage     2.00% 2.00% 2.00%
Combined physical therapy/speech language pathology expenses $ 3,700        
Reduction in combined physical therapy/speech language pathology expenses $ 3,000        
Percentage of practice expense component 100.00%        
Percentage reduction for service 50.00%        
Percentage of payment for outpatient therapy services 85.00%        
Net patient revenue from Medicare accounts $ 24,600,000        
Year 2017 [Member] | Maximum [Member]          
Medicare Reimbursement [Abstract]          
Annual limit on physical therapy and speech language pathology services 1,980        
Annual limit occupational therapy services $ 1,980        
Year 2018 [Member]          
Medicare Reimbursement [Abstract]          
Percentage of increase in medicare payment rates 0.50%        
Year 2019 [Member]          
Medicare Reimbursement [Abstract]          
Percentage of increase in medicare payment rates 0.25%        
Net Patient Revenues [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax [Abstract]          
Revenue related to the various categories $ 100,552,000 93,654,000      
Management Contract Revenues [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax [Abstract]          
Revenue related to the various categories 2,236,000 1,857,000      
Industrial Injury Prevention Services Revenues [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax [Abstract]          
Revenue related to the various categories 4,852,000 1,506,000      
Other Revenues [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax [Abstract]          
Revenue related to the various categories $ 702,000 $ 548,000      
From 2019 through 2024 [Member]          
Medicare Reimbursement [Abstract]          
Percentage of bonus payment by APM 5.00%        
From 2020 through 2025 [Member]          
Medicare Reimbursement [Abstract]          
Percentage of increase in medicare payment rates 0.00%        
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Computation of earnings per share - USPH shareholders    
Net income attributable to USPH shareholders $ 7,117 $ 4,816
Charges to Retained Earnings [Abstract]    
Revaluation of redeemable non-controlling interest (5,081) 0
Tax effect at statutory rate (federal and state) of 26.25% 1,334 0
Net income attributable to common shareholders $ 3,370 $ 4,816
Basic and diluted per share (in dollars per share) $ 0.27 $ 0.38
Federal and state statutory income tax rate 26.25%  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS (Details) - Therapy Practice [Member]
3 Months Ended
Mar. 31, 2018
Jun. 30, 2017
Minimum [Member]    
Business Acquisition [Line Items]    
Business acquisition, percentage of limited partnership acquired   50.00%
Maximum [Member]    
Business Acquisition [Line Items]    
Business acquisition, percentage of limited partnership acquired   90.00%
NewCo. [Member]    
Business Acquisition [Line Items]    
Percentage of equity interest of subsidiary contributed for acquisition   100.00%
Business acquisition, percentage of general partnership interest acquired   100.00%
Business acquisition, consideration payable, term of note 2 years  
Employment agreement renewal term 1 year  
Non-Compete agreement term under condition of termination of employment of employed selling shareholder 2 years  
NewCo. [Member] | Minimum [Member]    
Business Acquisition [Line Items]    
Employment agreement term 3 years  
Non-Compete agreement term regardless of whether the selling shareholder is employed 5 years  
Required redemption term, under condition of termination of employment of employed selling shareholders 3 years  
NewCo. [Member] | Maximum [Member]    
Business Acquisition [Line Items]    
Employment agreement term 5 years  
Non-Compete agreement term regardless of whether the selling shareholder is employed 6 years  
Required redemption term, under condition of termination of employment of employed selling shareholders 5 years  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
REDEEMABLE NON-CONTROLLING INTERESTS (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2018
Changes in Carrying Amount of Redeemable Non-Controlling Interests [Roll Forward]    
Beginning balance $ 102,572  
Ending balance 108,085  
Carrying Amount (Fair Value) of Redeemable Non-Controlling Interest [Abstract]    
Fair value 108,085 $ 108,085
Redeemable Non-Controlling Interest [Member]    
Changes in Carrying Amount of Redeemable Non-Controlling Interests [Roll Forward]    
Beginning balance 102,572  
Operating results allocated to redeemable non-controlling interest partners 1,736  
Distributions to redeemable non-controlling interest partners (1,359)  
Changes in the fair value of redeemable non-controlling interest 5,081  
Other 55  
Ending balance 108,085  
Carrying Amount (Fair Value) of Redeemable Non-Controlling Interest [Abstract]    
Contractual time period has lapsed but holder's employment has not been terminated   34,127
Contractual time period has not lapsed and holder's employment has not been terminated   73,958
Fair value $ 102,572 $ 108,085
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
GOODWILL (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2018
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 271,338
Goodwill acquired during the year 856
Goodwill adjustments for purchase price allocation of business acquired in prior year 1,576
Ending balance $ 273,770
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTANGIBLE ASSETS, NET - Intangible Assets, Net (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Finite Lived Intangible Assets [Line Items]    
Total $ 47,092 $ 48,954
Tradenames [Member]    
Finite Lived Intangible Assets [Line Items]    
Total 28,273 29,673
Referral Relationships [Member]    
Finite Lived Intangible Assets [Line Items]    
Total 16,527 16,811
Accumulated amortization $ 7,729 7,209
Referral Relationships [Member] | Minimum [Member]    
Finite Lived Intangible Assets [Line Items]    
Estimated useful life 6 years  
Referral Relationships [Member] | Maximum [Member]    
Finite Lived Intangible Assets [Line Items]    
Estimated useful life 16 years  
Non-compete Agreements [Member]    
Finite Lived Intangible Assets [Line Items]    
Total $ 2,292 2,470
Accumulated amortization $ 4,297 $ 4,100
Non-compete Agreements [Member] | Minimum [Member]    
Finite Lived Intangible Assets [Line Items]    
Estimated useful life 5 years  
Non-compete Agreements [Member] | Maximum [Member]    
Finite Lived Intangible Assets [Line Items]    
Estimated useful life 6 years  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTANGIBLE ASSETS, NET - Amortization Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Finite Lived Intangible Assets [Line Items]    
Total amortization expenses $ 717 $ 653
Referral Relationships [Member]    
Finite Lived Intangible Assets [Line Items]    
Total amortization expenses 520 458
Non-compete Agreements [Member]    
Finite Lived Intangible Assets [Line Items]    
Total amortization expenses $ 197 $ 195
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
INTANGIBLE ASSETS, NET - Amortization of Tradename, Referral Relationships and Non-Competition Agreements (Details)
$ in Thousands
Mar. 31, 2018
USD ($)
Referral Relationships [Member]  
Finite Lived Intangible Assets [Line Items]  
2018 $ 2,068
2019 1,965
2020 1,965
2021 1,965
2022 1,917
2023 1,809
Thereafter 5,358
Non-compete Agreements [Member]  
Finite Lived Intangible Assets [Line Items]  
2018 766
2019 693
2020 481
2021 403
2022 143
2023 $ 3
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Payables and Accruals [Abstract]    
Salaries and related costs $ 22,677 $ 16,828
Credit balances due to patients and payors 3,841 4,158
Group health insurance claims 2,637 2,929
Income taxes payable 2,139 2,833
Dividend payable to USPH shareholders 2,914 0
Other 4,134 6,594
Total $ 38,342 $ 33,342
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT - Summary of Notes Payable and Credit Agreement (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Payments/Long term debt, Total $ 48,099 $ 60,772
Less current portion (5,317) (4,044)
Long term portion 42,782 56,728
Credit Facility [Member]    
Debt Instrument [Line Items]    
Payments/Long term debt, Total $ 42,000 54,000
Average effective interest rate 3.80%  
3.25% through 4.25% Notes Payable due in Next Year [Member]    
Debt Instrument [Line Items]    
Payments/Long term debt, Total $ 6,099 $ 6,772
Annual installments $ 5,317  
3.25% through 4.25% Notes Payable due in Next Year [Member] | Minimum [Member]    
Debt Instrument [Line Items]    
Percentage of interest accrued 3.25%  
3.25% through 4.25% Notes Payable due in Next Year [Member] | Maximum [Member]    
Debt Instrument [Line Items]    
Percentage of interest accrued 4.25%  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2018
USD ($)
Clinic
Jan. 31, 2018
USD ($)
Nov. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Jan. 31, 2016
USD ($)
Mar. 31, 2018
USD ($)
Clinic
Dec. 31, 2017
Clinic
Dec. 05, 2013
USD ($)
Debt Instrument [Line Items]                
Number of clinic practices acquired | Clinic 2         2 2  
Aggregate principal payment due in 2018           $ 5,317,000    
Aggregate principal payment due in 2019           782,000    
Notes Payable [Member] | 2017 Acquisition [Member]                
Debt Instrument [Line Items]                
Aggregate amount of notes payable           2,200,000    
Aggregate principal payment due in 2018           1,300,000    
Aggregate principal payment due in 2019           $ 900,000    
Payment of debt   $ 250,000            
Notes Payable [Member] | 2018 Acquisition [Member]                
Debt Instrument [Line Items]                
Aggregate amount of notes payable $ 150,000              
Average effective interest rate 4.50%              
Minimum [Member]                
Debt Instrument [Line Items]                
Spread on Libor variable rate           1.25%    
Spread on variable rate           0.10%    
Percentage of unused commitment fee           0.25%    
Minimum [Member] | Notes Payable [Member]                
Debt Instrument [Line Items]                
Average effective interest rate           3.25%    
Maximum [Member]                
Debt Instrument [Line Items]                
Spread on Libor variable rate           2.00%    
Spread on variable rate           1.00%    
Percentage of unused commitment fee           0.30%    
Maximum [Member] | Notes Payable [Member]                
Debt Instrument [Line Items]                
Average effective interest rate           4.00%    
Credit Facility [Member]                
Debt Instrument [Line Items]                
Revolving credit facility commitment               $ 125,000,000
Revolving credit facility maturity date           Nov. 30, 2021    
Remaining revolving credit outstanding           $ 83,000,000    
Average effective interest rate           3.80%    
Credit Agreement [Member]                
Debt Instrument [Line Items]                
Cash and noncash consideration with respect to acquisition after amendment         $ 50,000,000      
Credit Agreement [Member] | Maximum [Member]                
Debt Instrument [Line Items]                
Cash dividends after amendment     $ 20,000,000 $ 15,000,000 $ 10,000,000      
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
NOTES PAYABLE AND AMENDED CREDIT AGREEMENT- Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Long Term Debt By Maturity [Abstract]    
During the twelve months ended March 31, 2019 $ 5,317  
During the twelve months ended March 31, 2020 782  
During the twelve months ended March 31, 2021 0  
During the twelve months ended March 31, 2022 42,000  
Payments/Long term debt, Total $ 48,099 $ 60,772
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMON STOCK (Details) - USD ($)
1 Months Ended 3 Months Ended
Mar. 31, 2009
Mar. 31, 2018
Dec. 31, 2008
Equity, Class of Treasury Stock [Line Items]      
Common stock authorized by the Board of Directors (in shares) 1,200,000   2,250,000
Total purchased shares (in shares) 859,499 0  
Additional estimated shares (in shares)   184,502  
Closing price (in dollars per share)   $ 81.30  
Maximum [Member]      
Equity, Class of Treasury Stock [Line Items]      
Maximum percentage of repurchase of common stock 10.00%    
Bank credit agreement to permit share repurchases of common stock $ 15,000,000    
EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 56 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 134 275 1 false 56 0 false 11 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://usph.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://usph.com/role/ConsolidatedBalanceSheetsUnaudited CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 010100 - Statement - CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://usph.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONSOLIDATED STATEMENTS OF NET INCOME (unaudited) Sheet http://usph.com/role/ConsolidatedStatementsOfNetIncomeUnaudited CONSOLIDATED STATEMENTS OF NET INCOME (unaudited) Statements 4 false false R5.htm 030000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://usph.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 5 false false R6.htm 040000 - Statement - CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (unaudited) Sheet http://usph.com/role/ConsolidatedStatementOfShareholdersEquityUnaudited CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (unaudited) Statements 6 false false R7.htm 060100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://usph.com/role/BasisOfPresentationAndSignificantAccountingPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 060200 - Disclosure - ACQUISITIONS OF BUSINESSES Sheet http://usph.com/role/AcquisitionsOfBusinesses ACQUISITIONS OF BUSINESSES Notes 8 false false R9.htm 060300 - Disclosure - REVENUE RECOGNITION Sheet http://usph.com/role/RevenueRecognition REVENUE RECOGNITION Notes 9 false false R10.htm 060400 - Disclosure - EARNINGS PER SHARE Sheet http://usph.com/role/EarningsPerShare EARNINGS PER SHARE Notes 10 false false R11.htm 060500 - Disclosure - MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS Sheet http://usph.com/role/MandatorilyRedeemableNoncontrollingInterests MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS Notes 11 false false R12.htm 060600 - Disclosure - REDEEMABLE NON-CONTROLLING INTERESTS Sheet http://usph.com/role/RedeemableNoncontrollingInterests REDEEMABLE NON-CONTROLLING INTERESTS Notes 12 false false R13.htm 060700 - Disclosure - GOODWILL Sheet http://usph.com/role/Goodwill GOODWILL Notes 13 false false R14.htm 060800 - Disclosure - INTANGIBLE ASSETS, NET Sheet http://usph.com/role/IntangibleAssetsNet INTANGIBLE ASSETS, NET Notes 14 false false R15.htm 060900 - Disclosure - ACCRUED EXPENSES Sheet http://usph.com/role/AccruedExpenses ACCRUED EXPENSES Notes 15 false false R16.htm 061000 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT Notes http://usph.com/role/NotesPayableAndAmendedCreditAgreement NOTES PAYABLE AND AMENDED CREDIT AGREEMENT Notes 16 false false R17.htm 061100 - Disclosure - COMMON STOCK Sheet http://usph.com/role/CommonStock COMMON STOCK Notes 17 false false R18.htm 070100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://usph.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 080100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://usph.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://usph.com/role/BasisOfPresentationAndSignificantAccountingPolicies 19 false false R20.htm 080200 - Disclosure - ACQUISITIONS OF BUSINESSES (Tables) Sheet http://usph.com/role/AcquisitionsOfBusinessesTables ACQUISITIONS OF BUSINESSES (Tables) Tables http://usph.com/role/AcquisitionsOfBusinesses 20 false false R21.htm 080300 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://usph.com/role/RevenueRecognitionTables REVENUE RECOGNITION (Tables) Tables http://usph.com/role/RevenueRecognition 21 false false R22.htm 080400 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://usph.com/role/EarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://usph.com/role/EarningsPerShare 22 false false R23.htm 080601 - Disclosure - REDEEMABLE NON-CONTROLLING INTERESTS (Tables) Sheet http://usph.com/role/RedeemableNoncontrollingInterestsTables REDEEMABLE NON-CONTROLLING INTERESTS (Tables) Tables http://usph.com/role/RedeemableNoncontrollingInterests 23 false false R24.htm 080700 - Disclosure - GOODWILL (Tables) Sheet http://usph.com/role/GoodwillTables GOODWILL (Tables) Tables http://usph.com/role/Goodwill 24 false false R25.htm 080800 - Disclosure - INTANGIBLE ASSETS, NET (Tables) Sheet http://usph.com/role/IntangibleAssetsNetTables INTANGIBLE ASSETS, NET (Tables) Tables http://usph.com/role/IntangibleAssetsNet 25 false false R26.htm 080900 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://usph.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://usph.com/role/AccruedExpenses 26 false false R27.htm 081000 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Tables) Notes http://usph.com/role/NotesPayableAndAmendedCreditAgreementTables NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Tables) Tables http://usph.com/role/NotesPayableAndAmendedCreditAgreement 27 false false R28.htm 090100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://usph.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://usph.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables 28 false false R29.htm 090102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Clinic Acquisition (Details) Sheet http://usph.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfClinicAcquisitionDetails BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Clinic Acquisition (Details) Details 29 false false R30.htm 090200 - Disclosure - ACQUISITIONS OF BUSINESSES (Details) Sheet http://usph.com/role/AcquisitionsOfBusinessesDetails ACQUISITIONS OF BUSINESSES (Details) Details http://usph.com/role/AcquisitionsOfBusinessesTables 30 false false R31.htm 090300 - Disclosure - REVENUE RECOGNITION (Details) Sheet http://usph.com/role/RevenueRecognitionDetails REVENUE RECOGNITION (Details) Details http://usph.com/role/RevenueRecognitionTables 31 false false R32.htm 090400 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://usph.com/role/EarningsPerShareDetails EARNINGS PER SHARE (Details) Details http://usph.com/role/EarningsPerShareTables 32 false false R33.htm 090500 - Disclosure - MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS (Details) Sheet http://usph.com/role/MandatorilyRedeemableNoncontrollingInterestsDetails MANDATORILY REDEEMABLE NON-CONTROLLING INTERESTS (Details) Details http://usph.com/role/MandatorilyRedeemableNoncontrollingInterests 33 false false R34.htm 090600 - Disclosure - REDEEMABLE NON-CONTROLLING INTERESTS (Details) Sheet http://usph.com/role/RedeemableNoncontrollingInterestsDetails REDEEMABLE NON-CONTROLLING INTERESTS (Details) Details http://usph.com/role/RedeemableNoncontrollingInterestsTables 34 false false R35.htm 090700 - Disclosure - GOODWILL (Details) Sheet http://usph.com/role/GoodwillDetails GOODWILL (Details) Details http://usph.com/role/GoodwillTables 35 false false R36.htm 090800 - Disclosure - INTANGIBLE ASSETS, NET - Intangible Assets, Net (Details) Sheet http://usph.com/role/IntangibleAssetsNetIntangibleAssetsNetDetails INTANGIBLE ASSETS, NET - Intangible Assets, Net (Details) Details 36 false false R37.htm 090802 - Disclosure - INTANGIBLE ASSETS, NET - Amortization Expenses (Details) Sheet http://usph.com/role/IntangibleAssetsNetAmortizationExpensesDetails INTANGIBLE ASSETS, NET - Amortization Expenses (Details) Details 37 false false R38.htm 090804 - Disclosure - INTANGIBLE ASSETS, NET - Amortization of Tradename, Referral Relationships and Non-Competition Agreements (Details) Sheet http://usph.com/role/IntangibleAssetsNetAmortizationOfTradenameReferralRelationshipsAndNoncompetitionAgreementsDetails INTANGIBLE ASSETS, NET - Amortization of Tradename, Referral Relationships and Non-Competition Agreements (Details) Details 38 false false R39.htm 090900 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://usph.com/role/AccruedExpensesDetails ACCRUED EXPENSES (Details) Details http://usph.com/role/AccruedExpensesTables 39 false false R40.htm 091000 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT - Summary of Notes Payable and Credit Agreement (Details) Notes http://usph.com/role/NotesPayableAndAmendedCreditAgreementSummaryOfNotesPayableAndCreditAgreementDetails NOTES PAYABLE AND AMENDED CREDIT AGREEMENT - Summary of Notes Payable and Credit Agreement (Details) Details 40 false false R41.htm 091002 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Details) Notes http://usph.com/role/NotesPayableAndAmendedCreditAgreementDetails NOTES PAYABLE AND AMENDED CREDIT AGREEMENT (Details) Details http://usph.com/role/NotesPayableAndAmendedCreditAgreementTables 41 false false R42.htm 091004 - Disclosure - NOTES PAYABLE AND AMENDED CREDIT AGREEMENT- Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility (Details) Notes http://usph.com/role/NotesPayableAndAmendedCreditAgreementSummaryOfAggregateAnnualPaymentsOfPrincipalRequiredToRevolvingCreditFacilityDetails NOTES PAYABLE AND AMENDED CREDIT AGREEMENT- Summary of Aggregate Annual Payments of Principal Required to Revolving Credit Facility (Details) Details 42 false false R43.htm 091100 - Disclosure - COMMON STOCK (Details) Sheet http://usph.com/role/CommonStockDetails COMMON STOCK (Details) Details http://usph.com/role/CommonStock 43 false false All Reports Book All Reports usph-20180331.xml usph-20180331.xsd usph-20180331_cal.xml usph-20180331_def.xml usph-20180331_lab.xml usph-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 61 0001140361-18-021886-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-18-021886-xbrl.zip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

[08#&WLW5X^>F2'II+4-2!)J.251!X)TCYARI/'>A6F/+CS$O[1/EB) MC/H;%P+W2(,4,)3I[+,CXILY05C=(]GS+OP4EIKC&R-.A(FGBV,SO,[2'IP3 MR5B1&B\"S$CYXJ6[H5E)M=/PX?,DK(N(M"^DAN^H 4..O?;JJ?)_XV[%K2KIA MPU3?>3^ MA7./N7=_] XLBI]HX"5T55RGU8"5\OCLIRJ,MP%X+WMTMZLJ40I_-08\:HJB M ]QO 3A/8#%IXG.^2DGA#:4)666T^6P3^BU ZAFOL]E!A0E;[K%@O ME9C6GPB9Y%?R]SC=D^+H"$3HQ7D+.FYU.Q:)^"L3F5^HYW,W_S,PA9B->W7N MRLF!>A'AWCS["(:'+-KR*8/M1(C ?\+RL PH\=?BJCT:_3*R?U?',#.!6=W( M>TD+@U<4XMQ<<.8&95%VAL+GC'R<6.FG(TDVM+SB]2P1)YE7D"%GN796DH&X M-%:69P>\61&L9 XY[G"W9XD^R;(3&7VHB\9/?,72B*N>V2.-MG[R?>-%](GN M.(PW7DQC<;LH7ZR(2T0;N+9EDSTPN5B-+"(=U6J0^Z[_\+?[[6-18?RP+F5W1:SZA$7O=75" MNW;!JG+0XU!MT1T]@[4XS;/QU8IQ;M2EC4\^M#2 %;-ZX-(GS!Z3#J&-J:K+00^>M$5+ M;563T[P<3VA.<$JQDP&JF-7[KMNN.H_"=G7%#@=IG-A)7R82F*]K:"XH)ALZ M#09=2>CD'+N6H9.>,,3025\P$H)G$G\LLE8Q^=D/LW_^\DZ0*XF8G",7MT?K MAD;>[O (A9_^LKUY6N>8O MK^QBK)H-M+-&CFRXI\CZ"4J+Y$YS]C_-. *+2 M/:*4>?;OX8I&GUF8>N"'-7SFAU[Z MQ^UV%[ ##,W_35??:<"%O8A=@0T+5BV])ET+*GI6NA-DU_+0E5[HWM^YJAV- M&)U*;LQ#/*;-(WDFTFPT_9!*J%43@IE)O5$@!MU61 W^6DLJ_VIW(Q87@XOG,?(AE M$LBM*CN1)9G5/4JFJ*CW)LNI)DKHGH35/0G-/$F>>)+YX$E>@/C-/ M@GN&(;N%IW+6OG8@/^M3#JH^K*%S>?/P@BE]?FI!G]ZJ;%17'/XY!4,-Y)6B M1@PEB[;TP"5W;WX<[_,.Y;4&&[NL;3]\4Z0=)]%5RAR*# ,=C2I1759E>:B9 M$H-;!=*Q U/1N/8 !PWR^\BJC9OJ+9XRTJMT\<#-!AE)PJ&1;WM&0(3 MF9B'!TSEXV)_5L%^Q9M?M3O^JTJ"[YV"7W8P8%CPHX:!3U1L'JZ>Z(JO3$ F M4L :-PS/O:#LI;@49.-TW.F%'JHZ5U7JQQQ+;@2_42:-_R,7I[JH[]E8^"FN M+OM%;[IXO^"&[7O1@5QQ@2]>M K \V;!=T2]F+.&Z#K>+S=5>2.'UP-8+AO4 M1NK>VYW,PLV[_EG3=4LX:P7W.H[DD*[!(V4^J)0@5AE7J'L4([<..1L7(EG^ MG+P/L5Q0N54.<>7E7M&1/,FLXDD:T;+TB69/*19Y 6[+M8AKK-3R0=R3+S''6FSO3 M8]V52S-1_ MGZ.O@]O]'3-]W!J?=/_'8#Z\&%\7I"9M?+AG_<165;E>*.J@FN?]^L;E9_[D MXZR.3 927DFK)NI,WPA'1?L$V&&+#@VF(&IDEXNAIP%8&0G".T08QG$=/)&#$YZ MY9CAA@<3MVW.!SS368!&,IE;@@9U\FV1\<1#@#*S+&NF%;4QII68E&)NVIN44/5*1CG M(+MJ6MHX-TO9T:9Z7^V47;F;=A>2DB.IL+Q88S^X3L \!5AB(W-RDX M#]&'K2E,I\-(G5:K%UK]],_;AG*22-K+S(_+@MS%89(90B4P=33_:'WIO=T[ M"JJN_AL-UB[1ZJPCUY$48YSJ=<5Z?F-GA"OU!E/ZP,)O\E1C[[9-TY$H8WAU MMTJ2N[V6W5^:GE#%7X.UT']XH?. M&"IK9+H$4A30F2L,4A[G6GJO 7+%)9$>SK260_VL5=="JDJ.;H^#) G557%K MB8JE]QFS$RZ]'\OJS+*"0YN=VWR@F@Y:X>TKC1;,/!VHKI%;\U,LOF^;$4^B MYGXLJS/+_0UM=:BA^A_4B^#3UHMUVK_,'D[S2QM/4.>%'MZVLI>::,OH^>]T MY2_A]O.=EY:L'/B@D0-&R=MAO<^TCN[ZN *J;>2XKQ@G8FKGJ_%R>2R3?SB1 M.VZT7ZPD6E!^LY;S^#%#Q)Q3.W.-]SM+WR\YY1-CUY3QL6O* M^(@X97QT.V5\U)HR/I[(E-%\.ZSWF;;B[F,[[CXB3QD?'4T9'_6FC(]M4\;' M:7D4]1?;/67TOUF<*>.CRRGCH]Z4\;%URCC9%]P]9?2_8-0I(_>%3]3?+O;\ MW8E"YD6AL6\IGJY$C/1VH,+-W6;+"SI0%#8!, M'#>N(/F$'.!07;3]?<=I5'JT5HU;=$3A M=ZPRD"[OZZ+-;)Z3P,42*0VL#HN419R152O7IA9 FN&,V;[^1IL8'39EUQA] MX8-"':D;EHE8/)!?5U!>$$$OA +E.5TE'_"N("UKK34,IFT;;^G*P^S#92(; M#]DS$__]KI M:^HU#+)10[%J_O$3"_=QEGSLV(-L&]:R\5@?AI5/KW)UNL78 M(D@I=7Y$5SF^5B_47\#((E.^B]B.Q>6!?3XH7(Y]2K_WM;?S]#&"CL NG#1OD_;90U!+MO> F"-B;QY]'+*F#4QI;[)YUCK5+ M:7:PQLSK*XCIR$WV4L\K8T@Y:#)U<&JOFVF_E6;6L(.NDASLYXYG%%_\-0^+ M>(Q#/]'DC=+P)I7\\@)-/Q):T>:)QC1ZI:6]QCRJ"QU/=-L0NH"GH;DV-3HOUZ>%P\A+H+$]!)L 'EHGE9$4 M*J:K41_(B3I.G*AMY!\P19?)(\U2.LG$DYLL[BQ\934:S?A4UBDQN8E)K@5Y M9J30HT98:-+"XN(K1P?"Q5FB;L2,J#EB@F?D7S%%ESFKN4RM\-(+5P:!Y,4W MCO[&+[[1X5;>T>^XI\D3?:7AGJL9:L8F5\3;[2+V0RPK@D,S*KFX$FQ(GYTKP6WHE&X+=BQO\R5PPRWI M$^:MGC0(K?H^*L(0HT]]P4@ GNGZ MWG<"8$D8YAS J$'231AR<:*I_\-RN=^)B;\\:LUE^\NCC+H>4?9X5(ELC%-- M!GI0I"56:I4:7.;IV/3R&L(JH_.>!23.QD_NJ+(F>)CQJZV;I1I]89(ZXH9! M+$X8I"F).1Q!DW+4$==$&*8HR<4 :"S J!!OS<] MHT2>QY@%.JCVB6:HVU!FI_.'#;0YQVASIM#D^DNZ%C1/;'N.:'?XVLKD>#@WN:-LY/,X3PA$9>:YP>GO2DS OA3WL4>T+ M<<_;3 %'>^'FRCBTLJ.]<^-Y[6)ENAOQHUJ9HZ[>183_E469N+OP8;WF_W^( M'@!1]Q#]Q_RI[-.B@N\T27@\U(RS,5D>=0NW88G3WM=< X==R*V54N@;;"FC MVF*XO"Q@S:+<#T%FDPEVA'_(@"$)1<*SPI(/3GE.+AA'A?UQ-V,-;[,Y7)F>4 .>=V4'WF(B.!([D6ZMVJB.=.+ M/?;#ZP0,$JTQOIT:3IKHVZODW"QG_3/GQ=#Z47,"AH8:V/]!O8A_^N^_T^V" M1@W#;/\R>T3-+VV,O\X+/0!N92^UR);1YF*8JQ8SY\W?DQH0(5SC>@.#BR'25Q9MT.OFG7*GJPX?[),!:2U MCKD(\L9E\.^%D#(,BJ]@V$^/X1_A[^&7Y_!O_'_??X+@:.LE5R)(HC^\[2Z@ M5WS4]1]_^?WZMR\_-17A?[((FG&MX9H3K@\+J9@). ?_E9(M"Y,-]-@)5WR\ MSX?2D*R\P]C=_C#LB.$"^BC.,F5:#:_L%!O1S-'2"+9*N#+P-&D 5ORP)AD/ M DQ(QB4]+E!8,3 B&:9 2,*]R1[!CD MB#;5"GR,\OJ%!8%7/V"\ _B: L4UZ7J5U@5%$ [?= M@[(?+!MD8ROM/-'#ATXQ4I/HH)K?EU=P$(!><2A^Y!B@YTTRY>=>1WG[^ +8 M7>S

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